EPICORE Embase Updates: EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 125

Results Generated From:
Embase <1980 to 2022 Week 44>
Embase Weekly Updates (updates since 2022-10-28)

<1>
Accession Number
2017953495
Title
Preoperative Short-Term Restriction of Sulfur-Containing Amino Acid Intake
for Prevention of Acute Kidney Injury After Cardiac Surgery: A Randomized,
Controlled, Double-Blind, Translational Trial.
Source
Journal of the American Heart Association. 11(17) (no pagination), 2022.
Article Number: e025229. Date of Publication: 06 Sep 2022.
Author
Osterholt T.; Gloistein C.; Todorova P.; Becker I.; Arenskrieger K.; Melka
R.; Koehler F.C.; Faust M.; Wahlers T.; Benzing T.; Muller R.-U.;
Grundmann F.; Burst V.
Institution
(Osterholt, Gloistein, Todorova, Arenskrieger, Melka, Koehler, Benzing,
Muller, Grundmann, Burst) Department II of Internal Medicine and Center
for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine
and University Hospital Cologne, Cologne, Germany
(Becker) Institute of Medical Statistics and Computational Biology,
Institute of Medical Statistics and Computational Biology, University of
Cologne, Faculty of Medicine and University Hospital Cologne, Cologne,
Germany
(Koehler, Benzing, Muller) Cologne Excellence Cluster on Cellular Stress
Responses in Aging-Associated Diseases (CECAD), Institute of Medical
Statistics and Computational Biology, University of Cologne, Faculty of
Medicine and University Hospital Cologne, Cologne, Germany
(Faust) Polyclinic for Endocrinology, Diabetes and Preventive Medicine,
University of Cologne, Faculty of Medicine and University Hospital
Cologne, Cologne, Germany
(Wahlers) Department of Cardiothoracic Surgery, University of Cologne,
Faculty of Medicine and University Hospital, Cologne, Germany
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: Acute kidney injury (AKI) is a major risk factor for chronic
kidney disease and increased mortality. Until now, no compelling
preventive or therapeutic strategies have been identified. Dietary
interventions have been proven highly effective in organ protection from
ischemia reperfusion injury in mice and restricting dietary intake of
sulfur-containing amino acids (SAA) seems to be instrumental in this
regard. The UNICORN trial aimed to evaluate the protective impact of
restricting SAA intake before cardiac surgery on incidence of AKI. METHODS
AND RESULTS: In this single-center, randomized, controlled, double-blind
trial, 115 patients were assigned to a SAA-reduced formula diet (LowS
group) or a regular formula diet (control group) in a 1:1 ratio for 7 days
before scheduled cardiac surgery. The primary end point was incidence of
AKI within 72 hours after surgery, secondary end points included increase
of serum creatinine at 24, 48, and 72 hours as well as safety parameters.
Quantitative variables were analyzed with nonparamet-ric methods, while
categorical variables were evaluated by means of Chi-square or Fisher
test. SAA intake in the group with SAA reduced formula diet was
successfully reduced by 77% (group with SAA reduced formula diet,
7.37[6.40-7.80] mg/kg per day versus control group, 32.33 [28.92- 33.60]
mg/kg per day, P<0.001) leading to significantly lower serum levels of
me-thionine. No beneficial effects of SAA restriction on the rate of AKI
after surgery could be observed (group with SAA reduced formula diet, 23%
versus control group, 16%; P=0.38). Likewise, no differences were recorded
with respect to secondary end points (AKI during hospitalization,
creatinine at 24, 48, 72 hours after surgery) as well as in subgroup
analysis focusing on age, sex, body mass index and diabetes.
 CONCLUSION(S): SAA restriction was feasible in the clinical setting
but was not associated with protective properties in AKI upon cardiac
surgery. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique
Identifier: NCT03715868. Copyright © 2022 The Authors. Published
on behalf of the American Heart Association, Inc., by Wiley.

<2>
Accession Number
2016175215
Title
Effects of Hypoxia-Hyperoxia Preconditioning on Indicators of Muscle
Damage After Acute Resistance Exercise in Male Athletes.
Source
Frontiers in Physiology. 13 (no pagination), 2022. Article Number: 824210.
Date of Publication: 19 Apr 2022.
Author
Chen P.-W.; Hsu C.-C.; Lai L.-F.; Chi C.-P.; Yu S.-H.
Institution
(Chen, Lai) Institute of Sports Sciences, University of Taipei, Taipei,
Taiwan (Republic of China)
(Hsu) Department of Aquatic Sports, University of Taipei, Taipei, Taiwan
(Republic of China)
(Chi) Center for General Education, Taipei Medical University, Taipei,
Taiwan (Republic of China)
(Yu) Department of Leisure Industry and Health Promotion, National Ilan
University, Yilan City, Taiwan (Republic of China)
Publisher
Frontiers Media S.A.
Abstract
Purpose: The purpose of this study was to investigate the effects of acute
repeated hypoxia-hyperoxia preconditioning on resistance exercise
(RE)-induced muscle damage in male athletes. Method(s): Eleven young
male athletes participated in this randomized double-blind
counter-balanced crossover study, and were divided into Normoxia (N) and
Hypoxia-Hyperoxia (HH) trials. Subjects of the respective trials were
supplied with normoxic (FiO<inf>2</inf> = 0.21), or alternating
hypoxic/hyperoxic air (FiO<inf>2</inf> = 0.10/0.99, 5 min each) for 60
min. Thirty minutes after preconditioning, subjects performed acute bouts
of RE consisting of bench press, deadlift, and squats. Each exercise
included 6 sets of 10 repetitions at 75% one-repetition maximum (1RM) with
2 min rest between sets. After a 2-week washout period, subjects changed
trials and completed the same study procedure after the alternate
preconditioning. Muscle soreness, maximal voluntary contraction (MVC), and
circulating biochemical markers were tested before preconditioning
(baseline) and during recovery at 0, 24, and 48 h after exercise.
 Result(s): Acute RE significantly increased levels of muscle
soreness, creatine kinase (CK) and myoglobin (Mb), and decreased levels of
peak knee extension torque in the N trial. Muscle soreness, CK, and Mb
levels of the HH trial were significantly lower than that of the N trial
after exercise. Interestingly, interleukin-6 (IL-6) levels of the HH trial
increased significantly 0 h after exercise compared to baseline and were
significantly higher than that of the N trial 0 and 24 h after exercise.
However, no significant differences of thiobarbituric acid reactive
substances (TBARS), cortisol, testosterone, peak torque, and average power
levels were found between N and HH trials during recovery.
 Conclusion(s): Our data suggest that pre-exercise treatment of
alternating hypoxic/hyperoxic air could attenuate muscle damage and pain
after acute RE, but has no effect on muscle strength recovery in young
male athletes. Copyright © 2022 Chen, Hsu, Lai, Chi and Yu.

<3>
Accession Number
638963099
Title
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in
Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized
Clinical Trial.
Source
JAMA Cardiology. 7(10) (pp 1000-1008), 2022. Date of Publication: October
2022.
Author
Van Mieghem N.M.; Deeb G.M.; Sondergaard L.; Grube E.; Windecker S.; Gada
H.; Mumtaz M.; Olsen P.S.; Heiser J.C.; Merhi W.; Kleiman N.S.; Chetcuti
S.J.; Gleason T.G.; Lee J.S.; Cheng W.; Makkar R.R.; Crestanello J.;
George B.; George I.; Kodali S.; Yakubov S.J.; Serruys P.W.; Lange R.;
Piazza N.; Williams M.R.; Oh J.K.; Adams D.H.; Li S.; Reardon M.J.
Institution
(Van Mieghem, Serruys) Department of Interventional Cardiology, Erasmus
University Medical Center, Rotterdam, Netherlands
(Deeb, Chetcuti) Department of Interventional Cardiology, University of
Michigan, Ann Arbor, United States
(Deeb) Department of Cardiac Surgery, University of Michigan, Ann Arbor,
United States
(Sondergaard, Olsen) Department of Cardiology, Heart Center,
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
(Grube) Department of Interventional Cardiology, University of Bonn, Bonn,
Germany
(Windecker) Department of Cardiology, Inselspital, University of Bern,
Bern, Switzerland
(Gada, Mumtaz) Department of Interventional Cardiology, University of
Pittsburgh Medical Center Pinnacle Health, Harrisburg, PA, United States
(Gada, Mumtaz) Department of Cardiothoracic Surgery, University of
Pittsburgh Medical Center Pinnacle Health, Harrisburg, PA, United States
(Heiser, Merhi) Department of Interventional Cardiology, Spectrum Health,
Grand Rapids, Michigan, United States
(Heiser, Merhi) Department of Cardiothoracic Surgery, Spectrum Health,
Grand Rapids, MI, United States
(Kleiman, Reardon) Department of Interventional Cardiology, Houston
Methodist DeBakey Heart and Vascular Center, Houston, TX, United States
(Kleiman, Reardon) Department of Cardiothoracic Surgery, Houston Methodist
DeBakey Heart and Vascular Center, Houston, TX, United States
(Gleason, Lee) Department of Interventional Cardiology, University of
Pittsburgh, Pittsburgh, PA, United States
(Gleason) Now with Division of Cardiac Surgery, Department of Surgery,
University of Maryland School of Medicine, Baltimore, United States
(Gleason, Lee) Department of Cardiothoracic Surgery, University of
Pittsburgh, Pittsburgh, PA, United States
(Cheng, Makkar) Department of Interventional Cardiology, Cedars-Sinai
Medical Center, Los Angeles, CA, United States
(Cheng, Makkar) Department of Cardiothoracic Surgery, Cedars-Sinai Medical
Center, Los Angeles, CA, United States
(Crestanello, George) Department of Interventional Cardiology, Ohio State
University Wexner Medical Center, Columbus, United States
(Crestanello) Now with Mayo Clinic, Rochester, MN, United States
(Crestanello, George) Department of Cardiovascular Surgery, Ohio State
University Wexner Medical Center, Columbus, United States
(George, Kodali) Department of Interventional Cardiology, New York
Presbyterian Hospital-Columbia University Irving Medical Center, New York,
United States
(George, Kodali) Department of Cardiothoracic Surgery, New York
Presbyterian Hospital-Columbia University Irving Medical Center, New York,
United States
(Yakubov) Department of Interventional Cardiology, OhioHealth Riverside
Methodist Hospital, Columbus, United States
(Serruys) Now with National University of Ireland, Galway, Ireland
(Lange) Department of Cardiac Surgery, German Heart Center, Munich,
Germany
(Piazza) Department of Interventional Cardiology, McGill University Health
Centre, Montreal, QC, Canada
(Williams) Department of Interventional Cardiology and Cardiac Surgery,
Langone-New York University, New York, United States
(Oh) Echocardiography Core Laboratory, Mayo Clinic, Rochester, MN, United
States
(Adams) Department of Cardiovascular Surgery, Mount Sinai Health System,
New York, NY, United States
(Li) Clinical Research, Medtronic, Minneapolis, MN, United States
Publisher
American Medical Association
Abstract
Importance: In patients with severe aortic valve stenosis at intermediate
surgical risk, transcatheter aortic valve replacement (TAVR) with a
self-expanding supra-Annular valve was noninferior to surgery for
all-cause mortality or disabling stroke at 2 years. Comparisons of
longer-Term clinical and hemodynamic outcomes in these patients are
limited. Objective(s): To report prespecified secondary 5-year
outcomes from the Symptomatic Aortic Stenosis in Intermediate Risk
Subjects Who Need Aortic Valve Replacement (SURTAVI) randomized clinical
trial. Design, Setting, and Participant(s): SURTAVI is a prospective
randomized, unblinded clinical trial. Randomization was stratified by
investigational site and need for revascularization determined by the
local heart teams. Patients with severe aortic valve stenosis deemed to be
at intermediate risk of 30-day surgical mortality were enrolled at 87
centers from June 19, 2012, to June 30, 2016, in Europe and North America.
Analysis took place between August and October 2021. Intervention(s):
Patients were randomized to TAVR with a self-expanding, supra-Annular
transcatheter or a surgical bioprosthesis. Main Outcomes and
Measures: The prespecified secondary end points of death or disabling
stroke and other adverse events and hemodynamic findings at 5 years. An
independent clinical event committee adjudicated all serious adverse
events and an independent echocardiographic core laboratory evaluated all
echocardiograms at 5 years. Result(s): A total of 1660 individuals
underwent an attempted TAVR (n = 864) or surgical (n = 796) procedure. The
mean (SD) age was 79.8 (6.2) years, 724 (43.6%) were female, and the mean
(SD) Society of Thoracic Surgery Predicted Risk of Mortality score was
4.5% (1.6%). At 5 years, the rates of death or disabling stroke were
similar (TAVR, 31.3% vs surgery, 30.8%; hazard ratio, 1.02 [95% CI,
0.85-1.22]; P =.85). Transprosthetic gradients remained lower (mean [SD],
8.6 [5.5] mm Hg vs 11.2 [6.0] mm Hg; P <.001) and aortic valve areas were
higher (mean [SD], 2.2 [0.7] cm2vs 1.8 [0.6] cm2; P
<.001) with TAVR vs surgery. More patients had moderate/severe
paravalvular leak with TAVR than surgery (11 [3.0%] vs 2 [0.7%]; risk
difference, 2.37% [95% CI, 0.17%-4.85%]; P =.05). New pacemaker
implantation rates were higher for TAVR than surgery at 5 years (289
[39.1%] vs 94 [15.1%]; hazard ratio, 3.30 [95% CI, 2.61-4.17]; log-rank P
<.001), as were valve reintervention rates (27 [3.5%] vs 11 [1.9%]; hazard
ratio, 2.21 [95% CI, 1.10-4.45]; log-rank P =.02), although between 2 and
5 years only 6 patients who underwent TAVR and 7 who underwent surgery
required a reintervention. Conclusions and Relevance: Among
intermediate-risk patients with symptomatic severe aortic stenosis, major
clinical outcomes at 5 years were similar for TAVR and surgery. TAVR was
associated with superior hemodynamic valve performance but also with more
paravalvular leak and valve reinterventions. Copyright © 2022
American Medical Association. All rights reserved.

<4>
Accession Number
2020564970
Title
Efficacy of High-Flow Nasal Cannula versus Conventional Oxygen Therapy in
Obese Patients during the Perioperative Period: A Systematic Review and
Meta-Analysis.
Source
Canadian Respiratory Journal. 2022 (no pagination), 2022. Article Number:
4415313. Date of Publication: 2022.
Author
Zhou R.; Wang H.-T.; Gu W.
Institution
(Zhou, Gu) Department of Anesthesiology, Nanjing Drum Tower Hospital, The
Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan
Road, Jiangsu, Nanjing 210008, China
(Wang) Queen Marry School, Nanchang University, 461 Bayi Road, Nanchang
330006, China
Publisher
Hindawi Limited
Abstract
Background. Obesity is a risk factor for severe airway obstruction and
hypoxemia. High-flow nasal cannula (HFNC) is considered as a novel method
for oxygen therapy, but the efficacy of HFNC for obese patients is
controversial. This meta-analysis aimed to assess the efficacy of HFNC
compared with conventional oxygen therapy (COT) in obese patients during
the perioperative period. Methods. We searched the PubMed, Embase, Web of
Science, the Cochrane Library, and Google scholar databases for randomized
controlled trials (RCTs) that compared the efficacy of HFNC with COT in
obese patients during the perioperative period. The primary outcome was
the incidence of hypoxemia, while the secondary outcomes included the
lowest SpO2, the need for additional respiratory support, and the hospital
length of stay (LOS). Results. Twelve trials with 798 obese patients
during the perioperative period were included. Compared with COT, HFNC
reduced the incidence of hypoxemia (RR, 0.60; 95% CI, 0.43 to 0.83;
P=0.002; I2 = 24%; 8 RCTs; n = 458), increased the lowest SpO2 (MD, 2.88;
95% CI, 1.53 to 4.22; P<0.0001; I2 = 32%; 5 RCTs; n = 264), decreased the
need for additional respiratory support (RR, 0.43; 95% CI, 0.21 to 0.88;
P=0.02; I2 = 0%; 3 RCTs; n = 305), and shortened the hospital LOS (MD,
-0.31; 95% CI, -0.57 to -0.04; P=0.02; I2 = 0%; 3 RCTs; n = 214).
Conclusions. This meta-analysis showed that compared with COT, the use of
HFNC was able to reduce the incidence of hypoxemia, increase the lowest
SpO2, decrease the need for additional respiratory support, and shorten
the hospital LOS in obese patients during the perioperative period.
Well-organized trials with large sample size should be conducted to
support our findings. Copyright © 2022 Rong Zhou et al.

<5>
Accession Number
2019764646
Title
The Comparison of High-Intensity Interval Training Versus
Moderate-Intensity Continuous Training after Coronary Artery Bypass Graft:
A Systematic Review of Recent Studies.
Source
Journal of Cardiovascular Development and Disease. 9(10) (no pagination),
2022. Article Number: 328. Date of Publication: October 2022.
Author
Schulte B.; Nieborak L.; Leclercq F.; Villafane J.H.; Sanchez Romero E.A.;
Corbellini C.
Institution
(Schulte, Nieborak, Leclercq, Corbellini) Department of Physiotherapy,
LUNEX International University of Health, Exercise and Sports, 50, Avenue
du Parc des Sports, Differdange 4671, Luxembourg
(Villafane) IRCCS Fondazione Don Carlo Gnocchi, Piazzale Morandi 6, Milan
20148, Italy
(Sanchez Romero) Musculoskeletal Pain and Motor Control Research Group,
Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid 28670,
Spain
(Sanchez Romero) Musculoskeletal Pain and Motor Control Research Group,
Faculty of Health Sciences, Universidad Europea de Canarias, Tenerife,
Canary Islands 38300, Spain
(Sanchez Romero) Department of Physiotherapy, Faculty of Sport Sciences,
Universidad Europea de Madrid, Villaviciosa de Odon, Madrid 28670, Spain
(Sanchez Romero) Department of Physiotherapy, Faculty of Health Sciences,
Universidad Europea de Canarias, Tenerife, Canary Islands 38300, Spain
Publisher
MDPI
Abstract
Currently, no international consensus on cardiac rehabilitation exists,
leading to great variability in the intensity recommendations for training
programs for cardiac patients, including those undergoing coronary artery
bypass graft surgery (CABG). While some countries prefer the
high-intensity interval training (HIIT) method to improve
cardiorespiratory fitness, other countries opt for moderate-intensity
continuous training (MICT). The aim of this systematic review was to
compare the effects of HIIT and MICT on aerobic fitness and quality of
life (QoL) in patients undergoing CABG with the intention of providing
support for a consensus on exercise therapy. Method(s): A systematic
review of randomized controlled trials (RCTs) was conducted using the
online publication databases PubMed, the Cochrane Library and the
Bibliotheque nationale du Luxembourg (BnL) covering the last ten years to
July 2022. Relevant identified studies respecting the inclusion/exclusion
criteria were selected, screened and extracted by four reviewers.
Furthermore, the methodological quality of the clinical trials was
assessed using the PEDro scale, which was reinforced using the Cochrane
Risk of Bias Tool for Randomized Trials (RoB2) for the evaluation of the
risk of bias to provide more detail in the evaluation. The certainty of
the evidence analysis was established using different levels of evidence
in accordance with the Grading of Recommendations, Assessment, Development
and Evaluation (GRADE) framework. Result(s): A total of 379 patients
from five RCTs diagnosed with coronary artery disease, including patients
undergoing CABG, performed aerobic exercise over different time periods
and were assessed based on peakVO2, VO<inf>2</inf>max and QoL. Overall,
both training methods provided improvements in cardiorespiratory fitness
and quality of life, with greater changes in HIIT groups.
 Conclusion(s): Both trainings methods provide improvements in
cardiorespiratory fitness and QoL, with greater increases from HIIT. The
moderate quality of evidence supports the use of HIIT and MICT to improve
cardiorespiratory fitness and QoL. Copyright © 2022 by the
authors.

<6>
Accession Number
2019463881
Title
The optimal timing for non-culprit percutaneous coronary intervention in
patients with multivessel coronary artery disease: A pairwise and network
meta-analysis of randomized trials.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 1000664. Date of Publication: 26 Sep 2022.
Author
Feng Y.; Li S.; Hu S.; Wan J.; Shao H.
Institution
(Feng, Li, Hu, Wan) Department of Cardiology, Zhongnan Hospital of Wuhan
University, Wuhan, China
(Shao) Department of Clinical Laboratory, Remin Hospital of Wuhan
University, Wuhan, China
Publisher
Frontiers Media S.A.
Abstract
Background and aims: Recently, several randomized trials have shown that
patients with multivessel disease (MVD) often pursue complete
revascularization during percutaneous coronary intervention (PCI) to
improve their prognosis. However, the optimal time for the non-culprit
artery has been controversial. This study aimed to determine the optimal
strategy for revascularization in ST-segment elevation myocardial
infarction (STEMI) patients with multivessel coronary artery disease
(CAD). Method(s): Randomized controlled trials (RCTs) comparing three
revascularization strategies [i.e., complete revascularization at the
index procedure (CR), complete revascularization as a staged procedure
(SR), or culprit-only revascularization (COR)] in STEMI patients with
multivessel coronary artery disease were included. We performed both
pairwise and network meta-analyses. Network meta-analysis was performed
using mixed treatment comparison models. Result(s): 17 trials with
8568 patients were included. In the network meta-analysis, the most
interesting finding was that staged revascularization increased the risk
of major adverse cardiac events (MACE) compared with complete
revascularization at the index procedure [odds ratio (OR): 1.93; 95%
confidence interval (CI): 1.07-3.49]. In the pairwise meta-analysis,
complete revascularization reduced the incidence of MACE [risk ratio (RR):
0.62, 95% CI: 0.48-0.79, p < 0.001], mainly because it reduced the
probability of unplanned repeat revascularization (RR: 0.49, 95% CI:
0.33-0.75, p = 0.001). There were no significant differences in all-cause
mortality, cardiac mortality, or nonfatal re-myocardial infarction (MI).
 Conclusion(s): Our analysis suggests that complete revascularization
should be performed in STEMI patients with multivessel coronary artery
disease, and complete revascularization at the index procedure is superior
to staged revascularization in reducing the risk of MACE
events. Copyright © 2022 Feng, Li, Hu, Wan and Shao.

<7>
Accession Number
2019429246
Title
Right displacement of trachea to reduce right bronchial misplacement of
left double lumen tube: a prospective, double-blind, randomized study.
Source
BMC Anesthesiology. 22(1) (no pagination), 2022. Article Number: 312. Date
of Publication: December 2022.
Author
Guan J.; Zhu W.; Xiao X.; Huang Z.; Xing J.; Hei Z.; Zhang Y.; Yao W.
Institution
(Guan, Zhu, Xiao, Huang, Xing, Hei, Zhang, Yao) Department of
Anesthesiology, The Third Affiliated Hospital of Sun Yat-Sen University,
Guangzhou 510630, China
Publisher
BioMed Central Ltd
Abstract
Background: Misplacement of double-lumen endobronchial tubes (DLTs) during
bronchial intubation, especially when bronchoscopy guidance is not
applicable, threatens effective lung isolation and brings about airway
injury during reposition. We aimed to examine whether a novel maneuver
called right tracheal displacement (RTD) can reduce left-sided DLT
misplacement during first-attempt intubation without bronchoscopy
guidance. Method(s): Patients that underwent thoracic surgeries
requiring one-lung ventilation during November 2020 to January 2021 were
recruited and randomized into control and RTD group, with 54 cases in each
group. The primary outcomes included the incidence of DLT misplacement and
the time to complete desired bronchial intubation. The secondary outcomes
included mucosal injury, sore throat and hoarseness upon emergence and at
24 h post-operatively. Result(s): The incidence of DLT misplacement
in RTD group was significantly lower compared to control group (0% vs.
16.7%) The time to complete bronchial intubation was also significantly
shortened in RTD group compared to control (52.88 +/- 9.36 s vs. 63.04 +/-
20.02 s). The incidence of mucosal injury, sore throat and hoarseness were
comparable between two groups. Conclusion(s): RTD maneuver can
effectively improve the success rate of first-attempt proper DLT
positioning and shorten the time required by bronchial intubation. Trial
registration: This prospective, double-blind, randomized study has
completed the registration of the Chinese Clinical Trial Center at
2/11/2020 with the registration number ChiCTR2000040212. It was conducted
from 26/11/2020 to 31/7/2021 in third affiliated hospital of Sun Yat-sen
university. Copyright © 2022, The Author(s).

<8>
Accession Number
2019345862
Title
Bleeding in women with venous thromboembolism during pregnancy: A
systematic review of the literature.
Source
Research and Practice in Thrombosis and Haemostasis. 6(6) (no pagination),
2022. Article Number: e12801. Date of Publication: August 2022.
Author
Simard C.; Gerstein L.; Cafaro T.; Filion K.B.; Douros A.; Malhame I.;
Tagalakis V.
Institution
(Simard, Cafaro, Tagalakis) Division of General Internal Medicine,
Department of Medicine, Jewish General Hospital, McGill University,
Montreal, QC, Canada
(Gerstein) Department of Medicine, McGill University, Montreal, QC, Canada
(Filion, Douros, Tagalakis) Centre for Clinical Epidemiology of the Lady
Davis Institute for Medical Research, Jewish General Hospital, Montreal,
QC, Canada
(Malhame) Division of General Internal Medicine, Department of Medicine,
McGill University Health Centre, McGill University, Montreal, QC, Canada
(Malhame) Research Institute of the McGill University Health Centre,
Montreal, QC, Canada
Publisher
John Wiley and Sons Inc
Abstract
Objectives: Venous thromboembolism (VTE) represents an important cause of
maternal morbidity and mortality. Estimates of bleeding associated with
therapeutic-dose anticoagulation are variable. We describe the frequency
of bleeding in pregnant women receiving therapeutic anticoagulation for
VTE by means of a systematic review of the literature. Data Sources:
Medical Literature Analysis and Retrieval System, Embase, Scopus, Web of
Science, and ClinicalTrials.gov were searched. Databases were searched
from inception to February 27, 2022. There was no language or geographic
location restriction. Methods of Study Selection: The search yielded 2773
articles with 2212 unique citations. Studies were included if they
described pregnant women treated for an acute VTE with therapeutic-dose
anticoagulation and a defined bleeding outcome was reported. Tabulation,
Integration, and Results: Five studies met inclusion criteria. Included
studies were judged to have a serious to critical risk of bias using the
Risk of Bias in Nonrandomized Studies of Intervention tool. The rate of
bleeding, as defined by respective studies, ranged between 2.9% and 30.0%.
Two studies included control groups, one of which found no significant
difference in the risk of bleeding between groups, while the other found a
significantly increased bleeding risk associated with therapeutic
anticoagulation. Conclusion(s): Among pregnant women anticoagulated
for VTE, the reported bleeding risk is variable. The ability to draw
definite conclusions is limited by the scarcity and low quality of the
studies, the small number of included patients, and the heterogeneity of
bleeding definitions used. Large-scale studies with standardized bleeding
definitions are required to provide acute bleeding estimates and optimize
the care of these patients. Systematic Review Registration: PROSPERO,
CRD42021276771. Copyright © 2022 The Authors. Research and
Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC
on behalf of International Society on Thrombosis and Haemostasis (ISTH).

<9>
Accession Number
2019287817
Title
Comparative effects of different types of cardioplegia in cardiac surgery:
A network meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 996744. Date of Publication: 13 Sep 2022.
Author
Tan J.; Bi S.; Li J.; Gu J.; Wang Y.; Xiong J.; Yu X.; Du L.
Institution
(Tan, Wang, Xiong, Yu, Du) Department of Anesthesiology, West China
Hospital, Sichuan University, Chengdu, China
(Bi) Department of Burn and Plastic Surgery, West China Hospital, Sichuan
University, Chengdu, China
(Li) West China School of Medicine, Sichuan University, Chengdu, China
(Gu) Department of Cardiovascular Surgery, West China Hospital, Sichuan
University, Chengdu, China
Publisher
Frontiers Media S.A.
Abstract
Objective: To compare the outcomes of four types of cardioplegia during
cardiac surgery: del Nido (DN), blood cardioplegia (BC),
histidine-tryptophan-ketoglutarate (HTK) and St. Thomas. Method(s):
Randomized controlled trials (RCTs) and observational cohort studies from
2005 to 2021 were identified in PubMed, Embase, and Cochrane databases.
Data were extracted for the primary endpoint of perioperative mortality as
well as the following secondary endpoints: atrial fibrillation, renal
failure, stroke, use of an intra-aortic balloon pump, re-exploration,
intensive care unit stay and hospital stay. A network meta-analysis
comparing all four types of cardioplegia was performed, as well as direct
meta-analysis comparing pairs of cardioplegia types. Result(s): Data
were extracted from 18 RCTs and 49 observational cohort studies involving
18,191 adult patients (55 studies) and 1,634 children (12 studies). Among
adult patients, risk of mortality was significantly higher for HTK (1.89,
95% CI 1.10, 3.52) and BC (RR 1.73, 95% CI 1.22, 2.79) than for DN. Risk
of atrial fibrillation was significantly higher for BC (RR 1.41, 95% CI
1.09, 1.86) and DN (RR 1.51, 95% CI 1.15, 2.03) than for HTK. Among
pediatric patients, no significant differences in endpoints were observed
among the four types of cardioplegia. Conclusion(s): This network
meta-analysis suggests that among adult patients undergoing cardiac
surgery, DN may be associated with lower perioperative mortality than HTK
or BC, while risk of atrial fibrillation may be lower with HTK than with
BC or DN. Copyright © 2022 Tan, Bi, Li, Gu, Wang, Xiong, Yu and
Du.

<10>
Accession Number
2020896091
Title
The Anti-Inflammatory and Antioxidant Effects of Propofol and Sevoflurane
in Children With Cyanotic Congenital Heart Disease.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2022.
Date of Publication: 2022.
Author
Karacaer F.; Biricik E.; Ilginel M.; Tunay D.L.; Dogus Y.; Ozturk O.G.;
Guzel Y.; Benli O.; Gunes Y.
Institution
(Karacaer, Biricik, Ilginel, Tunay, Gunes) Balcali Hospital, Cukurova
University, Anesthesiology and Reanimation Department, Adana, Turkey
(Dogus, Ozturk) Balcali Hospital, Cukurova University, Biochemistry
Department, Adana, Turkey
(Guzel) Balcali Hospital, Cukurova University, Cardiovascular Surgery
Department, Adana, Turkey
(Benli) Ministry of Health University, Adana City Training and Research
Hospital, Cardiovascular Surgery Department, Adana, Turkey
Publisher
W.B. Saunders
Abstract
Objective: The authors aimed to compare the anti-inflammatory and
antioxidant effects of propofol and sevoflurane in children with cyanotic
congenital heart disease (CCHD) undergoing cardiac surgery with
cardiopulmonary bypass. Design(s): Prospective, randomized,
double-blind study. Setting(s): Single center, university hospital.
 Participant(s): Children ages 1-10 years with CCHD undergoing
elective cardiac surgery with cardiopulmonary bypass.
 Intervention(s): Children were randomized to receive general
anesthesia with either sevoflurane (group S) or propofol (group P).
Systemic inflammatory response syndrome (SIRS) occurrence was assessed at
the end of the surgery and at the sixth, 12th, and 24th postoperative
hours. Blood samples were obtained at 4 times: after anesthesia induction
(T0), after release of the aortic cross-clamp (T1), at the end of the
surgery (T2), and at the postoperative 24th hour (T3). The serum levels of
interleukin 6 and tumor necrosis factor alpha, and the total antioxidant
status (TAS) and total oxidant status, were analyzed. Result(s): SIRS
was more common in group S than in group P at all times (p = 0.020, p =
0.036, p = 0.004, p = 0.008). There were no significant differences
between the groups in the mean tumor necrosis factor alpha and interleukin
6 levels at any time. The TAS level at T2 was higher in group P than group
S (p = 0.036). The serum TAS level increased at T2 compared with T0 in
group P, but it decreased in group S (p = 0.041). Conclusion(s): The
results showed that propofol provided a greater antioxidant effect and
reduced SIRS postoperatively more than sevoflurane in children with CCHD
undergoing cardiac surgery. Copyright © 2022 Elsevier Inc.

<11>
Accession Number
639192287
Title
Patient blood management and patient safety.
Source
Current opinion in anaesthesiology. 35(6) (pp 733-737), 2022. Date of
Publication: 01 Dec 2022.
Author
Zacharowski K.; Zoller H.; Steinbicker A.U.
Institution
(Zacharowski, Steinbicker) Department of Anaesthesiology, Intensive Care
Medicine and Pain Therapy, University Hospital Frankfurt, Goethe
University Frankfurt, Germany
(Zoller) Department of Medicine I and Christian Doppler Laboratory on Iron
and Phosphate Biology, Medical University of Innsbruck, Innsbruck, Austria
Publisher
NLM (Medline)
Abstract
PURPOSE OF REVIEW: The particular fields within patient blood management
(PBM) and patient safety reviewed here include novel insights into
bleeding therapy, autologous cell salvage, and perioperative anemia
therapy. RECENT FINDING: World Health Organization has published that
implementation of PBM is important but has not yet been performed in all
hospitals. Two antibodies that mimic the function of FVIII, Emicizumab,
and Mim8 have been developed. Tranexamic acid (TXA) has been investigated
further in patients with hip surgery and shows reduction of bleeding.
Thrombocytopenia in patients undergoing cardiac surgery is a particular
concern that has been investigated in another trial. The use of autologous
cell salvage was updated in form of a review and meta-analysis. And last
but not least, intravenous iron in preoperative anemia therapy can reduce
the number of transfusions, but especially iron carboxymaltose can cause
hypophosphatemia. SUMMARY: PBM should be further implemented in more
hospitals. Emicizumab and Mim8 are indicated in acquired hemophilia or
hemophilia A with inhibitors. TXA was confirmed to reduce bleeding.
Autologous cell salvage is state of the art to reduce transfusion
requirements in major cardiac and noncardiac surgery. Serum phosphate
concentrations should be monitored after administration of intravenous
iron compounds. Copyright © 2022 Wolters Kluwer Health, Inc. All
rights reserved.

<12>
Accession Number
638745161
Title
Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After
Transcatheter Aortic Valve Replacement in Japanese Patients- A Subanalysis
of the ENVISAGE-TAVI AF Trial.
Source
Circulation journal : official journal of the Japanese Circulation
Society. 86(11) (pp 1756-1763), 2022. Date of Publication: 25 Oct 2022.
Author
Watanabe Y.; Hayashida K.; Yamamoto M.; Yamanaka F.; Yamasaki K.; Naganuma
T.; Ohno Y.; Yamawaki M.; Morioka N.; Mizutani K.; Tada N.; Ueno H.;
Nishina H.; Izumo M.; Nakajima Y.; Ando K.; Takagi K.; Kimura T.; Sugio
K.; Dangas G.; Van Mieghem N.M.; Hengstenberg C.; Chen C.; Jin J.;
Unverdorben M.; Saito S.
Institution
(Watanabe) Division of Cardiology, Teikyo University Hospital
(Hayashida) Department of Cardiology, Keio University School of Medicine
(Yamamoto) Department of Cardiology, Toyohashi Heart Center
(Yamanaka) Shonan Kamakura General Hospital
(Yamasaki) Sapporo Higashi Tokushukai Hospital
(Naganuma) New Tokyo Hospital
(Ohno) Tokai University Hospital
(Yamawaki) Saiseikai Yokohama City Eastern Hospital
(Morioka) Department of Cardiology, Kishiwada Tokushukai Hospital
(Mizutani) Department of Cardiovascular Medicine, Osaka City University
Hospital
(Tada) Department of Cardiology, Sendai Kousei Hospital
(Ueno) Department of Cardiology, Toyama University Hospital
(Nishina) Department of Cardiology, Tsukuba Medical Center Hospital
(Izumo) Division of Cardiology, St. Marianna University School of Medicine
Hospital
(Nakajima) Division of Cardiology, Iwate Medical University
(Ando) Department of Cardiology, Kokura Memorial Hospital
(Takagi) Department of Cardiology, Ogaki Municipal Hospital
(Kimura, Sugio) Daiichi Sankyo Co., Ltd
(Dangas) Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai
Hospital
(Van Mieghem) Department of Cardiology, Erasmus University Medical Center,
Thoraxcenter
(Hengstenberg) Division of Cardiology, Vienna General Hospital, Medical
University
(Chen, Jin, Unverdorben) Daiichi Sankyo, Inc
(Saito) Division of Cardiology & Catheterization Laboratories, Shonan
Kamakura General Hospital
Publisher
NLM (Medline)
Abstract
BACKGROUND: Japanese patients undergoing transcatheter aortic valve
replacement (TAVR) are often female and have a small body size,
potentially impacting bleeding risk with antithrombotic therapy. Outcomes
of direct oral anticoagulant use in these patients with atrial
fibrillation (AF) need to be clarified.Methods and Results: This
prespecified analysis included Japanese patients from ENVISAGE-TAVI AF, a
prospective, randomized, open-label, adjudicator-masked trial that
compared treatment with edoxaban and vitamin K antagonists (VKAs) in
patients with AF after TAVR. The primary efficacy and safety outcomes were
net adverse clinical events (NACE; composite of all-cause death,
myocardial infarction, ischemic stroke, systemic embolic event, valve
thrombosis, and International Society on Thrombosis and Haemostasis
[ISTH]-defined major bleeding) and ISTH-defined major bleeding,
respectively. Intention-to-treat (ITT) and on-treatment analyses were
performed. Overall, 159 Japanese patients were enrolled (edoxaban group:
82, VKA group: 77) and followed for on average 483 days. Mean patient age
was 83.8 years; 52.2% were female. In the ITT analysis, NACE rates were
10.9%/year with edoxaban and 12.5%/year with VKA (hazard ratio [HR], 0.85;
95% confidence interval [CI], 0.38-1.90); major bleeding occurred in
8.9%/year and 7.3%/year, respectively (HR, 1.17; 95% CI, 0.45-3.05). In
edoxaban- and VKA-treated patients, rates of ischemic stroke were
1.8%/year and 1.0%/year, respectively; fatal bleeding rates were 0.9%/year
and 2.0 %/year. On-treatment results were similar to ITT.
 CONCLUSION(S): In Japanese patients with AF after successful TAVR,
edoxaban and VKA treatment have similar safety and efficacy profiles.

<13>
Accession Number
638124938
Title
A systematic review and meta-analysis of coronary artery disease and
revascularization in lung transplant patients.
Source
Coronary artery disease. 33(8) (pp 661-669), 2022. Date of Publication: 01
Dec 2022.
Author
Fialka N.M.; Bozso S.J.; El-Andari R.; Kang J.J.; Laing B.; Meyer S.R.;
Nagendran J.
Institution
(Fialka, El-Andari) Faculty of Medicine and Dentistry
(Bozso, Kang, Meyer, Nagendran, Nagendran) Division of Cardiac Surgery,
Department of Surgery
(Laing) Department of Surgery, University of Alberta, Edmonton, AB, Canada
Publisher
NLM (Medline)
Abstract
Coronary artery disease (CAD) is common in candidates for lung
transplantation (LTx) and has historically been considered a relative
contraindication to transplantation. We look to review the outcomes of LTx
in patients with CAD and determine the optimum revascularization strategy
in LTx candidates. PubMed, Medline and Web of Science were systematically
searched by three authors for articles comparing the outcomes of LTx in
patients with CAD and receiving coronary revascularization. In total 1668
articles were screened and 12 were included in this review.Preexisting CAD
in LTx recipients was not associated with significantly increased
postoperative morbidity or mortality. The pooled estimates of mortality
rate at 1, 3 and 5years indicated significantly inferior survival in LTx
recipients with a prior history of coronary artery bypass grafting (CABG)
[odds ratio (OR), 1.84; 95% confidence interval (CI), 1.53-2.22; P
<0.00001; I2 =0%; OR, 1.52; 95% CI, 1.21-1.91; P =0.0003; I2 =0%; OR,
1.62; 95% CI, 1.13-2.33; P =0.008; I2 =71%, respectively). However,
contemporary literature suggests that survival rates in LTx recipients
with CAD that received revascularization either by percutaneous coronary
intervention (PCI), previous or concomitant CABG, are similar to patients
who did not receive revascularization. Trends in postoperative morbidity
favored CABG in the rates of myocardial infarction and repeat
revascularization, whereas rates of stroke favored PCI. The composite
results of this study support the consideration of patients with CAD or
previous coronary revascularization for LTx. Prospective, randomized
controlled trials with consistent patient populations and outcomes
reporting are required to fully elucidate the optimum revascularization
strategy in LTx candidates. Copyright © 2022 Wolters Kluwer
Health, Inc. All rights reserved.

<14>
Accession Number
639388721
Title
Long-term Outcomes of Transcatheter Aortic Valve Replacement With the
Lotus Valve vs CoreValve/EvolutR: A Secondary Analysis of the REPRISE III
Randomized Clinical Trial.
Source
JAMA network open. 5(10) (pp e2238792), 2022. Date of Publication: 03 Oct
2022.
Author
Rizik D.G.; Rajagopal V.; Makkar R.R.; Bajwa T.; Kleiman N.S.; Linke A.;
Kereiakes D.J.; Waksman R.; Thourani V.H.; Stoler R.C.; Mishkel G.J.; Iyer
V.S.; Buchbinder M.; Gotberg M.; Bjursten H.; Allocco D.J.; Reardon M.J.
Institution
(Rizik) Department of Cardiology, HonorHealth and the Scottsdale-Lincoln
Health Network, Scottsdale, AZ, United States
(Rajagopal) Cardiology Department, Piedmont Hospital, Atlanta, Georgia
(Makkar) Cedars-Sinai Medical Center, Los Angeles, CA, United States
(Bajwa) Department of Medicine, Aurora St Luke's Medical Center,
Milwaukee, WI, United States
(Kleiman) Department of Cardiology, Houston Methodist DeBakey Heart and
Vascular Center, Houston, TX, United States
(Linke) Department of Internal Medicine and Cardiology, Technische
Universitat Dresden, Dresden, Germany
(Kereiakes) The Christ Hospital Heart and Vascular Center/The Lindner
Research Center Cincinnati, Cincinnati, OH, United States
(Waksman) Section of Interventional Cardiology, MedStar Washington
Hospital Center, WA, United States
(Thourani) Department of Cardiovascular Surgery, Marcus Valve Center,
Piedmont Heart Institute, Atlanta, Georgia
(Stoler) Baylor Heart & Vascular Hospital, Dallas, TX, United States
(Mishkel) Division of Cardiology, NorthShore University HealthSystem,
University of Chicago Pritzker School of Medicine, Chicago, IL, United
States
(Iyer) Gates Vascular Institute, Interventional Cardiology, University at
Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY, United
States
(Buchbinder) Department of Cardiology, Foundation for Cardiovascular
Medicine, Stanford University, Stanford, CA, United States
(Gotberg) Department of Cardiology, Clinical Sciences, Lund University,
Skane University Hospital, Lund, Sweden
(Bjursten) Department of Cardiothoracic Surgery, Skane University
Hospital, Lund, Sweden
(Allocco) Boston Scientific Corp, Marlborough, Massachusetts
(Reardon) Department of Cardiovascular Surgery, Houston Methodist DeBakey
Heart and Vascular Center, Houston, TX, United States
Publisher
NLM (Medline)
Abstract
Importance: Long-term follow-up after transcatheter aortic valve
replacement (TAVR) is of interest given that longitudinal data on
mortality and durability of transcatheter heart valves are limited. The
REPRISE III (Repositionable Percutaneous Replacement of Stenotic Aortic
Valve Through Implantation of Lotus Valve System-Randomized Clinical
Evaluation) randomized clinical trial compared the mechanically expanded
Lotus valve with the self-expanding CoreValve/EvolutR TAVR platforms.
 Objective(s): To describe the final 5-year outcomes of the REPRISE
III trial. Design, Setting, and Participant(s): This prespecified
secondary analysis assessed the final 5-year clinical, functional, and
echocardiographic outcomes of 912 patients from the REPRISE III trial,
which was conducted at 55 centers in North America, Europe, and Australia
between September 22, 2014, and December 24, 2015. Patients had high risk
for aortic stenosis or severe or symptomatic aortic stenosis. Data were
analyzed from September 22, 2014, to May 21, 2021. Intervention(s):
Lotus valve or CoreValve/EvolutR TAVR platforms. Main Outcomes and
Measures: Valve Academic Research Consortium-2 end points, hemodynamic
measures, functional status, and health status were examined through the
5-year follow-up. Result(s): A total of 912 patients (mean [SD] age,
82.8 [7.3] years; 463 women [50.8%]) were randomized to either the Lotus
valve group (n=607) or CoreValve/EvolutR group (n=305), with a baseline
Society of Thoracic Surgeons risk score of 6.8%. Clinical follow-up data
from the REPRISE III trial were available for 581 patients (95.7%) in the
Lotus valve group and 285 patients (93.4%) in the CoreValve/EvolutR group.
At 5 years, the cumulative event rate for all-cause mortality was 50.9% in
the Lotus valve group vs 52.8% in the CoreValve/EvolutR group (P=.59).
Disabling stroke was less frequent with the Lotus valve vs
CoreValve/EvolutR (cumulative event rates, 8.3% vs 12.2%; P=.04), whereas
the cumulative event rates for overall stroke were similar in both groups
(14.1% vs 15.3%; P=.38). Insertion of a new permanent pacemaker (38.9% vs
27.3%; P<.001) and detection of prosthetic aortic valve thrombosis (5.8%
vs 1.8%; P=.007) were more common in the Lotus valve group than in the
CoreValve/EvolutR group. A smaller proportion of patients who received the
Lotus valve experienced valve malpositioning (0% vs 2.6%; P<.001) and
required the use of a second valve (1.0% vs 3.8%; P<.001) during the
procedure compared with those who received the CoreValve/EvolutR. Compared
with the Lotus valve group, the CoreValve/EvolutR group had a
significantly lower mean (SD) aortic gradient (7.8 [4.2] mm Hg vs 12.6
[6.7] mm Hg; P<.001) and larger valve areas (1.57 [0.56] cm2 vs 1.42
[0.42] cm2; P=.10). After 5 years, the proportion of patients with
moderate or greater paravalvular leak was not significantly higher with
the CoreValve/EvolutR than with the Lotus valve (1.9% vs 0%; P=.31);
however, the proportion of patients with mild paravalvular leak was higher
in the CoreValve/EvolutR group compared with the Lotus valve group (23.1%
vs 7.8%; P=.006). Long-term, similar improvements in New York Heart
Association class and Kansas City Cardiomyopathy Questionnaire score were
observed in both groups. Conclusions and Relevance: The REPRISE III
trial found that, at 5 years, the clinical outcomes of the Lotus valve
were comparable to those of the CoreValve/EvolutR and that the Lotus valve
was safe and effective. Trial Registration: ClinicalTrials.gov Identifier:
NCT02202434.

<15>
Accession Number
639382389
Title
Nociception Level Index-Directed Erector Spinae Plane Block in Open Heart
Surgery: A Randomized Controlled Clinical Trial.
Source
Medicina (Kaunas, Lithuania). 58(10) (no pagination), 2022. Date of
Publication: 16 Oct 2022.
Author
Balan C.; Tomescu D.R.; Valeanu L.; Morosanu B.; Stanculea I.; Coman A.;
Stoian A.; Bubenek-Turconi S.I.
Institution
(Balan, Valeanu, Morosanu, Stanculea, Coman, Stoian, Bubenek-Turconi)
Cardiac Anesthesiology and Intensive Care Department I, Prof. Dr. C.C.
Iliescu Emergency Institute for Cardiovascular Diseases, Bucharest 022328,
Romania
(Balan, Tomescu, Valeanu, Morosanu, Bubenek-Turconi) Anesthesiology and
Intensive Care Department, Carol Davila University of Medicine and
Pharmacy, Bucharest 050474, Romania
(Tomescu) 3rd Department of Anesthesiology and Intensive Care, Fundeni
Clinical Institute, Bucharest 022328, Romania
Publisher
NLM (Medline)
Abstract
Background and Objectives: The erector spinae plane block (ESPB) is a
multimodal opioid-sparing component, providing chest-wall analgesia of
variable extent, duration, and intensity. The objective was to examine the
ESPB effect on perioperative opioid usage and postoperative rehabilitation
when used within a Nociception Level (NOL) index-directed anesthetic
protocol. Material(s) and Method(s): This prospective, randomized,
controlled, open-label study was performed in adult patients undergoing
on-pump cardiac surgery in a single tertiary hospital. Eighty-three adult
patients who met eligibility criteria were randomly allocated to group 1
(Control, n = 43) and group 2 (ESPB, n = 40) and received general
anesthesia with NOL index-directed fentanyl dosing. Preoperatively, group
2 also received bilateral single-shot ultrasound-guided ESPB (1.5
mg/kg/side 0.5% ropivacaine mixed with dexamethasone 8 mg/20 mL).
Postoperatively, both groups received intravenous paracetamol (1 g every 6
h). Morphine (0.03 mg/kg) was administered for numeric rating scale (NRS)
scores >=4. Result(s): The median (IQR, 25th-75th percentiles)
intraoperative fentanyl and 48 h morphine dose in group 2-to-group 1 were
1.2 (1.1-1.5) vs. 4.5 (3.8-5.5) microg.kg-1.h-1 (p < 0.001) and 22.1
(0-40.4) vs. 60.6 (40-95.7) microg/kg (p < 0.001). The median (IQR)
time to extubation in group 2-to-group 1 was 90 (60-105) vs. 360 (285-510)
min (p < 0.001). Two hours after ICU admission, 87.5% of ESPB patients
were extubated compared to 0% of controls (p < 0.001), and 87.5% were
weaned off norepinephrine compared to 46.5% of controls (p < 0.001).
The median NRS scores at 0, 6, 12, 24, and 48 h after extubation were
significantly decreased in group 2. There was no difference in
opioid-related adverse events and length of stay. Conclusion(s): NOL
index-directed ESPB reduced intraoperative fentanyl by 73.3% and 48 h
morphine by 63.5%. It also hastened the extubation and liberation from
vasopressor support and improved postoperative analgesia.

<16>
Accession Number
2019862341
Title
Comparison of the effect of double-lumen endotracheal tubes and bronchial
blockers on lung collapse in video-assisted thoracoscopic surgery: a
systematic review and meta-analysis.
Source
BMC Anesthesiology. 22(1) (no pagination), 2022. Article Number: 330. Date
of Publication: December 2022.
Author
Xiang Y.-Y.; Chen Q.; Tang X.-X.; Cao L.
Institution
(Xiang, Chen, Tang) Department of Anesthesiology, Chongqing Cancer
Institute, Chongqing University Cancer Hospital, Chongqing Cancer
Hospital, 181# Hanyu Road, Shapingba District, Chongqing 400030, China
(Cao) Department of Anesthesiology, Xinqiao Hospital of Army Military
Medical University, 83# Xinqiao Zhengjie, Shapingba District, Chongqing
400037, China
Publisher
BioMed Central Ltd
Abstract
Objective: This meta-analysis compared the quality of lung collapse and
the resultant adverse reactions between the use of double-lumen
endotracheal tubes (DLT) and bronchial blockers (BB) in minimally invasive
thoracic surgery. Method(s): A search was performed in five
bibliographic databases, namely PubMed, Springer, Medline, EMBASE, and
Cochrane Library ignoring the original language, which identified five
randomized controlled trials (RCTs) published on or before December 31,
2021. These studies were subsequently analyzed. All included studies
compared the efficacy and safety of DLT and BB as a lung isolation
technique in surgery. The methodological quality of each study was
assessed by the Cochrane Collaboration's risk of bias tool. The quality of
lung collapse and the malposition rate were adopted as the main outcome
indicators. Alternatively, the intubation time and the incidence of
postoperative sore throat were adopted as secondary indicators.
 Result(s): When either DLT or BB were utilized in minimally invasive
thoracic surgery, no differences were observed in the quality of lung
collapse (odds ratio [OR], 1.00; 95% confidence interval [CI], 0.63 to
1.58), the intubation time (mean difference [MD], 0.06; 95% CI, -1.02 to
1.14), or the malposition rate (OR, 0.88; 95% CI, 0.37 to 2.06). However,
the incidence of postoperative sore throat among patients treated with BB
was significantly lower than that among patients treated with DLT (OR,
5.25; 95% CI, 2.55 to 10.75). Conclusion(s): When utilized in
minimally invasive thoracic surgery, the quality of lung collapse with DLT
was identical to that with BB. However, patients treated with the latter
demonstrated a significantly lower incidence of postoperative sore
throat. Copyright © 2022, The Author(s).

<17>
Accession Number
2019861932
Title
The short-term efficacy of high flow nasal oxygen therapy on
cardiovascular surgical patients: a randomized crossover trial.
Source
BMC Anesthesiology. 22(1) (no pagination), 2022. Article Number: 331. Date
of Publication: December 2022.
Author
Shiho D.; Kusaka Y.; Nakano S.; Umegaki O.
Institution
(Shiho, Kusaka, Nakano, Umegaki) Department of Anesthesiology, Osaka
Medical and Pharmaceutical University, Daigaku-machi 2-7, Takatsuki, Osaka
569-8686, Japan
Publisher
BioMed Central Ltd
Abstract
Background: Oxygen therapy after extubation in the intensive care unit
(ICU) is essential in order to maintain adequate oxygenation, especially
in patients who have undertaken cardiovascular surgery. A Venturi mask
(VM) has been routinely used as an oxygen therapy in the ICU. Recently,
however, the high flow nasal cannula (HFNC) has become available, and this
device can deliver up to 60 L/min of humidified oxygen. The aim of this
study is to evaluate the short-term efficacy between HFNC and VM in
cardiovascular surgical patients. Method(s): Forty patients who
underwent cardiovascular surgery were randomized to either protocol A
(HFNC followed by VM) or protocol B (VM followed by HFNC). After
60-minutes of use with either device, arterial blood gas analysis was
performed, and the PaO<inf>2</inf>/FiO<inf>2</inf> ratio (PFR) was
calculated. Simultaneously, physiological data (respiratory rate, heart
rate, mean arterial pressure, continuous cardiac index, and mixed venous
oxygen saturation) were recorded. During this procedure, FiO<inf>2</inf>
and gas flow were maintained at a fixed rate. These variables were
compared by using the paired t-test, and a p value < 0.05 was considered
significant. All data were expressed as mean (standard deviation).
 Result(s): Thirty-five patients (17 from protocol A and 18 from
protocol B) were enrolled, and 5 patients were excluded from analysis in
accordance with the exit criteria. PaO<inf>2</inf> was significantly
higher in the HFNC group than in the VM group [101.7 (25.9) vs. 91.8
(23.0), mean difference 9.87 (18.5), 95% confidence interval 3.5 to 16.2,
p = 0.003]. Moreover, PFR was significantly higher in the HFNC group than
in the VM group [265.9 (81.4) vs. 238.7 (68.5), p = 0.002]. Moreover,
PaCO<inf>2</inf> was significantly lower in the HFNC group than in the VM
group [33.8 (3.5) vs. 34.7 (2.9), p = 0.033]. The respiratory rate was
significantly lower in the HFNC group than in the VM group [18 (4) vs. 21
(4), p = 0.006], and no significant differences were seen in any of the
other parameters. Conclusion(s): Compared to VM, HFNC ameliorated
oxygenation function and decreased patients' effort in breathing. The
hemodynamic state did not differ between HFNC and VM. Therefore, HFNC can
be used safely in cardiovascular surgical patients. Trial registration:
This trial was registered with the UMIN Clinical Trials Registry (ID
UMIN000016572). Copyright © 2022, The Author(s).

<18>
Accession Number
2019840043
Title
Ross Procedure in Neonate and Infant Populations: A Meta-Analysis Review.
Source
World Journal for Pediatric and Congenital Heart Surgery. 13(6) (pp
759-769), 2022. Date of Publication: November 2022.
Author
Tohme S.; Jiang S.; Farooqi K.; Crystal M.A.; Blitzer D.; Ferrari G.;
Bacha E.; Kalfa D.
Institution
(Tohme, Bacha, Kalfa) Section of Congenital and Pediatric Cardiac Surgery,
Division of Cardiac, Thoracic and Vascular Surgery, Morgan Stanley
Children's Hospital, NewYork -Presbyterian Hospital, Columbia University
Irving Medical Center, New York, NY, United States
(Jiang) Department of Epidemiology, Columbia University Mailman School of
Public Health, New York, NY, United States
(Farooqi, Crystal) Division of Pediatric Cardiology, Morgan Stanley
Children's Hospital, NewYork -Presbyterian Hospital, Columbia University
Irving Medical Center, New York, NY, United States
(Blitzer, Ferrari) Division of Cardiothoracic and Vascular Surgery,
Department of Surgery, Columbia University Irving Medical Center, New
York, NY, United States
Publisher
SAGE Publications Inc.
Abstract
Objective: This study aims to perform a meta-analysis of early and late
outcomes of the Ross/Ross-Konno procedures in neonates/infants.
 Method(s): A meta-analysis was performed in accordance with PRISMA
guidelines. We used Ovid versions of MEDLINE/PubMed for relevant studies
and included those that reported Ross/Ross-Konno operations in
neonates/infants and at least one of the predetermined clinical outcomes.
I2 and double arcsine methods assessed the heterogeneity
between pooled estimates. We used a random-effect model to account for
heterogeneity with MetaXL. We calculated point estimates of a pooled
estimates along with its 95% CI. Result(s): 587 neonate/infant
patients were included with median age of 87.5 days old. The follow-up
range was five days to 23 years. Early mortality reported in 25 studies
with pooled estimates of 18.3% (95% CI: 13.6%-23.5%). Estimates ranged
from 0% to 50% with relatively substantial heterogeneity (P =.01,
I2 = 48.6%). Late mortality reported in 22 studies with pooled
incidence of 9.7% (95% CI: 5.9%-14.3%). Estimates ranged from 0% to 53%
with relatively substantial heterogeneity (P =.01, I2 = 46.1%).
Autograft reintervention reported in 18 studies with pooled estimate of
19.2% (95% CI: 7.3%-34.5%). Estimates ranged from 0% to 81.8% with high
heterogeneity (P <.001, I2 = 90.5%). Right
ventricle-to-pulmonary artery conduit reintervention reported in 16
studies with pooled estimates of 32.0% (95% CI: 20.9%-44.12%). Estimates
ranged from 0% to 92.3% with high heterogeneity (P <.001, I2 =
75.9%). Conclusion(s): The data suggest that the Ross/Ross-Konno
procedure in neonates/infants still carries significant risk of early/late
mortality and autograft/conduit reintervention. The high variability of
results among centers confirms the need for surgical expertise and good
patient selection. Prospective multicenter studies are warranted to
investigate the rate of autograft reintervention and the impact on
long-term survival in this specific population. Copyright © The
Author(s) 2022.

<19>
Accession Number
2019795820
Title
Added Sugar, Sugar-Sweetened Beverages, and Artificially Sweetened
Beverages and Risk of Cardiovascular Disease: Findings from the Women's
Health Initiative and a Network Meta-Analysis of Prospective Studies.
Source
Nutrients. 14(20) (no pagination), 2022. Article Number: 4226. Date of
Publication: October 2022.
Author
Yang B.; Glenn A.J.; Liu Q.; Madsen T.; Allison M.A.; Shikany J.M.; Manson
J.E.; Chan K.H.K.; Wu W.-C.; Li J.; Liu S.; Lo K.
Institution
(Yang, Li, Liu, Lo) Global Health Research Center, Guangdong Provincial
People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou
510030, China
(Yang, Liu, Chan, Wu, Li, Liu, Lo) Centre for Global Cardiometabolic
Health, Departments of Epidemiology and Medicine, Brown University,
Providence, RI 02912, United States
(Glenn) Department of Nutritional Sciences, University of Toronto,
Toronto, ON M5S 1A8, Canada
(Glenn) Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical
Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
Toronto, ON M5C 2T2, Canada
(Glenn) Department of Nutrition, Harvard T.H. Chan School of Public
Health, Boston, MA 02115, United States
(Madsen) Department of Emergency Medicine, Brown University, Providence,
RI 02912, United States
(Allison) Department of Family Medicine, University of California San
Diego, La Jolla, CA 92093, United States
(Shikany) Division of Preventive Medicine, University of Alabama at
Birmingham, Birmingham, AL 35294, United States
(Manson) Division of Preventive Medicine, Department of Medicine, Brigham
and Women's Hospital, Harvard Medical School, Boston, MA 02115, United
States
(Chan) Department of Biomedical Sciences, Department of Electrical
Engineering, City University of Hong Kong, Hong Kong
(Lo) Research Institute for Smart Ageing, The Hong Kong Polytechnic
University, Hong Kong
(Lo) Department of Applied Biology and Chemical Technology, The Hong Kong
Polytechnic University, Hung Hom, Hong Kong
Publisher
MDPI
Abstract
Much remains unknown about the role of added sugar in relation to
cardiovascular disease (CVD) and the relative contributions of
sugar-sweetened beverages (SSB) or artificially sweetened beverages (ASB)
to CVD risk. Among the 109,034 women who participated in Women's Health
Initiative, we assessed average intakes of added sugar, SSB and ASB, and
conducted Cox regression to estimate the hazard ratios (HRs) and their 95%
confidence intervals for CVD risk. The consistency of findings was
compared to a network meta-analysis of all available cohorts. During an
average of 17.4 years of follow-up, 11,597 cases of total CVD (nonfatal
myocardial infarction, coronary heart disease (CHD) death, stroke,
coronary revascularization, and/or incident heart failure) were confirmed.
Added sugar as % energy intake daily (%EAS) at >=15.0% was positively
associated with total CVD (HR = 1.08 [1.01, 1.15]) and CHD (HR = 1.20
[1.09, 1.32]). There was also a higher risk of total CVD associated with
>=1 serving of SSB intake per day (HR = 1.29 [1.17, 1.42]), CHD (1.35
[1.16, 1.57]), and total stroke (1.30 [1.10, 1.53]). Similarly, ASB intake
was associated with an increased risk of CVD (1.14 [1.03, 1.26]) and
stroke (1.24 [1.04, 1.48]). According to the network meta-analysis, there
was a large amount of heterogeneity across studies, showing no consistent
pattern implicating added sugar, ASB, or SSB in CVD outcomes. A diet
containing %EAS >=15.0% and consuming >=1 serving of SSB or ASB may be
associated with a higher CVD incidence. The relative contribution of added
sugar, SSB, and ASB to CVD risk warrants further
investigation. Copyright © 2022 by the authors.

<20>
Accession Number
2018385586
Title
FDG PET/CT in Cardiac Infection: Does It Matter? A Narrative Review.
Source
Infectious Diseases and Therapy. 11(5) (pp 1769-1777), 2022. Date of
Publication: October 2022.
Author
Ghanem-Zoubi N.
Institution
(Ghanem-Zoubi) Infectious Diseases Institute, Rambam Health Care Campus,
Ha-Aliya 8 St, Haifa 3109601, Israel
(Ghanem-Zoubi) The Ruth and Bruce Rappaport Faculty of Medicine, Technion,
Israel Institute of Technology, Haifa, Israel
Publisher
Adis
Abstract
The limited performance of echocardiography in specific infectious
processes involving the heart led to the search for additional diagnostic
tools. Fluorodeoxyglucose positron emission tomography computed tomography
(FDG PET/CT) has been proposed for its diagnostic abilities in several
infectious diseases including cardiac infections. A literature review of
studies evaluating FDG PET/CT in native valve infective endocarditis (IE),
prosthetic valve IE, cardiac implantable electrical device (CIED)
infection, and left ventricular assist device (LVAD) infection is
presented, focusing on studies published in recent years. Overall, in
prosthetic valve endocarditis (PVE), FDG PET/CT demonstrate high
sensitivity (73-93%) and specificity (80-95%), while in native valve
endocarditis (NVE) the sensitivity is very low (22-68%), with high
specificity (97-100%) similar to PVE. For CIED, LVAD infection, and
transcatheter aortic valve implantation associated endocarditis, data come
from small studies and show good diagnostic performance of FDG PET/CT.
International guidelines are increasingly recommending FDG PET/CT for the
diagnosis of specific conditions of cardiac infections. Beyond the
diagnostic performance ability, few studies have evaluated the added
benefit of FDG PET/CT in terms of clinical outcomes of patients with
suspected cardiac infection. This should be the focus in future
studies. Copyright © 2022, The Author(s).

<21>
Accession Number
2015666572
Title
A novel nomogram predicting the risk of postoperative pneumonia for
esophageal cancer patients after minimally invasive esophagectomy.
Source
Surgical Endoscopy. 36(11) (pp 8144-8153), 2022. Date of Publication:
November 2022.
Author
Jin D.; Yuan L.; Li F.; Wang S.; Mao Y.
Institution
(Jin, Yuan, Li, Wang, Mao) Department of Thoracic Surgery, National Cancer
Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College,
Beijing 100021, China
Publisher
Springer
Abstract
Background: Pneumonia is a common complication after minimally invasive
esophagectomy (MIE), which prolongs hospital stay, adding to the cost and
increasing the risk to patients' lives. This study aimed to identify risk
factors and establish a predictive nomogram for postoperative pneumonia
(PP). Method(s): This case control study included 609 patients with
esophageal cancer who underwent MIE between March 2015 and August 2019 in
Cancer Hospital, Chinese Academy of Medical Sciences. We randomly divided
the data into training and validation sets in the ratio of 7:3 and
performed univariate and multivariate logistic regression analyses to
acquire independent risk factors of the training set. We constructed a
nomogram based on the independent risk factors. The concordance index
(C-index), receiver operating characteristic (ROC) curve, calibration
plot, and decision curve analysis (DCA) plots were used to evaluate the
discrimination of the nomogram. Validation set was applied to confirm the
predictive value of the nomogram. Result(s): In the univariate
analysis, age, gender, abdominal procedure method, thoracic operative
time, duration of chest tube placement, anastomotic leakage, and recurrent
laryngeal nerve palsy were found to be correlated with the incidence of
PP. In multivariate analysis, all variables except thoracic operative time
were found to be independent risk factors for PP. A nomogram was
constructed based on these independent risk factors. The C-index of the
training and validation sets was 0.769 and 0.734, respectively, and the
areas under the curve (AUC) of ROC curves of the training and validation
sets were 0.769 and 0.686, respectively. The calibration plots and DCA
plots of the training and validation sets showed the accuracy and
predictive value of the nomogram. Conclusion(s): The nomogram could
accurately identify the risk factors for PP. We could predict the
occurrence of PP based on this nomogram and take corresponding measures to
reduce the incidence of PP. Graphical abstract: [Figure not available: see
fulltext.]. Copyright © 2022, The Author(s), under exclusive
licence to Springer Science+Business Media, LLC, part of Springer Nature.

<22>
Accession Number
639389752
Title
Feasibility of selective coronary angiography and percutaneous coronary
intervention following self-expanding transcatheter aortic valve
replacement: a systematic review and meta-analysis.
Source
Coronary artery disease. 33(8) (pp 678-681), 2022. Date of Publication: 01
Dec 2022.
Author
Gin J.H.; Castles A.; Koshy A.N.; Yudi M.B.
Institution
(Gin, Castles, Koshy, Yudi) Department of Cardiology, Austin Health
(Castles, Koshy, Yudi) Department of Medicine, University of Melbourne,
Melbourne, VIC, Australia
Publisher
NLM (Medline)

<23>
Accession Number
2020958017
Title
Pulsatile Perfusion during Cardiopulmonary Bypass: A Literature Review.
Source
Journal of Extra-Corporeal Technology. 2022(54) (pp 50-60), 2022. Date of
Publication: 2022.
Author
Tan A.; Newey C.; Falter F.
Institution
(Tan, Falter) Department of Anaesthetics and Intensive Care, Royal
Papworth Hospital, Cambridge, United Kingdom
(Newey) Department of Clinical Perfusion, Royal Papworth Hospital,
Cambridge, United Kingdom
Publisher
American Society of Extra-Corporeal Technology
Abstract
The use of cardiopulmonary bypass (CPB) in cardiac surgery has often been
associated with postoperative organ dysfunction. Roller and centrifugal
pumps produce non-pulsatile flow (NPF) by default, and this still is the
most widely used mode of perfusion. The development of pulsatile pumps has
allowed comparisons to be made with NPF. Pulsatile flow (PF) mimics the
arterial pulse generated by the heart and is thought to be more
physiological by some. This review aims to examine the proposed mechanisms
behind the potential physiological benefits of PF during CPB and to
summarize the current clinical evidence. MEDLINE and EMBASE were used to
identify articles published over a 25 year period from 1995 to 2020. A
literature review was conducted to determine the effects of PF on organ
functions. A total of 44 articles were considered. Most of the articles
published on PF were randomized controlled trials (RCTs). However, there
was a wide variation in study methodology, method of pulse generation and
how pulsatility was measured. Most of the evidence in favor of PF showed a
marginal improvement on renal and pulmonary outcomes. In these studies,
pulsatility was generated by an intra-aortic balloon pump. In conclusion,
there is a lack of good quality RCTs that can inform on the short- and
long-term clinical outcomes of PF. Further research is required in order
to draw a conclusion with regards to the benefits of PF on organ
function. Copyright © 2022 American Society of Extra-Corporeal
Technology. All rights reserved.

<24>
Accession Number
2020869964
Title
Effects of propofol and inhaled anesthetics on postoperative complications
for the patients undergoing one lung ventilation: A meta-analysis.
Source
PLoS ONE. 17(10 October) (no pagination), 2022. Article Number: e0266988.
Date of Publication: October 2022.
Author
Yang J.; Huang Q.; Cao R.; Cui Y.
Institution
(Yang, Huang, Cao, Cui) Department of Anesthesiology, The Affiliated
Hospital, School of Medicine, UESTC Chengdu Women's & Children's Central
Hospital, Chengdu, China
Publisher
Public Library of Science
Abstract
Introduction With the widespread use of one-lung ventilation (OLV) in
thoracic surgery, it is unclear whether maintenance anesthetics such as
propofol and inhaled anesthetics are associated with postoperative
complications. The purpose of this study was to compare the effects of
propofol and inhaled anesthetics on postoperative complications in OLV
patients. Methods PubMed, EMBASE, Medline, and Cochrane Library were
searched for relevant randomized controlled trials until 09/2021. All
randomized controlled trials comparing the effect of propofol versus
inhaled anesthetics on postoperative complications in OLV patients were
included. All randomized controlled trials comparing:(a) major
complications (b) postoperative pulmonary complications (c) postoperative
cognitive function (MMSE score) (d) length of hospital stay (e) 30-day
mortality, were included. Results Thirteen randomized controlled trials
involving 2522 patients were included in the analysis. Overall, there was
no significant difference in major postoperative complications between the
inhaled anesthetic and propofol groups (OR 0.78, 95%CI 0.54 to 1.13, p =
0.19; I2 = 0%). However, more PPCs were detected in the
propofol group compared to the inhalation anesthesia group (OR 0.62, 95%CI
0.44 to 0.87, p = 0.005; I2 = 37%). Both postoperative MMSE
score (SMD -1.94, 95%CI -4.87 to 0.99, p = 0.19; I2 = 100%) and
hospital stay (SMD 0.05, 95%CI -0.29 to 0.39, p = 0.76; I2 =
73%) were similar between the two groups. The 30-day mortality rate was
also not significantly different between groups (OR 0.79, 95%CI 0.03 to
18, p = 0.88; I2 = 63%). Conclusions In patients undergoing
OLV, general anesthesia with inhaled anesthetics reduced PPC compared to
propofol, but did not provide clear benefits on other major complications,
cognitive function, length of hospital stay, or mortality. Copyright:
© 2022 Yang et al. This is an open access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.

<25>
Accession Number
639392510
Title
Stroke prevention of thoracoscopic left atrial appendage clipping in
patients with non-valvular atrial fibrillation at high risk of stroke and
bleeding: study protocol for a non-randomised controlled clinical trial.
Source
BMJ open. 12(10) (pp e063931), 2022. Date of Publication: 28 Oct 2022.
Author
Ye C.; Han X.; Chen Y.; Liu F.; Ma H.; Yang Y.; Liu Y.; Hu Q.; Yao Q.; Xie
W.; Xu D.
Institution
(Ye) Department of Cardiac Surgery, Capital Medical University, Beijing,
China
(Ye, Han, Chen, Liu, Ma, Yang, Liu, Hu, Yao, Xie, Xu) Department of
Cardiac Surgery, Beijing Tiantan Hospital, Beijing, China
Publisher
NLM (Medline)
Abstract
INTRODUCTION: Non-valvular atrial fibrillation (NVAF) is a high-risk
factor for ischaemic stroke. The 2016 European Society of Cardiology
Atrial Fibrillation Management guidelines recommend oral anticoagulants
(OACs) to prevent stroke in men with CHA2DS2-VASc scores >=2and women >=3.
However, in patients with a high risk of stroke and a high risk of
bleeding (HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke,
Bleeding history or predisposition, Labile international normalized ratio,
Elderly (> 65 years), Drugs/alcohol concomitantly) score>=3), OAC had a
higher risk of bleeding. Left atrial appendage closure (LAAC) is
non-inferior to OAC as a means of preventing stroke in several studies. As
a minimally invasive intervention to prevent stroke, transthoracic LAAC
(TS-LAAC) has a high successful closure rate, but there is a lack of
literature reports directly comparing it with OAC. Our research compares
TS-LAAC with novel oral anticoagulants (NOACs) and provides an appropriate
programme for stroke prevention in a specific population. METHODS AND
ANALYSIS: This is a non-randomised controlled trial study protocol, and we
will conduct this study from April 2022 to April 2025. The study included
186 patients with confirmed NVAF, 93 of whom completed thoracoscopic LAAC,
and the control group treated with NOACs. The primary outcome was the
incidence of stroke and systemic embolism, as well as the composite
endpoint events (stroke, systemic embolism, myocardial infarction,
bleeding, cardiovascular death, etc). Secondary outcomes were ischaemic
stroke, haemorrhagic stroke, any bleeding events, death from
cardiovascular causes, death from all causes, residual root rate in the
surgery group, device-related thrombosis in the surgery group, changes in
blood pressure, cardiac chamber size changes, etc. Each subject completed
at least 1year of follow-up. ETHICS AND DISSEMINATION: The study has been
approved by the Medical Ethics Committee of Beijing Tiantan Hospital,
Capital Medical University, China (approval number: KY2022-013-02). The
results from this study will be disseminated through manuscript
publications and national/international conferences. TRIAL REGISTRATION
NUMBER: ChiCTR2200058109. Copyright © Author(s) (or their
employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use.
See rights and permissions. Published by BMJ.

<26>
Accession Number
639392143
Title
Recruitment manoeuvres during mechanical ventilation with sequential
high-flow nasal oxygen after extubation to prevent postoperative pulmonary
complications in patients undergone thoracic surgery: a protocol,
prospective randomised controlled trial.
Source
BMJ open. 12(10) (pp e056438), 2022. Date of Publication: 28 Oct 2022.
Author
Wang Z.; Wang B.; Xia W.; Wang P.; Liang G.; Mei J.D.; Zhang Y.-G.; Yan K.
Institution
(Wang, Xia) Department of Respiratory Care, Sichuan University West China
Hospital, Chengdu, Sichuan, China
(Wang) Department of Critical Care Medicine, Sichuan University West China
Hospital, Chengdu, Sichuan, China
(Wang) Department of Respiratory Care, Sichuan University, Chengdu,
Sichuan, China
(Liang) Department of Critical Care Medicine, Sichuan University West
China Hospital, Chengdu, Sichuan, China
(Liang) Sichuan Provincial Clinical Research Center for Emergency and
Critical Care Medicine, Sichuan University West China Hospital, Chengdu,
Sichuan, China
(Mei) Department of Thoracic Surgery, Sichuan University, Chengdu,
Sichuan, China
(Zhang) Department of Periodical Press and National Clinical Research
Center for Geriatrics, West China Hospital, Chengdu, Sichuan, China
(Yan) Department of Critical Care Medicine, Sichuan University West China
Medical Center, Chengdu, Sichuan, China
Publisher
NLM (Medline)
Abstract
INTRODUCTION: The incidence of postoperative pulmonary complications
(PPCs) following thoracic surgery is high, which increases the mortality
rate, prolongs the length of hospital stay and increases medical costs.
Some studies have confirmed that preoperative risk assessment,
intraoperative anaesthesia methods and intraoperative mechanical
ventilation strategies, including recruitment manoeuvres (RMs), can reduce
the incidence of PPCs. Despite these improved strategies, the incidence of
PPCs remains high. However, mechanical ventilation strategies have not
been studied in the postoperative period. METHODS AND ANALYSIS: We assume
that RM during mechanical ventilation with sequential high-flow nasal
oxygen therapy (HFNO) after extubation can maintain the opening of the
postoperative alveoli and ultimately reduce the incidence of PPCs after
thoracic surgery. We will include thoracic surgery patients and divide
them into the RM with sequential HFNO group and the control group. They
will be given RMs and sequential HFNO or be given conventional treatment.
The sample size is 654 adult patients (327 per group) undergone thoracic
surgery and presenting to the intensive care unit. ETHICS AND
DISSEMINATION: This study was approved by the Biomedical Research Ethics
Committee of West China Hospital of Sichuan University (REC2019-730). It
is expected that this study will lead to a randomised controlled trial. We
assume that the findings will provide more evidence about PPCs and improve
the management of patients undergone thoracic surgery. TRIAL REGISTRATION
NUMBER: ChiCTR2100046356. Copyright © Author(s) (or their
employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use.
See rights and permissions. Published by BMJ.

<27>
Accession Number
639392088
Title
Vitamin C supplementation attenuates oxidative stress and improves
erythrocyte deformability in cardiac surgery with cardiopulmonary bypass.
Source
The Chinese journal of physiology. 65(5) (pp 241-249), 2022. Date of
Publication: 01 Sep 2022.
Author
Tai Y.-H.; Wu H.-L.; Chu Y.-H.; Huang C.-H.; Ho S.-T.; Lin T.-C.; Lu C.-C.
Institution
(Tai) Department of Anesthesiology, Shuang Ho Hospital, Taipei Medical
University, New Taipei City; Department of Anesthesiology, School of
Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
(Wu) Department of Anesthesiology, Taipei Veterans General Hospital;
School of Medicine, National Yang Ming Chiao Tung University, Taipei,
Taiwan
(Chu) Department of Anesthesiology, Taipei Veterans General Hospital;
Graduate Institute of Life Sciences, National Defense Medical Center,
Taipei, Taiwan
(Huang) School of Medicine, National Yang Ming Chiao Tung University;
Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans
General Hospital, Taipei, Taiwan
(Ho) Department of Anesthesiology, Tri-Service General Hospital, National
Defense Medical Center, Taipei; Department of Anesthesiology, Kaohsiung
Medical University Hospital, Kaohsiung Medical University, Kaohsiung,
Taiwan
(Lin) Department of Anesthesiology, Tri-Service General Hospital, National
Defense Medical Center, Taipei, Taiwan (Republic of China)
(Lu) Department of Anesthesiology, Taipei Veterans General Hospital;
Graduate Institute of Life Sciences; Institute of Aerospace Medicine,
National Defense Medical Center, Taipei, Taiwan
Publisher
NLM (Medline)
Abstract
Cardiopulmonary bypass (CPB) depletes endogenous Vitamin C and generates
oxidative stress in cardiac surgery. This study aimed to clarify whether
Vitamin C supplementation reduces oxidant production and improves
erythrocyte deformability in cardiac surgery with CPB. In a randomized and
controlled design, 30 eligible patients undergoing cardiac surgery with
hypothermic CPB were equally assigned to the Vitamin C group and control
group. Subjects of the Vitamin C group and control group received an
intravenous infusion of Vitamin C 20 mg.kg-1 and a placebo during
rewarming period of CPB, respectively. We measured the plasma level of
reactive oxygen species (ROS) and phosphorylation levels of non-muscle
myosin IIA (NMIIA) in erythrocyte membrane, as an index of erythrocyte
deformability, before and after CPB. Vitamin C supplementation attenuated
the surge in plasma ROS after CPB, mean 1.661 +/- standard deviation 0.801
folds in the Vitamin C group and 2.743 +/- 1.802 in the control group. The
tyrosine phosphorylation level of NMIIA after CPB was upregulated in the
Vitamin C group compared to the control group, 2.159 +/- 0.887 folds and
1.384 +/- 0.445 (P = 0.0237). In addition, the phosphorylation of
vasodilator-stimulated phosphoprotein (VASP) and focal adhesion kinase
(FAK) in erythrocytes was concurrently enhanced in the Vitamin C group
after CPB. The phosphorylation level of endothelial nitric oxide synthase
in erythrocytes was significantly increased in the Vitamin C group (1.734
+/- 0.371 folds) compared to control group (1.102 +/- 0.249; P = 0.0061).
Patients receiving Vitamin C had lower intraoperative blood loss and
higher systemic vascular resistance after CPB compared to controls.
Vitamin C supplementation attenuates oxidative stress and improves
erythrocyte deformability via VASP/FAK signaling pathway in erythrocytes
during CPB.

<28>
Accession Number
639392020
Title
Development and internal validation of a prediction model for acute kidney
injury following cardiac valve replacement surgery.
Source
International journal of cardiology. (no pagination), 2022. Date of
Publication: 25 Oct 2022.
Author
Pan L.; Deng Y.; Dai S.; Feng X.; Feng L.; Yang Z.; Liao Y.; Zheng B.
Institution
(Pan, Deng, Dai, Feng, Yang) Department of Nephrology, First Affiliated
Hospital of Guangxi Medical University, China
(Feng) Department of Cardiac surgery, First Affiliated Hospital of Guangxi
Medical University, China
(Liao) Department of Nephrology, First Affiliated Hospital of Guangxi
Medical University, China
(Zheng) Department of Cardiac surgery, First Affiliated Hospital of
Guangxi Medical University, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: Acute kidney injury (AKI) is a common complication after
cardiac surgery. This study aims to develop and validate a risk model for
predicting AKI after cardiac valve replacement surgery. METHOD(S):
Data from patients undergoing surgical valve replacement between January
2015 and December 2018 in our hospital were retrospectively analyzed. The
subjects were randomly divided into a derivation cohort and a validation
cohort at a ratio of 7:3. The primary outcome was defined as AKI within
7days after surgery. Logistic regression analysis was conducted to select
risk predictors for developing the prediction model. Receiver operator
characteristic curve (ROC), calibration plot and clinical decision curve
analysis (DCA) will be used to evaluate the discrimination, precision and
clinical benefit of the prediction model. RESULT(S): A total of 1159
patients were involved in this study. The prevalence of AKI following
surgery was 37.0% (429/1159). Logistic regression analysis showed that
age, hemoglobin, fibrinogen, serum uric acid, cystatin C, bicarbonate, and
cardiopulmonary bypass time were independent risk factors associated with
AKI after surgical valve replacement (all P<0.05). The areas under the ROC
curves (AUCs) in the derivation cohort and the validation cohort were
0.777 (95% CI 0.744-0.810) and 0.760 (95% CI 0.706-0.813), respectively.
The calibration plots indicated excellent consistency between the
prediction probability and actual probability. DCA demonstrated great
clinical benefit of the prediction model. CONCLUSION(S): We developed
a prediction model for predicting AKI after cardiac valve replacement
surgery that was internally validated to have good discrimination,
calibration, and clinical practicability. Copyright © 2022.
Published by Elsevier B.V.

<29>
Accession Number
639388663
Title
Volatile Versus Total Intravenous Anesthesia on Postoperative Delirium in
Adult Patients Undergoing Cardiac Valve Surgery: A Randomized Clinical
Trial.
Source
Anesthesia and analgesia. (no pagination), 2022. Date of Publication: 27
Oct 2022.
Author
Jiang J.-L.; Zhang L.; He L.-L.; Li X.-F.; Dai S.-H.; Yu H.
Institution
(Jiang, Zhang, Yu, Li, Dai, Yu) From the Department of Anesthesiology,
West China Hospital, Sichuan University, Chengdu, China
(He) Department of Anesthesiology, Sichuan Jinxin Women and Children's
Hospital, Chengdu, Sichuan, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: The effect of anesthesia regimens on postoperative delirium
after on-pump cardiac valve surgery is yet undetermined. This study aimed
to evaluate the effect of volatile anesthesia compared with propofol-based
total intravenous anesthesia (TIVA) on the occurrence of delirium after
on-pump cardiac valve surgery. METHOD(S): This randomized clinical
trial was conducted at a university academic hospital in China, from
February 2019 to January 2021. Patients scheduled for on-pump cardiac
valve surgery or combined valve with coronary artery bypass grafting
(CABG) surgeries were randomly assigned to receive anesthesia maintenance
with either a volatile anesthetic (sevoflurane or desflurane) or
propofol-based TIVA. The primary outcome was the incidence of delirium
during the first 7 days after surgery, assessed using the confusion
assessment method for the intensive care unit (ICU). The secondary
outcomes included duration of delirium, subtypes of delirium, 30-day
mortality, pain score, major morbidity (including cerebral infarction,
respiratory failure, and pneumonia), duration of mechanical ventilation,
and lengths of ICU and hospital stay. The statistical analysis of the
primary outcome variable was by Pearson's chi2 test. RESULT(S): Among
the 684 patients analyzed (mean age, 53.8 years; 381 [55.7%] women), 676
were assessed for the primary outcome. Postoperative delirium occurred in
63 of 337 (18.7%) patients receiving volatile anesthesia versus 76 of 339
(22.4%) patients receiving propofol-based TIVA (relative risk, 0.80; 95%
confidence interval [CI], 0.55-1.16; P = .231). There were no significant
differences between the groups in any of the secondary outcomes.
 CONCLUSION(S): Among patients undergoing on-pump cardiac valve
surgery, anesthesia maintenance with a volatile agent did not result in
significantly fewer occurrences of postoperative delirium than
propofol-based TIVA. Copyright © 2022 International Anesthesia
Research Society.

<30>
Accession Number
639396489
Title
Days at Home after Transcatheter or Surgical Aortic Valve Replacement in
High-Risk Patients.
Source
American heart journal. (no pagination), 2022. Date of Publication: 26
Oct 2022.
Author
Chung M.; Butala N.-M.; Faridi K.-F.; Almarzooq Z.-I.; Liu D.; Xu J.; Song
Y.; Baron S.-J.; Shen C.; Kazi D.-S.; Yeh R.-W.
Institution
(Chung) Department of Anesthesia, Critical Care and Pain Medicine,
Massachusetts General Hospital, Boston, MA; Smith Center for Outcomes
Research in Cardiology, Division of Cardiovascular Medicine, Department of
Medicine, Beth Israel Deaconess Medical Center, Boston, MA
(Butala) Department of Medicine, University of Colorado School of
Medicine, Aurora, CO, United States
(Faridi) Section of Cardiovascular Medicine, Department of Medicine, Yale
School of Medicine, New Haven, CT, United States
(Almarzooq) Smith Center for Outcomes Research in Cardiology, Division of
Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess
Medical Center, Boston, MA; Division of Cardiovascular Medicine,
Department of Medicine, Brigham and Women's Hospital, Boston, MA
(Liu) Baim Institute for Clinical Research, Boston, MA, United States
(Xu, Song, Kazi, Yeh) Smith Center for Outcomes Research in Cardiology,
Division of Cardiovascular Medicine, Department of Medicine, Beth Israel
Deaconess Medical Center, Boston, MA; Division of Cardiovascular Medicine,
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
(Baron) Smith Center for Outcomes Research in Cardiology, Division of
Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess
Medical Center, Boston, MA; Department of Cardiology, Lahey Hospital &
Medical Center, Burlington, MA
(Shen) Smith Center for Outcomes Research in Cardiology, Division of
Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess
Medical Center, Boston, MA; Biogen, Cambridge, MA
Publisher
NLM (Medline)
Abstract
BACKGROUND: DAH quantifies time spent at home after a medical event but
has not been fully evaluated for TAVR. We sought to compare 1- and 5-year
Days at Home (DAH365, DAH1825) among high-risk patients participating in a
randomized trial of transcatheter aortic valve replacement (TAVR) with a
self-expanding bioprosthesis versus surgical aortic valve replacement
(SAVR). METHOD(S): We linked data from the U.S. CoreValve High Risk
Trial to Medicare Fee-for-Service claims in 456 patients with 450 (234
TAVR/216 SAVR) and 427 (222 TAVR/205 SAVR) analyzed at 1- and 5-years. DAH
was calculated as the number of days alive and spent outside of a
hospital, skilled nursing facility, rehabilitation, long-term acute care
hospital, emergency department, or observation stay. RESULT(S): Mean
DAH365 was higher in patients who underwent TAVR compared with SAVR
(295.1+/-106.9 vs. 267.8+/-122.3, difference in days 27.2 [95% CI 6.0,
48.5], p=0.01). Compared with SAVR, TAVR patients had a shorter index
length of stay (LOS) (7.4+/-4.5 vs. 12.5+/-9.0, difference in days -5.1
[-6.5, -3.8], p<0.001). The largest contributions to decreased DAH365 were
mortality days and total facility days after discharge from the index
hospitalization (mortality days-TAVR:34.7+/-93.1 vs. SAVR:48.0+/-108.8,
difference in days -13.3 [95% CI -32.1, 5.5], p=0.17; total facility
days-TAVR: 27.9+/-47.4 vs. SAVR: 36.7+/-48.9, difference in days -8.8
[-17.8, 0.1], p=0.05). Mean DAH1825 was numerically but not statistically
significantly higher in TAVR (TAVR:1154.2+/-659.0 vs. SAVR:1067.6+/-697.3,
difference in days 86.6 [95% CI -42.3, 215.6], p=0.19). Landmark analysis
showed no difference in DAH from years 1-5 (TAVR:1040.4+/-477.5 vs.
SAVR:1022.9+/-489.3, p=0.74). CONCLUSION(S): In the U.S. CoreValve
High Risk Trial linked to Medicare, high-risk patients undergoing TAVR
spend an average of 27 additional DAH compared with SAVR in the first year
after the procedure due to a shorter index LOS and the additive effect of
fewer but non-significantly different mortality and total facility days
after discharge from the index hospitalization compared with SAVR. After
the first year, both groups spend a similar number of days at home. These
results describe the postprocedural course of high-risk patients from a
patient-centered perspective, which may guide expectations regarding
longitudinal healthcare needs and inform shared
decision-making. Copyright © 2022. Published by Elsevier Inc.

<31>
Accession Number
639395973
Title
Big Data in cardiac surgery: real world and perspectives.
Source
Journal of cardiothoracic surgery. 17(1) (pp 277), 2022. Date of
Publication: 29 Oct 2022.
Author
Montisci A.; Palmieri V.; Vietri M.T.; Sala S.; Maiello C.; Donatelli F.;
Napoli C.
Institution
(Montisci) Division of Cardiothoracic Intensive Care, Cardiothoracic
Department, ASST Spedali Civili, Brescia 25123, Italy
(Palmieri, Maiello) Department of Cardiac Surgery and Transplantation,
Naples, Italy
(Vietri) Department of Precision Medicine, University of Campania Luigi
Vanvitelli, Naples, Italy
(Sala) Division of Anesthesiology, Intensive Care and Emergency Medicine,
University of Brescia, Brescia, Italy
(Donatelli) Department of Cardiac Surgery, Istituto Clinico Sant'Ambrogio,
Milan, Italy
(Donatelli) Chair of Cardiac Surgery, University of Milan, Milan, Italy
(Napoli) Clinical Department of Internal Medicine and Specialistics,
University Department of Advanced Clinical and Surgical Sciences,
University of Campania Luigi Vanvitelli, Naples, Italy
Publisher
NLM (Medline)
Abstract
Big Data, and the derived analysis techniques, such as artificial
intelligence and machine learning, have been considered a revolution in
the modern practice of medicine. Big Data comes from multiple sources,
encompassing electronic health records, clinical studies, imaging data,
registries, administrative databases, patient-reported outcomes and OMICS
profiles. The main objective of such analyses is to unveil hidden
associations and patterns. In cardiac surgery, the main targets for the
use of Big Data are the construction of predictive models to recognize
patterns or associations better representing the individual risk or
prognosis compared to classical surgical risk scores. The results of these
studies contributed to kindle the interest for personalized medicine and
contributed to recognize the limitations of randomized controlled trials
in representing the real world. However, the main sources of evidence for
guidelines and recommendations remain RCTs and meta-analysis. The extent
of the revolution of Big Data and new analytical models in cardiac surgery
is yet to be determined. Copyright © 2022. The Author(s).

<32>
Accession Number
639394766
Title
The Effect of Massage Therapy on Pain after Surgery: A Comprehensive
Meta-analysis.
Source
Complementary therapies in medicine. (pp 102892), 2022. Date of
Publication: 26 Oct 2022.
Author
Liu C.; Wu S.; Chen X.
Institution
(Liu, Wu) Second Affiliated Hospital of Wenzhou Medical University
(Chen) The Second Affiliated Hospital of Wenzhou Medical University;
Director of Rehabilitation Department, The Second Affiliated Hospital of
Wenzhou Medical University. Electronic address: 516307535@qq.com
Publisher
NLM (Medline)
Abstract
BACKGROUND: Findings on the usefulness of massage therapy (MT) in
postoperative pain management are often inconsistent among studies.
 OBJECTIVE(S): This study's aim is to conduct a meta-analysis of
randomized controlled trials (RCT) to clarify the effects of massage
therapy in the treatment of postoperative pain. METHOD(S): Three
databases (PubMed, Embase, and Cochrane Central Register of Controlled
Trials) were searched for RCTs published from database inception through
January 26, 2021. The primary outcome was pain relief. The quality of RCTs
was appraised with the Cochrane Collaboration risk of bias tool. The
random-effect model was used to calculate the effect sizes and
standardized mean difference (SMD) with 95% confidential intervals (CIs)
as a summary effect. The heterogeneity test was conducted through I2.
Subgroup and sensitivity analyses were used to explore the source of
heterogeneity. Possible publication bias was assessed using visual
inspection of funnel plot asymmetry. RESULT(S): The analysis included
33 RCTs and showed that MT is effective in reducing postoperative pain
(SMD, -1.32; 95% CI, -2.01 to -0.63; p = 0.0002; I2 = 98.67%). A similar
significant effect was found for both short (immediate assessment) and
long terms (assessment performed 4 to 6 weeks after the MT). Remarkably,
we found neither the duration per session nor the dose had an impact on
the effect of MT and there seemed to be no difference in the effects of
different MT types. In addition, MT seemed to be more effective for
adults. Furthermore, MT had better analgesic effects on cesarean section
and heart surgery than orthopedic surgery. LIMITATIONS: Publication bias
is possible due to the inclusion of studies in English only. Additionally,
the included studies were extremely heterogeneous. Double-blind research
on MT is difficult to implement, and none of the included studies is
double-blind. There was some heterogeneity and publication bias in the
included studies. In addition, there is no uniform evaluation standard for
the operation level of massage practitioners, which may lead to research
implementation bias. CONCLUSION(S): MT is effective in reducing
postoperative pain in both short and long terms. Copyright ©
2022. Published by Elsevier Ltd.

<33>
Accession Number
639396916
Title
Early anticoagulation after aortic valve replacement with porcine
bioprosthesis randomized control trial(ANTIPRO).
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. (no pagination), 2022.
Date of Publication: 29 Oct 2022.
Author
Fernandez A.; Loza G.; Parma G.; Florio L.; Estigarribia J.; Soca G.;
Robaina R.; Duran A.; Brusich D.; Dayan V.
Institution
(Fernandez, Estigarribia, Soca, Robaina, Dayan) Instituto Nacional de
Cirugia Cardiaca. Montevideo, Uruguay
(Loza, Parma, Florio, Duran, Brusich, Dayan) Centro Cardiovascular
Universitario, Universidad de la Republica del Uruguay. Montevideo,
Uruguay
Publisher
NLM (Medline)
Abstract
OBJECTIVE: Most evidence for anticoagulation in aortic bioprosthesis is
centered on embolic events, bleeding and reintervention risk. The effect
of anticoagulation on haemodynamics has not been previously assessed. Our
hypothesis was that patients with early AC after aortic valve replacement
with porcine bioprosthesis have better haemodynamics at 1year of
follow-up. METHOD(S): Prospective, randomized, open label trial
conducted at two cardiac surgery centers. All patients undergoing aortic
valve replacement with porcine bioprosthesis were consecutively recruited.
The anticoagulated group received warfarin+aspirin and the
non-anticoagulated(control) only aspirin. The primary outcome was mean
gradient after 1year of aortic valve replacement and change in New York
Heart Association class. Secondary outcomes were major and minor bleeding,
embolic events and prosthetic leak. RESULT(S): Of 140 participants in
the study, 71 were assigned to the anticoagulated group and 69 to the
control group. Mean age of the overall population was 72.4(SD: 7.1) years.
Global euroSCORE was 7.65(SD: 5.73). At 1year the mean gradient was
similar between both groups (18.6(SD: 1.1mmHg) and 18.1(SD: 1.0mmHg) in
the control and anticoagulated group respectively, p=0.701). No
differences in functional class at 3months or 1year were found among
groups. No differences were found among groups in the in the secondary
outcomes. CONCLUSION(S): The addition of 3months of oral
anticoagulation to anti-aggregation treatment was not detected to affect
bioprosthetic haemodynamics nor functional class at one year after aortic
valve replacement. Likewise, anticoagulation does not lead to higher
incidence of complications. CLINICAL TRIAL REGISTRY NUMBER:
NCT03807921. Copyright © The Author(s) 2022. Published by Oxford
University Press on behalf of the European Association for Cardio-Thoracic
Surgery. All rights reserved.

<34>
Accession Number
2016884135
Title
Meta-Analysis Comparing Direct Oral Anticoagulants Versus Vitamin K
Antagonists in Patients With Atrial Fibrillation Who Underwent
Bioprosthetic Valve Replacement.
Source
American Journal of Cardiology. 169 (pp 148-149), 2022. Date of
Publication: 15 Apr 2022.
Author
Shaikh S.; Mohamed M.M.G.; Osman M.; Kheiri B.
Institution
(Shaikh, Mohamed) Internal Medicine Department, SSM Health St. Mary's
Hospital-St. Louis, Missouri, St Louis
(Osman, Kheiri) Knight Cardiovascular Institute, Oregon Health & Science
University, Oregon, Portland
Publisher
Elsevier Inc.

<35>
Accession Number
2016445086
Title
End-Diastolic Forward Flow and Restrictive Physiology in Repaired
Tetralogy of Fallot: A Systematic Review and Meta-Analysis.
Source
Journal of the American Heart Association. 11(7) (no pagination), 2022.
Article Number: e024036. Date of Publication: 05 Apr 2022.
Author
Van den Eynde J.; Derdeyn E.; Schuermans A.; Shivaram P.; Budts W.;
Danford D.A.; Kutty S.
Institution
(Van den Eynde, Danford, Kutty) Helen B. Taussig Heart Center, The Johns
Hopkins Hospital and School of Medicine, Baltimore, MD, United States
(Van den Eynde, Schuermans, Budts) Department of Cardiovascular Diseases,
University Hospitals Leuven and Department of Cardiovascular Sciences, KU
Leuven, Leuven, Belgium
(Derdeyn) Faculty of Medicine and Health Sciences, University of Antwerp,
Antwerp, Belgium
(Schuermans) Division of Cardiovascular Medicine, Radcliffe Department of
Medicine, Oxford Cardiovascular Clinical Research Facility, University of
Oxford, United Kingdom
(Shivaram) Division of Pediatric Cardiology, Augusta University, Augusta,
GA, United States
(Budts) Congenital and Structural Cardiology, UZ Leuven, Leuven, Belgium
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: Pulmonary arterial end-diastolic forward flow (EDFF) following
repaired tetralogy of Fallot has been thought to represent right
ventricular (RV) restrictive physiology, but is not fully understood. This
systematic review and meta-analysis sought to clarify its physiological
and clinical correlates, and to define a framework for understanding EDFF
and RV restrictive physiology. METHODS AND RESULTS: PubMed/MEDLINE,
Embase, Scopus, and reference lists of relevant articles were searched for
observational studies published before March 2021. Random-effects
meta-analysis was performed to identify factors associated with EDFF.
Forty-two individual studies published between 1995 and 2021, including a
total of 2651 participants (1132 with EDFF; 1519 with no EDFF), met
eligibility criteria. The pooled estimated prevalence of EDFF among
patients with repaired tetralogy of Fallot was 46.5% (95% CI,
41.6%-51.3%). Among patients with EDFF, the use of a transannular patch
was significantly more common, and their stay in the intensive care unit
was longer. EDFF was associated with greater RV indexed volumes and mass,
as well as smaller E-wave velocity at the tricuspid valve. Finally,
pulmonary regurgitation fraction was greater in patients with EDFF, and
moderate to severe pulmonary regurgitation was more common in this
population. CONCLUSION(S): EDFF is associated with dilated,
hypertrophied RVs and longstanding pulmonary regurgitation. Although
several studies have defined RV restrictive physiology as the presence of
EDFF, our study found no clear indicators of poor RV compliance in
patients with EDFF, suggesting that EDFF may have multiple causes and
might not be the precise equivalent of RV restrictive
physiology. Copyright © 2022 The Authors.

<36>
Accession Number
2019352800
Title
Comparison of Post-operative Outcomes Between Direct Axillary Artery
Cannulation and Side-Graft Axillary Artery Cannulation in Cardiac Surgery:
A Systematic Review and Meta-Analysis.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 925709. Date of Publication: 10 Jun 2022.
Author
Xie Y.; Liu Y.; Yang P.; Lu C.; Hu J.
Institution
(Xie, Liu, Yang, Lu, Hu) Department of Cardiovascular Surgery, West China
Hospital, Sichuan University, Chengdu, China
(Hu) Department of Cardiovascular Surgery, West China Guang'an Hospital,
Sichuan University, Guang'an, China
Publisher
Frontiers Media S.A.
Abstract
Background: There is a growing perception of using axillary artery
cannulation to improve operative outcomes in cardiopulmonary bypass
surgery. Two techniques, direct cannulation or side-graft cannulation, can
be used for axillary artery cannulation, but which technique is better is
controversial. Method(s): A meta-analysis of comparative studies
reporting operative outcomes using direct cannulation vs. side-graft
cannulation was performed. We searched the PubMed, EMbase, Web of Science,
and Cochrane Library. Outcomes of interest were neurological dysfunction,
cannulation-related complications and early mortality. The fixed effects
model was used. Result(s): A total of 1,543 patients were included in
the final analysis. Direct cannulation was used in 846 patients, and
side-graft cannulation was used in 697 patients. Meta-analysis showed a
higher occurrence of neurological Complication in direct cannulation group
[odds ratio, 1.45, 95% CI (1.00, 2.10), chi2 = 4.40, P = 0.05]
and a significantly higher incidence of cannulation-related complications
in the direct cannulation group [odds ratio, 3.12, 95% CI (1.87, 5.18),
chi2 = 2.54, P < 0.0001]. The incidence of early mortality did
not have a difference [odds ratio, 0.95, 95% CI (0.64, 1.41),
chi2 = 6.35, P = 0.79]. Conclusion(s): This study suggests
that side-graft axillary artery cannulation is a better strategy as it
reduces the incidence of neurological dysfunction and cannulation-related
complications. Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/, identifier:
CRD42022325456. Copyright © 2022 Xie, Liu, Yang, Lu and Hu.

<37>
Accession Number
2019352787
Title
Alcohol Septal Ablation or Septal Myectomy? An Updated Systematic Review
and Meta-Analysis of Septal Reduction Therapy for Hypertrophic Obstructive
Cardiomyopathy.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 900469. Date of Publication: 25 May 2022.
Author
Zheng X.; Yang B.; Hui H.; Lu B.; Feng Y.
Institution
(Zheng, Yang, Lu) Department of Geriatrics, Affiliated Hospital of
Guangdong Medical University, Zhanjiang, China
(Hui) Department of Cardiology, Affiliated Hospital of Guangdong Medical
University, Zhanjiang, China
(Feng) Department of Nuclear Medicine, Affiliated Hospital of Guangdong
Medical University, Zhanjiang, China
Publisher
Frontiers Media S.A.
Abstract
Objective: To evaluate the safety and effectiveness of alcohol septal
ablation (ASA) and septal myectomy (SM) for the treatment of hypertrophic
obstructive cardiomyopathy. Method(s): We searched the PubMed,
MEDLINE, EMBASE, and CBM databases for observational research articles
related to ASA and SM published from the establishment of the databases to
November 2021. All ultimate selected articles were highly related to our
target. The Newcastle-Ottawa Scale was used to evaluate the literature
quality. A fixed or random effect model was performed in the meta-analysis
depending on the heterogeneity of the included studies. The
Mantel-Haenszelt test with relative risk ratio (RR) and 95% confidence
interval (CI) was used to measure the effect indicator of binary data,
while the inverse variance method with weighted mean difference (WMD) and
95% CI was used to measure the effect indicator of continuous data.
 Result(s): A totally of 3,647 cases (1,555 cases treated with ASA and
2,092 cases treated with SM) were included. The results of the systematic
review indicated no statistically significant difference in postoperative
all-cause mortality (RR = 0.82; 95% CI: 0.65-1.04; P = 0.10) between
patients treated with ASA and SM, but both the reduction in the
postoperative left ventricular outflow tract pressure gradient (WMD = 9.35
mmHg, 95% CI: 5.38-13.31, P < 0.00001) and the post-operative improvement
on cardiac function, assessed by the grade of New York Heart Association
(NYHA), compared to pre-operative measurements (WMD = 0.13; 95% CI:
0.00-0.26; P < 0.04) in the ASA group were slightly inferior to those in
the SM group. In addition, both the risk of pacemaker implantation (RR =
2.83, 95% CI: 2.06-3.88; P < 0.00001) and the risk of reoperation (RR =
11.23, 95% CI: 6.21-20.31; P < 0.00001) are recorded at a higher level
after ASA procedure. Conclusion(s): Both ASA and SM have a high
degree of safety, but the reduction in the postoperative left ventricular
outflow tract pressure gradient and the improvement on cardiac function
are slightly inferior to SM. In addition, both the risk of pacemaker
implantation and the risk of reoperation are recorded at a higher level
after ASA procedure. The operative plan should be chosen through
multidisciplinary discussions in combination with the wishes of the
patients and the actual clinical situation. Copyright © 2022
Zheng, Yang, Hui, Lu and Feng.

<38>
Accession Number
2018225513
Title
The quality and quantity of sleep on dexmedetomidine during high-flow
nasal cannula oxygen therapy in critically ill patients.
Source
Journal of Medical Investigation. 69(3.4) (pp 266-272), 2022. Date of
Publication: 2022.
Author
Ueno Y.; Sato K.; Momota K.; Sato H.; Nakano Y.; Akimoto Y.; Nunomura T.;
Tane N.; Itagaki T.; Oto J.
Institution
(Ueno, Sato, Momota, Sato, Nakano) Emergency and Critical Care Medicine,
Tokushima University Hospital, 2-50-1, Kuramoto, Tokushima 770-8503, Japan
(Nakano) Emergency and Critical Care Medicine, Tokushima Prefectural
Miyoshi Hospital, 815-2, Ikeda-cho Shima, Miyoshi 778-8503, Japan
(Akimoto, Tane, Oto) Emergency and Critical Care Medicine, Tokushima
University Graduate School of Biomedical Sciences, 3-18-15, Kuramoto,
Tokushima 770-8503, Japan
(Nunomura, Itagaki) Emergency and Disaster Medicine, Tokushima University
Hospital, 2-50-1, Kuramoto, Tokushima 770-8503, Japan
Publisher
University of Tokushima
Abstract
Purpose: High-flow nasal cannula oxygen therapy (HFNC) is a new type of
non-invasive respiratory support for acute respiratory failure patients.
However, patients receiving HFNC often develop sleep disturbances. We
therefore examined whether dexmedetomidine could preserve the sleep
characteristics in patients who underwent HFNC. Patients and Methods:
This was a pilot, randomized controlled study. We assigned critically ill
patients treated with HFNC to receive dexmedetomidine (0.2 to 0.7 microg /
kg / h, DEX group) or not (non-DEX group) at night (9:00 p.m. to 6:00
a.m.). Polysomnograms were monitored during the study period. The primary
outcomes were total sleep time (TST), sleep efficiency and duration of
stage 2 non-rapid eye movement (stage N2) sleep. Result(s): Of the 28
patients who underwent randomization, 24 were included in the final
analysis (12 patients per group). Dexmedetomidine increased the TST (369
min vs. 119 min, p = 0.024) and sleep efficiency (68% vs. 22%, P = 0.024).
The duration of stage N2 was increased in the DEX group compared with the
non-DEX group, but this finding did not reach statistical significance.
The incidences of respiratory depression and hemodynamic insta-bility were
similar between the two groups. Conclusion(s): In critically ill
patients who underwent HFNC, dexme-detomidine may optimize the sleep
quantity without any adverse events. J. Med. Invest. 69: 266-272, August,
2022. Copyright © 2022, University of Tokushima. All rights
reserved.

<39>
Accession Number
2012844249
Title
Modular minimally invasive extracorporeal circulation ensures perfusion
safety and technical feasibility in cardiac surgery; a systematic review
of the literature.
Source
Perfusion (United Kingdom). 37(8) (pp 852-862), 2022. Date of Publication:
November 2022.
Author
Anastasiadis K.; Antonitsis P.; Asteriou C.; Deliopoulos A.; Argiriadou H.
Institution
(Anastasiadis, Antonitsis, Asteriou, Deliopoulos, Argiriadou)
Cardiothoracic Department, School of Medicine, Aristotle University of
Thessaloniki, Thessaloniki, Greece
Publisher
SAGE Publications Ltd
Abstract
Introduction: Despite extensive evidence that shows clinical of
superiority of MiECC, worldwide penetration remains low due to concerns
regarding air handling and volume management in the context of a closed
system. The purpose of this study is to thoroughly investigate perfusion
safety and technical feasibility of performing all cardiac surgical
procedures with modular (hybrid) MiECC, as experienced from the
perfusionist's perspective. Method(s): We retrospectively reviewed
perfusion charts of consecutive adult patients undergoing all types of
elective, urgent, and emergency cardiac surgery under modular MiECC. The
primary outcome measure was perfusion safety and technical feasibility, as
evidenced in the need for conversion from a closed to an open circuit. A
systematic review of the literature was conducted aiming to ultimately
clarify whether there are any safety issues regarding MiECC technology.
 Result(s): We challenged modular MiECC use in a series of 403
consecutive patients of whom a significant proportion (111/403; 28%)
underwent complex surgery including reoperations (4%), emergency repair of
acute type A aortic dissection and composite aortic surgery (1.7%).
Technical success rate was 100%. Conversion to an open circuit was
required in 18/396 patients (4.5%), excluding procedures performed under
circulatory arrest. Open configuration accounted for 40% +/- 21% of total
procedural perfusion time and was related to significant hemodilution and
increase in peak lactate levels. Systematic review revealed that safety of
the procedure challenged originated from a single report, while no
clinical adverse event related to MiECC was identified.
 Conclusion(s): Use of modular MiECC secures safety and ensures
technical feasibility in all cardiac surgical procedures. It represents a
type III active closed system, while its stand-by component is reserved
for a small (<5%) proportion of procedures and for a partial procedural
time. Thus, it eliminates any safety concern regarding air handling and
volume management, while it overcomes any unexpected intraoperative
scenario. Copyright © The Author(s) 2021.

<40>
Accession Number
2019835019
Title
Propofol versus insulin cardioplegia in valvular heart surgeries assessed
by myocardial histopathology and troponin I.
Source
Egyptian Journal of Anaesthesia. 38(1) (pp 587-596), 2022. Date of
Publication: 2022.
Author
Mohamed O.S.; Al-Elwany S.E.; Raouf M.M.; Tawfik H.M.; Youssef I.A.
Institution
(Mohamed, Raouf, Youssef) Department of Anesthesia and Intensive Care
Unit, Minia University Hospital, Faculty of Medicine, Minia University,
Minya, Egypt
(Al-Elwany) Department of Cardiothoracic Surgery. Faculty of Medicine,
Minia University, Minya, Egypt
(Tawfik) Department of Histopathology, Faculty of Medicine, Minia
University, Minya, Egypt
Publisher
Taylor and Francis Ltd.
Abstract
Background and Aims: Despite of the effectiveness of on pump cardiac
surgeries in valvular diseases, cardioplegic arrest and myocardial
reperfusion injury are still an obstacle. Many cardioprotective additives
are tried but the obtained laboratory results are mixed. Our objective was
to compare the effects of supplementing the cardioplegia solution with
propofol or insulin evaluated not only by laboratory biomarkers but also
with papillary muscle biopsy in patients undergoing on pump valvular
surgeries. Method(s): Sixty adult patients were randomly assigned
into three equal groups to receive: cold blood cadioplegia (control (C)
group), supplemented with either 9 mg/L propofol 10% (P group), or 10 IU/L
regular insulin (I group) Results: Propofol induced significant higher
myocardial protection presented by better histopathological grading of the
obtained muscle biopsies when compared to either group C (P = 0.0460) or
group I (P = 0.014), lower postoperative dysrhythmia (P = 0.004), lower
troponin I release (40.57 +/- 8.5 vs 47.7 +/- 6.22-fold increase), and
more eukalemic state with lower need for K supplementation than insulin.
 Conclusion(s): Propofol was superior to insulin in providing higher
grade of myocardial protection with lower troponin I release, more steady
K level and lower postoperative complications. Copyright © 2022
The Author(s). Published by Informa UK Limited, trading as Taylor &
Francis Group.

<41>
Accession Number
2020807078
Title
Aortic valve neocuspidization using the Ozaki technique: A meta-analysis
of reconstructed patient-level data.
Source
American Heart Journal. 255 (pp 1-11), 2023. Date of Publication: January
2023.
Author
Mylonas K.S.; Tasoudis P.T.; Pavlopoulos D.; Kanakis M.; Stavridis G.T.;
Avgerinos D.V.
Institution
(Mylonas, Pavlopoulos, Stavridis, Avgerinos) Department of Cardiac
Surgery, Onassis Cardiac Surgery Center, Athens, Greece
(Tasoudis) Faculty of Medicine, School of Health Sciences, University of
Thessaly, Larissa, Biopolis, Greece
(Kanakis) Department of Pediatric and Adult Congenital Cardiac Surgery,
Onassis Cardiac Surgery Center, Athens, Greece
Publisher
Elsevier Inc.
Abstract
Background: Aortic valve neocuspidization using the Ozaki technique has
shown promising results both in adults and children. Method(s): A
systematic search of the PubMed and Cochrane databases was performed up to
November 13, 2021. Individual patient data were reconstructed and analyzed
from the Kaplan-Meier curves of all eligible studies for time-to-event
outcomes. Result(s): We included a total of 22 studies reporting on
1,891 patients that underwent Ozaki reconstruction. Mean age at the time
of surgery was 43.2 +/- 24.5 years (65 +/- 12.3 years for adult patients
and 12.3 +/- 3.8 years for pediatric patients). The most common indication
was aortic stenosis (46.4%, 95% CI 34.1-58.6). Mean cross-clamp and
cardiopulmonary bypass duration were 106.8 +/- 24.8 minutes and 135.2 +/-
35.1 minutes, respectively. Permanent pacemaker was implanted in 0.7% (95%
CI 0.4-1.2) of the patients. At discharge, mean effective orifice area was
2.1 +/- 0.5 cm2/m2. At latest follow-up, peak
gradient was 15.7 +/- 7.4 mm Hg and only 0.25% (95% CI 0-2.3) had moderate
aortic insufficiency. In-hospital mortality was 0.7% (95% CI 0.1-1.7).
Late mortality was 1.9% during a mean follow-up of 38.1 +/- 23.8 months.
One-year, 3-year, and 5-year freedom from reoperation rates were 98.0 %,
97.0 % and 96.5%, respectively. More than half of the reoperations were
due to infective endocarditis (51.5%, 95% CI 18.3-84.0). In our cohort,
the risk of endocarditis per patient per year was 0.5%.
 Conclusion(s): The midterm outcomes of the Ozaki procedure are
excellent in terms of hemodynamics, survival, and freedom from
reoperation. Acquiring long-term follow-up will help solidify this
technique in the cardiac surgery armamentarium. Copyright © 2022

<42>
Accession Number
2020109457
Title
Surgery for early-stage lung cancer with video-assisted thoracoscopic
surgery versus open thoracotomy: A narrative review.
Source
Seminars in Oncology. 49(3-4) (pp 261-264), 2022. Date of Publication:
June 2022.
Author
Alban J.; Kennedy K.; Hulbert A.; Lighter M.; Pasquinelli M.; Rubinstein
I.; Ghelani S.; Clayburn A.; Feldman L.E.
Institution
(Alban) Department of Medicine, University of Chicago Medical Center,
Chicago, Illinois, United States
(Kennedy, Feldman) Division of Hematology/Oncology, Department of
Medicine, University of Illinois at Chicago
(Hulbert, Lighter) Department of Surgery, University of Illinois at
Chicago, College of Medicine, Chicago, Illinois, United States
(Pasquinelli, Rubinstein) Division of Pulmonary, Critical Care, Sleep, and
Allergy Medicine, Department of Medicine, University of Illinois at
Chicago
(Hulbert, Feldman) Section of Hematology/Oncology, Medical Service, Jesse
Brown VA Medical Center
(Rubinstein) Section of Pulmonary, Critical Care, and Sleep Medicine,
Medical Service, Jesse Brown VA Medical Center
(Ghelani) Department of Emergency Medicine, Johns Hopkins University,
Baltimore, Maryland
(Clayburn) New York University School of Medicine, New York, New York
Publisher
W.B. Saunders
Abstract
Recommending video-assisted thoracic surgery (VATS) over open thoracotomy
to patients with early-stage non-small-cell lung cancer (NSCLC) is
controversial. Accordingly, we reviewed randomized comparative studies to
determine the risks and benefits of VATS lobectomy. Electronic searches on
PubMed with standard search terms revealed 97 comparative studies
published between 1990 and 2022. Of those, only 5 were randomized
controlled clinical trials (RCT) and 1 is still ongoing although initial
data has been published as an abstract form. A total of 918 patients were
evaluated in 5 RCT's. All studies included patients with known or
suspected primary lung cancer randomized in a 1:1 ratio to VATS or
thoracotomy. Between 2 studies, reports of 1-year, 3-year and 5-year
overall survival were found to be similar across surgical modalities.
Additionally, no differences were found in the rates of locoregional and
distant recurrence. Three studies reported no statistical differences in
the number of hilar and mediastinal lymph nodes sampled. Two studies found
decreased length of stay following VATS (4 days v 5 days, P = 0.027 and P
= 0.008), while 2 found no difference. Increased in-hospital complications
were seen in 2 studies (P = 0.008 and P = 0.039). VATS was associated with
decreased pain scores, better self-reported QOL at 52 weeks (P = 0.014).
Few randomized clinical trials comparing VATS lobectomy to open
thoracotomy and lobectomy in early stage NSCLC have been reported. These
studies suggest that VATS lobectomy offers similar outcomes with decreased
in-hospital complications, pain, length of stay, and improved physical
functioning when compared to thoracotomy. Copyright © 2022
Elsevier Inc.

<43>
Accession Number
2019205637
Title
Atrial Mitral and Tricuspid Regurgitation: Sex Matters. A Call for Action
to Unravel the Differences Between Women and Men.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 877592. Date of Publication: 13 Jun 2022.
Author
Gual-Capllonch F.; Saenz de Ibarra J.I.; Bayes-Genis A.; Delgado V.
Institution
(Gual-Capllonch, Saenz de Ibarra) Heart Institute, Clinica Rotger, Palma,
Spain
(Saenz de Ibarra) Cardiac Surgery Department, Clinica Rotger, Palma, Spain
(Bayes-Genis, Delgado) Heart Institute, Hospital Universitari Germans
Trias i Pujol, Barcelona, Spain
(Bayes-Genis) Department of Medicine, Universitat Autonoma de Barcelona,
Barcelona, Spain
(Bayes-Genis) CIBERCV, Instituto de Salud Carlos III, Madrid, Spain
Publisher
Frontiers Media S.A.
Abstract
Atrial functional regurgitation is caused by atrioventricular annulus
dilation, with normal leaflets and ventricular dimensions and function
within the normal range. Its occurrence, in both mitral and tricuspid
valves, implies a worse prognosis due to the hemodynamic derangement they
produce, but also constitutes a marker of greater comorbidity and more
advanced disease. Predisposing conditions for these heart valve
dysfunctions are mainly atrial fibrillation and heart failure with
preserved ejection fraction. However, other factors like female sex also
may be involved and influence their incidence, especially for atrial
tricuspid regurgitation. In the present review, we analyze sex differences
in the reported prevalence of atrial mitral and tricuspid regurgitation,
and suggest possible mechanisms involved. Finally, we underline potential
therapeutic and preventive strategies to reduce the burden of these heart
valve disorders and discuss research gaps. Copyright © 2022
Gual-Capllonch, Saenz de Ibarra, Bayes-Genis and Delgado.

<44>
Accession Number
2018074434
Title
1,5-Anhydroglucitol as a Marker of Acute Hyperglycemia in Cardiovascular
Events.
Source
Review of Diabetic Studies. 18(2) (pp 68-75), 2022. Date of Publication:
2022.
Author
Migala M.; Chalubinska-Fendler J.; Zielinska M.
Institution
(Migala, Zielinska) Department of Intensive Cardiac Therapy, Medical
University of Lodz, Lodz, Poland
(Chalubinska-Fendler) Department of Radiation Oncology, Military Institute
of Medicine, Warsaw, Poland
Publisher
Lab and Life Press
Abstract
1,5-anhydroglucitol (1,5-AG) is a biomarker of acute hyperglycemia in
diabetology and also in cardiodiabetology. It is used to monitor
fluctuating glucose levels. 1,5-AG is a monosaccharide that is
biochemically similar to D-glucose and originates from the nutrition. The
presence of 1,5-AG in blood and tissue is nearly constant due to
reabsorption in the renal proximal tubule. In acute hyperglycemia, renal
reabsorption is inhibited by glucose and 1,5-AG is excreted in the urine,
while its serum level decreases rapidly. 1,5-AG reflects glucose
excursions over 1-3 days to 2 weeks. In this regard, low levels of serum
1,5-AG can be a clinical marker of short-term glycemic derangements such
as postprandial hyperglycemia, which is an important risk factor for the
pathogenesis of coronary artery disease (CAD) as low levels of 1,5-AG
reflect severe plaque calcification in CAD and correlate with high-density
lipoprotein cholesterol (HDL-C) levels. For these reasons, 1,5-AG may also
be a marker for atherosclerosis; in fact an even better marker than HbA1c
or fructosamine which are normally used. 1,5-AG may also be a predictor of
cardiovascular disease, left ventricular dysfunction after acute coronary
syndrome (ACS), and mortality after ACS. This articles reviews the current
knowledge on 1,5-AG related to its use as predictor for cardiovascular
events. Copyright © 2022, Lab and Life Press. All rights
reserved.

<45>
Accession Number
2016632529
Title
Mortality after transcatheter aortic valve replacement for aortic stenosis
among patients with malignancy: a systematic review and meta-analysis.
Source
BMC Cardiovascular Disorders. 22(1) (no pagination), 2022. Article Number:
210. Date of Publication: December 2022.
Author
Siddiqui M.U.; Yacob O.; Junarta J.; Pasha A.K.; Mookadam F.; Mamas M.A.;
Fischman D.L.
Institution
(Siddiqui, Junarta) Department of Internal Medicine, Thomas Jefferson
University Hospitals, 833 Chestnut Street, Suite 701, Philadelphia, PA
19107, United States
(Yacob) Cardiovascular Medicine, MercyOne North Iowa Heart Center, Mason
City, IA, United States
(Pasha) Cardiovascular Medicine, UHS Wilson Medical Center, Johnson City,
NY, United States
(Mookadam) Cardiovascular Medicine, Mayo Clinic Health System, Phoenix,
AZ, United States
(Mamas) Cardiovascular Research Group, Center for Prognosis Research,
Keele University, Keele, United Kingdom
(Fischman) Cardiovascular Medicine, Thomas Jefferson University Hospital,
Philadelphia, PA, United States
Publisher
BioMed Central Ltd
Abstract
Background: With advancements in cancer treatment, the life expectancy of
oncology patients has improved. Thus, transcatheter aortic valve
replacement (TAVR) may be considered as a feasible option for oncology
patients with severe symptomatic aortic stenosis (AS). We aim to evaluate
the difference in short- and long-term all-cause mortality in cancer and
non-cancer patients treated with TAVR for severe AS. Method(s):
Medline, PubMed, and Cochrane Central Register of Controlled Trials were
searched for relevant studies. Patients with cancer who underwent
treatment with TAVR for severe AS were included and compared to an
identical population without cancer. The primary endpoints were short- and
long-term all-cause mortality. Result(s): Of 899 studies included, 8
met inclusion criteria. Cancer patients had significantly higher long-term
all-cause mortality after TAVR when compared to patients without cancer
(risk ratio [RR] 1.43; 95% confidence interval (CI) 1.26-1.62; P < 0.01).
Four studies evaluated short-term mortality after TAVR and demonstrated no
difference in it in patients with and without cancer (RR 0.72; 95% CI
0.47-1.08; P = 0.11). Conclusion(s): Patients with cancer and severe
AS have higher long-term all-cause mortality after TAVR. However, we found
no difference in short-term all-cause mortality when comparing patients
with and without cancer. The decision to perform TAVR in cancer patients
should be individualized based on life expectancy and existing
co-morbidities. Copyright © 2022, The Author(s).

<46>
Accession Number
2020772087
Title
Effect of Ascorbic Acid on Cardiac Surgery-Associated Acute Kidney Injury
Incidence.
Source
Thoracic and Cardiovascular Surgeon. 70(7) (pp 566-574), 2022. Date of
Publication: 01 Oct 2022.
Author
Djordjevic A.; Susak S.; Kotnik P.; Gorenjak M.; Knez Z.; Antonic M.
Institution
(Djordjevic, Antonic) Department of Cardiac Surgery, University Medical
Centre Maribor, Maribor, Slovenia
(Susak) Department of Cardiovascular Surgery, Institute of Cardiovascular
Diseases of Vojvodina, Sremska Kamenica, Vojvodina, Serbia
(Kotnik, Gorenjak, Knez) Faculty of Medicine, University of Maribor,
Maribor, Slovenia
Publisher
Georg Thieme Verlag
Abstract
Objectives a Acute kidney injury (AKI) is associated with higher
perioperative mortality and morbidity. Oxidative stress has been proposed
as a cause of postoperative AKI. Ascorbic acid (AA) supplementation was
suggested as a novel and promising antioxidant. The aim of this study was
to evaluate the capability of AA to reduce the incidence of postoperative
AKI in cardiac surgery patients. Methods a A prospective randomized trial
was conducted in patients scheduled for on-pump cardiac surgery. Subjects
in the AA group received 2 g of AA intravenously during the induction of
anesthesia, 2 g before aortic cross-clamp removal and 1 g every 8 hours
for five postoperative days (the JERICA protocol). Postoperatively, the
patients were monitored for AKI and other complications. Malondialdehyde
levels were monitored in a subpopulation of 100 patients to evaluate the
effect of AA on oxidative stress level. Results a The AA and control group
consisted of 163 and 169 patients, respectively. The groups were well
matched for baseline demographics and had similar intraoperative
characteristics. The incidence of AKI in the AA and control group was 20.9
and 28.4%, respectively (p = 0.127). The estimated glomerular filtration
rate did not differ between the study groups in the entire postoperative
period. There was a trend toward higher malondialdehyde values with
statistical significance on postoperative day 1 and lower in-hospital
mortality in the AA group (0.6 vs. 4.1%, p = 0.067). Conclusion a Our
results do not support the effectiveness of AA supplementation in reducing
the incidence of postoperative AKI in on-pump cardiac surgery patients.
Clinical Registration Number a This study was registered with the ISRCTN
Registry under the trial registration number ISRCTN98572043. Copyright
© 2022 Georg Thieme Verlag. All rights reserved.

<47>
Accession Number
639357450
Title
Long-Term Mortality Follow-Up of Radial Artery Versus Saphenous Vein in
Coronary Artery Bypass Grafting: A Multicenter, Randomized Trial.
Source
Circulation. 146(17) (pp 1323-1325), 2022. Date of Publication: 25 Oct
2022.
Author
Goldman S.; McCarren M.; Sethi G.K.; Holman W.; Bakaeen F.G.; Wagner T.H.;
Wang Y.; Shih M.-C.; Edson R.
Institution
(Goldman) Sarver Heart Center (S.G.), University of Arizona, Tucson,
United States
(McCarren) Hines VA Pharmacy Benefits Management
(Sethi) University of Arizona
(Holman) University of Alabama, Birmingham VA Medical Center (W.H.)
(Bakaeen) Department of Thoracic and Cardiovascular Surgery, Cleveland
Clinic
(Wagner) VA Health Economics Resource Center, Palo Alto VA
(Wagner, Wang, Shih, Edson) Department of Surgery, Stanford University,
Palo Alto, Mexico
Publisher
NLM (Medline)

<48>
Accession Number
638985208
Title
Five-Year Results of Coronary Artery Bypass Grafting With or Without
Carotid Endarterectomy in Patients With Asymptomatic Carotid Artery
Stenosis: CABACS RCT.
Source
Stroke. 53(11) (pp 3270-3277), 2022. Date of Publication: 01 Nov 2022.
Author
Knipp S.C.; Holst T.; Bilbilis K.; von Velsen O.; Ose C.; Diener H.-C.;
Jakob H.; Ruhparwar A.; Jockel K.-H.; Weimar C.
Institution
(Knipp, Jakob, Ruhparwar) Department of Thoracic and Cardiovascular
Surgery, University Hospital Essen, Germany (S.C.K., Germany
(Holst) Department of Cardiac Surgery, Medical Faculty and University
Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Germany
(T.H.), Germany
(Bilbilis, von Velsen, Ose, Jockel) Center for Clinical Trials Essen
(ZKSE), c/o Institute for Medical Informatics, Biometry and Epidemiology
(IMIBE), University Hospital Essen, Germany (K.B., C.O
(Diener, Jockel, Weimar) Institute for Medical Informatics, Biometry and
Epidemiology (IMIBE), University Hospital Essen, Germany (H.-C.D., Germany
(Weimar) BDH Clinic Elzach GmbH, Germany (C.W.), Germany
Publisher
NLM (Medline)
Abstract
BACKGROUND: In patients with coronary artery disease and concomitant
asymptomatic severe carotid stenosis, combined simultaneous coronary
artery bypass grafting (CABG) and carotid endarterectomy (CEA) has been
widely performed despite lack of evidence from randomized trials. We
recently showed that the risk of stroke or death within 30 days was higher
following CABG+CEA compared with CABG alone. Here, we report long-term
outcomes following CABG with versus without CEA. METHOD(S): The
CABACS (Coronary Artery Bypass Graft Surgery in Patients With Asymptomatic
Carotid Stenosis Study) is a randomized, controlled, multicenter, open
trial. Patients with asymptomatic severe (>=70%) carotid stenosis
undergoing CABG were allocated either CABG+CEA or CABG alone, and
follow-up was 5 years. Major secondary end points included nonfatal stroke
or death, any death and any nonfatal stroke. Due to low recruitment, the
study was stopped prematurely after randomization of 127 patients in 17
centers. RESULT(S): By 5 years, the rate of stroke or death did not
significantly differ between groups (CABG+CEA 40.6% [95% CI, 0.285-0.536],
CABG alone 35.0% [95% CI, 0.231-0.484]; P=0.58). Higher albeit
statistically nonsignificant rates of nonfatal strokes occurred at any
time following CABG+CEA versus CABG alone (1 year: 19.3% versus 7.1%,
P=0.09; 5 years: 29.4% versus 18.8%, P=0.25). All-cause mortality up to 5
years was similar in both groups (CABG+CEA: 25.4% versus CABG alone:
23.3%, hazard ratio, 1.148 [95% CI, 0.560-2.353]; P=0.71). Subgroup
analyses did not reveal any significant effect of age, sex, preoperative
modified Rankin Scale and center on outcome events. CONCLUSION(S):
During 5-years follow-up, combined simultaneous CABG+CEA was associated
with a higher albeit statistically nonsignificant rate of stroke or death
compared with CABG alone. This was mainly due to a nonsignificantly higher
perioperative risk following CABG+CEA. Since the power of our study was
not sufficient, no significant effect of either procedure could be
observed at any time during follow-up. REGISTRATION: URL:
http://www.controlled-trials.com; Unique identifier: ISRCTN13486906.

<49>
Accession Number
2020219778
Title
Cardiac surgery's long opioid dependency: time to recalibrate pain
therapy?.
Source
British Journal of Anaesthesia. 129(5) (pp 655-658), 2022. Date of
Publication: November 2022.
Author
Rong L.Q.; Shen L.; Bartels K.
Institution
(Rong, Shen) Department of Anesthesiology, Weill Cornell Medicine, New
York, NY, United States
(Bartels) Department of Anesthesia, University of Nebraska Medical Center,
Omaha, NE, United States
Publisher
Elsevier Ltd
Abstract
Opioid analgesia is the cornerstone of anaesthetic management during
cardiac surgery. However, a subset of patients use opioids persistently
after three months of surgery. We discuss a recent meta-analysis and
systematic review by Liu and colleagues describing both patient and
peri-procedural risk factors that contribute to this phenomenon in the
context of chronic pain after cardiac surgery. Anaesthetists for cardiac
surgery should consider opioid alternatives and individual patient risk
factors to optimise recovery and pain control. Copyright © 2022
British Journal of Anaesthesia

<50>
Accession Number
2019738017
Title
Comparing the efficacy of N-acetylcysteine plus carvedilol versus
carvedilol in the prevention of atrial fibrillation following coronary
artery bypass graft surgery.
Source
Journal of Cardiac Surgery. (no pagination), 2022. Date of Publication:
2022.
Author
Jalalian R.; Maleki M.; Ghafari R.; Habibi V.; Heydari S.; Iranian M.
Institution
(Jalalian, Maleki) Department of Cardiology, Faculty of Medicine,
Mazandaran University of Medical Sciences, Sari, Iran, Islamic Republic of
(Ghafari, Habibi) Department of Cardiac Surgery, Faculty of Medicine,
Mazandaran University of Medical Sciences, Sari, Iran, Islamic Republic of
(Heydari) Faculty of Medicine, Guilan University of Medical Sciences,
Rasht, Iran, Islamic Republic of
(Iranian) Rajaie Cardiovascular Medical and Research Center, School of
Medicine, Iran University of Medical Science, Tehran, Iran, Islamic
Republic of
Publisher
John Wiley and Sons Inc
Abstract
Background: Atrial fibrillation (AF) is the most common arrhythmia
following open-heart surgery. Agents with antioxidant properties may
reduce postoperative complications like postoperative AF (POAF) in
patients undergoing open-heart surgery. This study was conducted to assess
the effect of N-acetylcysteine (NAC) in prevention of AF following
coronary artery bypass graft (CABG) surgery. Method(s): Three hundred
patients who underwent CABG surgery were entered in the study. Patients
with contraindications for beta-blockers and patients were simultaneously
replacing or repairing the valve with open-heart surgery were excluded.
The patients were randomly divided into two groups (n = 150) and they were
received NAC plus carvedilol or carvedilol. The patients were monitored
for 5 days after surgery and the incidence of AF during hospitalization
was recorded. Result(s): AF was detected in 14 patients in the NAC
with Carvedilol group (9.33%) and 23 patients in Carvedilol group
(15.33%). There was no significant difference in the incidence of POAF
between the two groups (p value = 0.112). The result of multivariable
regression model represented that although the incidence of POAF was lower
in NAC plus carvedilol group, it wasn't statistically significant (p value
= 0.10). Conclusion(s): NAC was not associated with a decreased
incidence of AF following CABG surgery. Copyright © 2022 Wiley
Periodicals LLC.

<51>
Accession Number
2020851619
Title
Comparison of subcutaneous analgesic system and epidural analgesia for
postoperative pain control in open pediatric oncology operations: A
randomized controlled trial.
Source
Journal of Pediatric Surgery. (no pagination), 2022. Date of Publication:
2022.
Author
Mehl S.C.; Johnson B.; Patel N.; Todd H.; Vasudevan S.; Nuchtern J.;
Naik-Mathuria B.
Institution
(Mehl, Todd, Vasudevan, Nuchtern, Naik-Mathuria) Michael E DeBakey
Department of Surgery, Baylor College of Medicine, Houston, TX, United
States
(Mehl, Johnson, Vasudevan, Nuchtern, Naik-Mathuria) Department of Surgery,
Division of Pediatric Surgery, Texas Children's Hospital, Houston, TX,
United States
(Patel) Department of Pediatric Anesthesiology, Perioperative and Pain
Medicine, Texas Children's Hospital, Houston, TX, United States
Publisher
W.B. Saunders
Abstract
Purpose: Children undergoing open oncologic surgery can have significant
post-operative pain. The purpose of this trial was to compare a
surgeon-placed subcutaneous analgesic system (SAS) to epidural analgesia.
 Method(s): Single center randomized controlled trial including
children <=18 years undergoing open tumor resection between October 2018
and April 2021. Randomization to SAS or epidural was done preoperatively
and perioperative pain management was standardized. Families were blinded
to the modality. Comparisons of oral morphine equivalents (OME) and pain
scores for three postoperative days, clinical outcome parameters, and
parental satisfaction following unblinding were completed using
non-parametric analyses. Result(s): Of 36 patients (SAS 18, Epidural
18), median age was 5 years (range <1-17). The Epidural cohort had less
OME demand on postoperative day one (SAS 0.76 mg/kg, Epidural 0.11 mg/kg;
p<0.01) and two (SAS 0.48 mg/kg, Epidural 0.07 mg/kg, p = 0.03). Pain
scores were similar on postoperative days 1-3 (0-2 in both groups). The
Epidural cohort had more device complications (SAS 11%, Epidural 50%; p =
0.03) and higher urinary catheter use (SAS 50%, Epidural 89%; p = 0.03).
More than 80% of parents would use the same device in the future (SAS
100%, Epidural 84%, p = 0.23). Conclusion(s): For children undergoing
open oncologic abdominal or thoracic surgery, early post-operative pain
control appears to be better with epidural analgesia; however, SAS has
decreased incidence of device complications and urinary catheter use.
Parental satisfaction is excellent with both modalities. SAS could be
considered as an alternative to epidural, especially in settings when
epidural placement is not available or contraindicated. Type of
Study: Treatment study, Randomized controlled trial. Level of
Evidence: Level 1. Copyright © 2022

<52>
Accession Number
2020586665
Title
Prevalence of Post-Heart Transplant Malignancies: A Systematic Review and
Meta-Analysis.
Source
Current Problems in Cardiology. 47(12) (no pagination), 2022. Article
Number: 101363. Date of Publication: December 2022.
Author
Lateef N.; Farooq M.Z.; Latif A.; Ahmad S.; Ahsan M.J.; Tran A.; Nickol
J.; Wasim M.F.; Yasmin F.; Kumar P.; Arif A.W.; Shaikh A.; Mirza M.
Institution
(Lateef, Nickol) Department of Cardiovascular Medicine, University of
Nebraska Medical Center, Omaha, NB, United States
(Farooq) Department of Hematology/Oncology, Moffitt Cancer Center,
Florida, FL
(Latif) Department of Cardiovascular Medicine, Baylor University, Houston,
TX
(Ahmad) Department of Internal Medicine, East Carolina University, NC
(Ahsan) Division of Cardiovascular Medicine, Iowa Heart Center, Iowa
(Tran, Mirza) Department of Internal Medicine, Creighton University, NB
(Wasim) Department of Medicine, Baqai Medical University, Karachi,
Pakistan
(Yasmin, Kumar) Department of Medicine, Dow University of Health Sciences,
Karachi, Pakistan
(Arif) Department of Cardiovascular Medicine, Cook County Health Sciences,
Chicago, IL
(Shaikh) Department of Internal Medicine, Rochester General Hospital,
Rochester, NY
Publisher
Elsevier Inc.
Abstract
The prevalence of different cancers after heart transplant (HT) is unclear
due to small and conflicting prior studies. Herein, we report a systematic
review and meta-analysis to highlight the prevalence and pattern of
malignancies post-HT. We conducted an extensive literature search on
PubMed, Scopus, Cochrane databases for prospective or retrospective
studies reporting malignancies after HT. The proportions from each study
were subjected to random effects model that yielded the pooled estimate
with 95% confidence intervals (CI). Fifty-five studies comprising 60,684
HT recipients reported 7759 total cancers during a mean follow-up of 9.8
+/- 5.9 years, with an overall incidence of 15.3% (95% CI = 12.7%-18.1%).
Mean time from HT to cancer diagnosis was 5.1 +/- 4 years. The most
frequent cancers were gastrointestinal (7.6%), skin (5.7%), and
hematologic/blood (2.5%). Meta-regression showed no association between
incidence of cancer and mean age at HT (coeff: -0.008; P = 0.25),
percentage of male recipients (coeff: -0.001; P = 0.81), donor age (coeff:
-0.011; P = 0.44), 5-year (coeff: 0.003; P = 0.12) and 10-year (coeff:
0.02; P = 0.68) post-transplant survival. There is a substantial risk of
malignancies in HT recipients, most marked for gastrointestinal, skin, and
hematologic. Despite their occurrence, survival is not significantly
impacted. Copyright © 2022 Elsevier Inc.

<53>
Accession Number
2019799993
Title
Patients with Bicuspid Aortopathy and Aortic Dilatation.
Source
Journal of Clinical Medicine. 11(20) (no pagination), 2022. Article
Number: 6002. Date of Publication: October 2022.
Author
Nappi F.; Giacinto O.; Lusini M.; Garo M.; Caponio C.; Nenna A.; Nappi P.;
Rousseau J.; Spadaccio C.; Chello M.
Institution
(Nappi, Rousseau) Department of Cardiac Surgery, Centre Cardiologique du
Nord, Saint-Denis 93200, France
(Giacinto, Lusini, Garo, Caponio, Nenna, Chello) Department of
Cardiovascular Surgery, Universita Campus Bio-Medico di Roma, Rome 00128,
Italy
(Nappi) Department of Clinical and Experimental Medicine, University of
Messina, Messina 98122, Italy
(Spadaccio) Department of Cardiac Surgery, Massachusetts General Hospital
& Harvard Medical School, Boston, MA 02115, United States
Publisher
MDPI
Abstract
(1) Background: Bicuspid aortic valve (BAV) is the most frequent
congenital cardiac disease. Alteration of ascending aorta diameter is a
consequence of shear stress alterations due to haemodynamic abnormalities
developed from inadequate valve cusp coaptation. (2) Objective: This
narrative review aims to discuss anatomical, pathophysiological,
genetical, ultrasound, and radiological aspects of BAV disease, focusing
on BAV classification related to imaging patterns and flux models involved
in the onset and developing vessel dilatation. (3) Methods: A
comprehensive search strategy was implemented in PubMed from January to
May 2022. English language articles were selected independently by two
authors and screened according to the following criteria. (4) Key Contents
and Findings: Ultrasound scan is the primary step in the diagnostic
flowchart identifying structural and doppler patterns of the valve.
Computed tomography determines aortic vessel dimensions according to the
anatomo-pathology of the valve. Magnetic resonance identifies hemodynamic
alterations. New classifications and surgical indications derive from
these diagnostic features. Currently, indications correlate morphological
results, dissection risk factors, and genetic alterations. Surgical
options vary from aortic valve and aortic vessel substitution to aortic
valve repair according to the morphology of the valve. In selected
patients, transcatheter aortic valve replacement has an even more impact
on the treatment choice. (5) Conclusion(s): Different imaging
approaches are an essential part of BAV diagnosis. Morphological
classifications influence the surgical outcome. Copyright © 2022
by the authors.

<54>
Accession Number
2020871225
Title
Evaluation of the cardiovascular risk in patients undergoing major
non-cardiac surgery: role of cardiac-specific biomarkers.
Source
Biochimica Clinica. 46(3) (pp 255-267), 2022. Date of Publication: 01 Sep
2022.
Author
Clerico A.; Zaninotto M.; Aimo A.; Musetti V.; Perrone M.; Padoan A.;
Dittadi R.; Sandri M.T.; Bernardini S.; Sciacovelli L.; Trenti T.;
Malloggi L.; Moretti M.; Burgio M.A.; Manno M.L.; Plebani M.
Institution
(Clerico, Aimo, Musetti) Scuola Superiore sant'Anna e Fondazione CNR -
Regione Toscana G. Monasterio, Pisa, Italy
(Zaninotto, Sciacovelli) Dipartimento di Medicina di Laboratorio,
Universita-Ospedale di Padova, Italy
(Zaninotto, Sciacovelli) Azienda Ospedaliera Universitaria di Padova, E
Dipartimento di Medicina, Universita di Padova, Italy
(Perrone, Bernardini) Dipartimento di Medicina Sperimentale, Universita di
Roma Tor Vergata, Roma, Italy
(Padoan, Plebani) Dipartimento di Medicina di Laboratorio-DIMED,
Universita di Padova, Italy
(Padoan, Plebani) Ospedale dell'Angelo, Mestre, Italy
(Dittadi) Laboratorio Bianalisi, MB, Carate Brianza, Italy
(Sandri) Dipartimento di Medicina di Laboratorio e Anatomia Patologica,
Azienda Ospedaliera Universitaria e USL di Modena, Italy
(Trenti) Laboratorio Analisi, Azienda Ospedaliera-Universitaria di Pisa,
Italy
(Malloggi) Medicina di Laboratorio, AOU Ospedali Riuniti Ancona, Italy
(Moretti) Patologia Clinica P.O. Barone Lombardo, Canicatti, Agrigento,
Italy
(Burgio) U.O. Patologia Clinica, P.O. Santa Maria Novella, Galatina,
Lecce, Italy
Publisher
Biomedia
Abstract
Patients undergoing major surgery have a substantial risk of
cardiovascular events during the perioperative period. Despite the
introduction of several risk scores based on medical history, classical
risk factors and non-invasive cardiac tests, the possibility to predict
cardiovascular events in patients undergoing non-cardiac surgery remains
limited. The cardiac-specific biomarkers natriuretic peptides (NPs) and
cardiac troponins (cTn) have been proposed as additional tools for risk
prediction in the peri-operative period. This Consensus Document aims to
discuss the value of preoperative levels and perioperative changes in
cardiac-specific biomarkers to predict adverse outcomes in patients
undergoing major non-cardiac surgery. Based on several prospective
observational studies and 6 meta-analyses, some guidelines recommended the
measurement of NPs to refine perioperative cardiac risk estimation in
patients undergoing noncardiac surgery. More recently, several studies
reported a higher mortality in surgical patients presenting an elevation
in high-sensitivity cTnT and cTnI, especially in elderly patients or those
with comorbidities. This evidence should be considered in future
international guidelines on the evaluation of perioperative risk in
patients undergoing major noncardiac surgery. Copyright © 2022
Biomedia. All rights reserved.

<55>
Accession Number
2020931239
Title
Impact of pharmacological interventions on intrapulmonary shunt during
one-lung ventilation in adult thoracic surgery: a systematic review and
component network meta-analysis.
Source
British Journal of Anaesthesia. (no pagination), 2022. Date of
Publication: 2022.
Author
Schorer R.; Dombret A.-L.; Hagerman A.; Bedat B.; Putzu A.
Institution
(Schorer, Dombret, Hagerman, Putzu) Department of Acute Medicine, Geneva
University Hospitals, Geneva, Switzerland
(Bedat) Division of Thoracic and Endocrine Surgery, Geneva University
Hospitals, Geneva, Switzerland
Publisher
Elsevier Ltd
Abstract
Background: Intrapulmonary shunt is a major determinant of oxygenation in
thoracic surgery under one-lung ventilation. We reviewed the effects of
available treatments on shunt, PaO<inf>2</inf>/FiO<inf>2</inf> and
haemodynamics through systematic review and network meta-analysis.
 Method(s): Online databases were searched for RCTs comparing
pharmacological interventions and intrapulmonary shunt in thoracic surgery
under one-lung ventilation up to March 30, 2022. Random-effects
(component) network meta-analysis compared 24 treatments and 19 treatment
components. The Confidence in Network Meta-Analysis (CINeMA) framework
assessed evidence certainty. The primary outcome was intrapulmonary shunt
fraction during one-lung ventilation. Result(s): A total of 55 RCTs
were eligible for systematic review (2788 participants). The addition of
N<inf>2</inf>O (mean difference [MD]=-15%; 95% confidence interval [CI],
-25 to -5; P=0.003) or almitrine (MD=-13%; 95% CI, -20 to -6; P<0.001) to
propofol anaesthesia were efficient at decreasing shunt. Combined epidural
anaesthesia (MD=3%; 95% CI, 1-5; P=0.005), sevoflurane (MD=5%; 95% CI,
2-8; P<0.001), isoflurane (MD=6%; 95% CI, 4-9; P<0.001), and desflurane
(MD=9%; 95% CI, 4-14; P=0.001) increased shunt vs propofol. Almitrine
(MD=147 mmHg; 95% CI, 58-236; P=0.001), dopexamine (MD=88 mmHg; 95% CI,
4-171; P=0.039), and iloprost (MD=81 mmHg; 95% CI, 4-158; P=0.038)
improved PaO<inf>2</inf>/FiO<inf>2</inf>. Certainty of evidence ranged
from very low to moderate. Conclusion(s): Adding N<inf>2</inf>O and
almitrine to propofol anaesthesia reduced intrapulmonary shunt during
one-lung ventilation. Halogenated anaesthetics increased shunt in
comparison with propofol. The effects of N<inf>2</inf>O, iloprost, and
dexmedetomidine should be investigated in future research. N<inf>2</inf>O
results constitute a research hypothesis currently not backed by any
direct evidence. The clinical availability of almitrine is limited.
Systematic review protocol: PROSPERO CRD42022310313. Copyright ©
2022 British Journal of Anaesthesia

<56>
Accession Number
2019701246
Title
Severe ischemia after radial artery catheterization: A literature review
of published cases.
Source
Journal of Vascular Access. (no pagination), 2022. Date of Publication:
2022.
Author
Ying Y.; Lin X.-J.; Chen M.-J.; Cao Y.; Yao Y.-T.
Institution
(Ying, Lin, Chen, Cao) Department of Anesthesiology, Taizhou Hospital of
Zhejiang Province, Wenzhou Medical University, Zhejiang, Linhai, China
(Yao) Department of Anesthesiology, Fuwai Hospital, National Center for
Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking
Union Medical College, Beijing, China
Publisher
SAGE Publications Ltd
Abstract
Introduction: Severe ischemia is a rare complication of radial artery
catheterization (RAC). This study aims to summarize risk factors of
RAC-elicited severe hand ischemia, preventive, and therapeutic management.
 Method(s): Literature search was conducted in eight electronic
English and Chinese databases to identify relevant published cases. Data
of interest was extracted and analyzed. Result(s): Database search
identified 28 articles reporting cases of 57 patients developing hand
ischemia following RAC. Patients aged between 1 day and 88 years. The
indications for RAC included surgery, shock, cardiac arrest, and Neonatal
Intensive Care Unit (NICU) admission. Identified risk factors included
pre-existing vascular diseases, hypotension, arterial anatomical
abnormality or small diameter, vasoconstrictors, and catheter-related
problems. Totally, 18 patients complained pain; 32 developed
discoloration; 19 pulselessness; 3 paresthesia; 13 swolleness and 19
coldness. Eventually, 30 patients recovered well, but 20 patients
unfortunately underwent digital amputation and three patients deceased due
to non-RAC-related causes. Conclusion(s): Severe hand ischemia
following RAC is a rare complication, with the reported incidence of
approximately 0.09%. There is no definite predictor for RAC-related hand
ischemia, but patients with risk factors are prone to the occurrence of
hand ischemia. It's vital to initiate early recognition and proactive
strategies for a best practice RAC insertion. Copyright © The
Author(s) 2022.

<57>
Accession Number
2020810831
Title
Clinical outcomes of off-pump coronary artery bypass graft in patients
with diabetes and non-diabetics: A systematic review and meta-analysis.
Source
Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 16(11) (no
pagination), 2022. Article Number: 102643. Date of Publication: November
2022.
Author
aeen F.B.; Pakzad R.; Tayebi Z.; Kashkooli R.I.; Abdi F.
Institution
(aeen, Kashkooli) Student Research Committee, School of Nursing and
Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran, Islamic
Republic of
(Pakzad) Department of Epidemiology, Faculty of Health, Ilam University of
Medical Sciences, Ilam, Iran, Islamic Republic of
(Tayebi) Faculty of Nursing and Midwifery, Alborz University of Medical
Sciences, Karaj, Iran, Islamic Republic of
(Abdi) Non-communicable Diseases Research Center, Alborz University of
Medical Sciences, Karaj, Iran, Islamic Republic of
Publisher
Elsevier Ltd
Abstract
Background and aim: Diabetes mellitus is a prevalent risk factor for
developing coronary artery disease which worsens the clinical outcomes of
patients undergoing coronary artery bypass grafting (CABG). This study
aimed to determine the clinical outcomes of patients with diabetes and
non-diabetic patients who underwent off-pump CABG surgery. Method(s):
Medline, Scopus, Proquest, Embase, Web of Science, and Google scholar were
searched until September 10, 2021. The effect sizes including
unstandardized mean difference and odds ratio with 95% confidence interval
were calculated using "Metan" package. The Cochran's Q-test and
I2 statistic were used to assess heterogeneity, a
random-effects model was applied to estimate the pooled effect sizes, and
meta-regression was used to investigate the factors affecting
heterogeneity between studies. Result(s): 10 studies with 6200 sample
sizes were included in the study. In groups with diabetes, Summary odds
ratio (SOR) and 95% confidence interval of infection was 2.18 more than
non-diabetic groups. Also, odds renal complication was 1.74 more than
non-diabetic groups, and the odds cardiovascular complication in groups
with diabetes was 1.30 more than non-diabetics. There were no differences
in mortality, neurologic, respiratory and surgical complications between
groups with diabetes and non-diabetics. Based on meta-regression results,
age (Coefficient: 0.942; p = 0.009) had a significant direct relationship
and sample size (Coefficient: 0.001; p = 0.009) had an indirect
significant relationship with heterogeneity of neurologic outcomes. There
was no significant publication bias in our results. Conclusion(s):
Our study revealed that off-pump CABG led to some significant outcomes in
patients with diabetes compared to non-diabetics. Renal and infection
complications were higher in patients with diabetes but no significant
differences were seen in most of other postoperative outcomes between the
two groups. Copyright © 2022

<58>
Accession Number
2000825445
Title
Dabigatran in patients with myocardial injury after non-cardiac surgery
(MANAGE): an international, randomised, placebo-controlled trial.
Source
The Lancet. 391(10137) (pp 2325-2334), 2018. Date of Publication: 09 Jun
2018.
Author
Devereaux P.J.; Duceppe E.; Guyatt G.; Tandon V.; Rodseth R.; Biccard
B.M.; Xavier D.; Szczeklik W.; Meyhoff C.S.; Vincent J.; Franzosi M.G.;
Srinathan S.K.; Erb J.; Magloire P.; Neary J.; Rao M.; Rahate P.V.;
Chaudhry N.K.; Mayosi B.; de Nadal M.; Iglesias P.P.; Berwanger O.; Villar
J.C.; Botto F.; Eikelboom J.W.; Sessler D.I.; Kearon C.; Pettit S.;
Connolly S.J.; Bangdiwala S.I.; Rao-Melacini P.; Hoeft A.; Yusuf S.; Pogue
J.; Di Diodato S.; Gasic Z.; Mastrangelo L.J.; Molnar S.H.; Swanson J.L.;
Tosh M.L.; Wells J.R.; Diaz R.; Chow C.K.; Gonzales B.; Vasquez S.; Jansky
P.; Dusek R.; Coriat P.; Wittmann M.; Yonga G.; Mathur N.; Seletti E.;
Malaga G.; Tumanan-Mendoza B.A.; Tagle M.P.A.; Alonso-Coello P.; Popova
E.; Shields M.; Le Manach Y.; Moayyedi P.; van Zanten S.; Fleischmann E.;
Garg A.; Karaye K.; McFalls E.; Sigamani A.; Belley-Cote E.; Biedron G.;
Borges F.; Frosi Stella S.; Haarmark Nielsen C.; Leong D.P.; Spence J.;
Tran A.; Wawrzycka-Adamczyk K.; Yang S.S.; Yung T.; Wyse D.G.; Cheng D.;
Johnstone D.E.; Wells G.A.; Joseph P.; Patel A.; Gregus K.; Lawrence K.;
Doharris L.; Conen D.; Cheung J.; Douketis J.; Wright D.; Wikkerink S.;
Dechert W.; Panju M.; Azzam K.; Rapanos T.; Van Helder T.; Shroff A.; Hare
J.; Kidane B.; Nguyen T.; Leydier L.; Bayaraa V.; Parlow J.; DuMerton
D.A.; Thakrar A.; Shelley J.; Deligne B.; Carling R.D.; Mrkobrada M.;
Dresser G.K.; Jacka M.J.; Hornstein D.; Winkelaar G.B.; Haider Z.H.;
Lanjewar P.P.; Varughese V.; Calton R.; Ahuja H.; George P.; Sharma A.;
Bhatt K.S.; Mangukiya D.O.; Nandaniya K.V.; Parekh V.V.; Pillai A.B.;
Menon V.P.; Desai S.C.; Sidhu R.S.; Gupta S.K.; George R.K.; Gurunath
T.R.; Drummond L.W.; Torborg A.M.; Kusel B.S.; Naidoo P.; Naidoo D.P.;
Rajah C.; Farina Z.; von Rahden R.P.; Gumede S.; Chishala C.; Coetzee E.;
Dyer R.A.; Diedericks J.; Bielanski P.; Kaczmarek B.; Studzinska D.;
Zaniewski M.; Libura M.J.; Zacharias-Nalichowski T.M.; Sega A.A.S.; Salwa
J.; Kozka M.; Gorka J.; Wludarczyk A.; Nowak-Kozka I.; Grudzien P.S.;
Gucwa J.W.; Slowiaczek M.P.; Dobosz P.P.D.; Gogenur I.; Eriksen J.R.;
Borup T.; Kirkegaard T.; Isbye D.; Sonne A.; Rasmussen L.S.; Pedersen S.;
Troensegaard H.; Duus C.L.; Halle B.M.; Gundel O.N.; Bernholm K.F.;
Martinsen K.R.; Itenov T.S.; Camio E.; Vazquez C.; Matarin S.; Cano E.;
Alvarez-Garcia J.; India I.; Gonzalez-Osuna A.; Vives M.; Rossello E.;
Serrano A.B.; Turiel M.; Drago L.; Colombo C.; Marra F.; Mos L.; Arteni
F.; Lembo R.; Ortalda A.; Passarani S.; Mokini Z.; Figueiredo E.L.; Werner
G.F.; Petriz J.L.; Maia L.N.; Bergo R.R.; Precoma D.B.; Saraiva J.F.K.;
Vilamajo O.G.; Allegrini E.; Benzadon M.; Parody M.L.; Duronto E.A.;
Ingaramo A.C.; Parra G.A.; Novoa D.; Miller S.A.; Thomas S.; Karlapudi
S.P.; Bourji M.H.; Banerjee S.; Gupta A.; Opole I.O.; Fischer M.; Mendoza
V.L.; Reyes E.B.; Pierson R.J.; Shields M.O.; Piriou V.; Zacharowski K.;
Rotta-Rotta A.; Paper M.; Rahate P.; Chaudhry N.; Paniagua Iglesias P.;
Sharma M.
Institution
(Devereaux, Duceppe, Guyatt, Kearon, Bangdiwala, Yusuf) Department of
Health Research Methods, Evidence, and Impact, McMaster University,
Hamilton, ON, Canada
(Devereaux, Guyatt, Tandon, Magloire, Neary, Eikelboom, Kearon, Sharma,
Connolly, Yusuf) Department of Medicine, McMaster University, Hamilton,
ON, Canada
(Devereaux, Vincent, Pettit, Sharma, Connolly, Bangdiwala, Rao-Melacini,
Yusuf) Population Health Research Institute, Hamilton, ON, Canada
(Duceppe) Department of Medicine, University of Montreal, Montreal, QC,
Canada
(Rodseth) Department of Anaesthesia, University of KwaZulu-Natal,
Pietermaritzburg, South Africa
(Biccard) Department of Anaesthesia and Perioperative Medicine, Groote
Schuur Hospital and University of Cape Town, Cape Town, South Africa
(Mayosi) Department of Medicine, Groote Schuur Hospital and University of
Cape Town, Cape Town, South Africa
(Xavier, Rao) Department of Pharmacology, St John's Medical College and
Research Institute, Bangalore, India
(Szczeklik) Department of Intensive Care and Perioperative Medicine,
Jagiellonian University Medical College, Krakow, Poland
(Meyhoff) Department of Anaesthesia and Intensive Care, Bispebjerg and
Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark
(Franzosi) Department of Cardiovascular Research, IRCCS Istituto di
Ricerche Farmacologiche Mario Negri, Milan, Italy
(Srinathan) Department of Surgery, University of Manitoba, Winnipeg, MB,
Canada
(Erb) Department of Anesthesiology and Perioperative Medicine, Queen's
University, Kingston, ON, Canada
(Rahate) Department of Surgery, Rahate Surgical Hospital, Nagpur, India
(Chaudhry) Department of Surgery, Christian Medical College Hospital,
Ludhiana, India
(de Nadal) Department of Anesthesiology, Hospital Universitari Vall
d'Hebron, Barcelona, Spain
(Iglesias) Department of Anesthesiology, Hospital de la Santa Creu i Sant
Pau, Barcelona, Spain
(Berwanger) Instituto de Ensino e Pesquisa do Hospital do Coracao
(IEP-HCor), Sao Paulo, Brazil
(Villar) Departamento de Investigaciones, Fundacion
Cardioinfantil-Instituto de Cardiologia (Bogota) and Facultad de Ciencias
de la Salud, Universidad Autonoma de Bucaramanga, Colombia
(Botto) Estudios Clinicos Latinoamerica (ECLA), Rosario and Hospital
Austral, Pilar, Argentina
(Sessler) Department of Outcomes Research, Cleveland Clinic,
Anesthesiology Institute, Cleveland, OH, United States
(Hoeft) Department of Anesthesiology and Intensive Care Medicine,
University Hospital Bonn, Bonn, Germany
Publisher
Lancet Publishing Group (E-mail: cususerv@lancet.com)
Abstract
Background: Myocardial injury after non-cardiac surgery (MINS) increases
the risk of cardiovascular events and deaths, which anticoagulation
therapy could prevent. Dabigatran prevents perioperative venous
thromboembolism, but whether this drug can prevent a broader range of
vascular complications in patients with MINS is unknown. The MANAGE trial
assessed the potential of dabigatran to prevent major vascular
complications among such patients. Method(s): In this international,
randomised, placebo-controlled trial, we recruited patients from 84
hospitals in 19 countries. Eligible patients were aged at least 45 years,
had undergone non-cardiac surgery, and were within 35 days of MINS.
Patients were randomly assigned (1:1) to receive dabigatran 110 mg orally
twice daily or matched placebo for a maximum of 2 years or until
termination of the trial and, using a partial 2-by-2 factorial design,
patients not taking a proton-pump inhibitor were also randomly assigned
(1:1) to omeprazole 20 mg once daily, for which results will be reported
elsewhere, or matched placebo to measure its effect on major upper
gastrointestinal complications. Research personnel randomised patients
through a central 24 h computerised randomisation system using block
randomisation, stratified by centre. Patients, health-care providers, data
collectors, and outcome adjudicators were masked to treatment allocation.
The primary efficacy outcome was the occurrence of a major vascular
complication, a composite of vascular mortality and non-fatal myocardial
infarction, non-haemorrhagic stroke, peripheral arterial thrombosis,
amputation, and symptomatic venous thromboembolism. The primary safety
outcome was a composite of life-threatening, major, and critical organ
bleeding. Analyses were done according to the intention-to-treat
principle. This trial is registered with ClinicalTrials.gov, number
NCT01661101. Finding(s): Between Jan 10, 2013, and July 17, 2017, we
randomly assigned 1754 patients to receive dabigatran (n=877) or placebo
(n=877); 556 patients were also randomised in the omeprazole partial
factorial component. Study drug was permanently discontinued in 401 (46%)
of 877 patients allocated to dabigatran and 380 (43%) of 877 patients
allocated to placebo. The composite primary efficacy outcome occurred in
fewer patients randomised to dabigatran than placebo (97 [11%] of 877
patients assigned to dabigatran vs 133 [15%] of 877 patients assigned to
placebo; hazard ratio [HR] 0.72, 95% CI 0.55-0.93; p=0.0115). The primary
safety composite outcome occurred in 29 patients (3%) randomised to
dabigatran and 31 patients (4%) randomised to placebo (HR 0.92, 95% CI
0.55-1.53; p=0.76). Interpretation(s): Among patients who had MINS,
dabigatran 110 mg twice daily lowered the risk of major vascular
complications, with no significant increase in major bleeding. Patients
with MINS have a poor prognosis; dabigatran 100 mg twice daily has the
potential to help many of the 8 million adults globally who have MINS to
reduce their risk of a major vascular complication. Funding(s):
Boehringer Ingelheim and Canadian Institutes of Health
Research. Copyright © 2018 Elsevier Ltd

<59>
Accession Number
2020853388
Title
A meta-analysis of pharmacological treatments for preventing acute renal
injury after juvenile heart surgery.
Source
Progress in Pediatric Cardiology. 67 (no pagination), 2022. Article
Number: 101573. Date of Publication: December 2022.
Author
Saeed H.; Abdelrahim M.E.A.
Institution
(Saeed, Abdelrahim) Clinical Pharmacy Department, Faculty of Pharmacy,
Beni-Suef University, Beni-Suef, Egypt
Publisher
Elsevier Ireland Ltd
Abstract
Background: Children who have had heart surgery frequently develop an
acute renal injury, which complicates postoperative care and is associated
with a high mortality rate. Several pharmacological interventions are
introduced for preventing postoperative renal dysfunction. Aim of review:
The current meta-analysis aims to evaluate the effectiveness of
pharmacological interventions in preventing postoperative renal
dysfunction after congenital heart surgery in pediatric subjects. Key
scientific concepts of review: A systematic literature search up to July
2021 was performed and 20 studies included 2612 subjects with congenital
heart surgery at the start of the study; 1527 of them were administered
pharmacological interventions and 1070 were placebo. The odds ratio (OR)
with 95 % confidence intervals (CIs) was calculated to assess the effects
of pharmacological interventions compared to placebo on preventing
postoperative renal dysfunction after congenital heart surgery in
pediatric subjects using the dichotomous method with a random or
fixed-effect model. Pharmacological interventions had significantly lower
postoperative renal dysfunction after congenital heart surgery in
pediatric subjects when using dexmedetomidine (OR, 0.44; 95 % CI,
0.28-0.68, p < 0.001), and compared to placebo. However, pharmacological
interventions had no significant effect on postoperative renal dysfunction
after congenital heart surgery in pediatric subjects when using
corticosteroids (OR, 0.86; 95 % CI, 0.60-1.25, p = 0.44), fenoldopam (OR,
0.47; 95 % CI, 0.22-1.02, p = 0.06), and aminophylline (OR, 0.72; 95 % CI,
0.22-2.33, p = 0.58) compared to placebo. Dexmedetomidine may reduce
postoperative renal impairment after congenital heart surgery in children
compared to placebo. Pediatric corticosteroids, fenoldopam, and
aminophylline did not affect postoperative renal impairment after
congenital heart surgery compared to placebo. Additional research is
needed to confirm these results. Copyright © 2022 Elsevier B.V.

<60>
Accession Number
2015481891
Title
A systematic review and meta-analysis of the impact of the left atrial
appendage closure on left atrial function.
Source
Clinical Cardiology. 45(6) (pp 614-621), 2022. Date of Publication: June
2022.
Author
Mostafa M.R.; Magdi M.; Al-abdouh A.; Abusnina W.; Elbanna M.; Abdelazeem
B.; Renjithal S.L.M.; Mamas M.A.; Shah J.
Institution
(Mostafa, Magdi, Renjithal) Department of Internal Medicine, Rochester
Regional Health, Unity Hospital, Greece, NY, United States
(Al-abdouh) Department of Medicine, University of Kentucky, Lexington, KY,
United States
(Abusnina) Department of Cardiology, Creighton University School of
Medicine, Omaha, NE, United States
(Elbanna) Department of Medicine, Mayo Clinic, Phoenix, AZ, United States
(Abdelazeem) Department of Medicine, McLaren Health System, Flint, MI,
United States
(Mamas) Department of Cardiology, University of Manchester, Manchester,
United Kingdom
(Shah) New York State Department of Health, New York, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Left atrial (LA) appendage closure (LAAC) is effective in
patients with atrial fibrillation who are not candidates for long-term
anticoagulation. However, the impact of LAAC on LA function is unknown.
The aim of this study is to evaluate the impact of LAAC on atrial
function. Method(s): This meta-analysis was conducted according to
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
guidelines. A search strategy was designed to utilize PubMed/Medline,
EMBASE, and Google scholar for studies showing the effect of LAAC on the
LA function from inception to November 20, 2021. The standardized mean
difference (SMD) was calculated from the means and standard deviations.
 Result(s): Of 247 studies initially identified, 8 studies comprising
260 patients were included in the final analysis. There was a significant
increase in LA emptying fraction following LAAC compared with preoperative
function (SMD: 0.53; 95% confidence interval [CI]: 0.04-1.01; p =.03;
I2 = 75%). In contrast, there were no significant differences
in LA volume (SMD: -0.07; 95% CI: -0.82-0.69; p =.86; I2 = 92%)
peak atrial longitudinal strain (SMD: 0.50; 95% CI: -0.08-1.08; p =.09;
I2 = 89%), peak atrial contraction strain (SMD: 0.38; 95% CI:
-0.22-0.99; p =.21; I2 = 81%), strain during atrial contraction
(SMD: -0.24; 95% CI: -0.61-0.13; p =.20; I2 = 0%), strain
during ventricular systole (SMD: 0.47; 95% CI: -0.32-1.27; p =.24;
I2 = 89%), strain during ventricular diastole (SMD: 0.09; 95%
CI: -0.32-0.51; p =.66; I2 = 65%). Conclusion(s): LAAC is
associated with improvement in the left atrial emptying fraction, but did
not significantly influence other parameters. Copyright © 2022
The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.

<61>
Accession Number
2015207234
Title
Cardiac Surgery in Patients With Blood Disorders.
Source
Heart Lung and Circulation. 31(2) (pp 167-176), 2022. Date of Publication:
February 2022.
Author
Nair D.; Sreejith N.; Bhambra A.; Bruce J.; Mellor S.; Brown L.J.; Harky
A.
Institution
(Nair, Bhambra, Bruce) College of Medical and Dental Sciences, University
of Birmingham, Birmingham, UK, United Kingdom
(Sreejith) Medical Sciences Division, University of Oxford, Oxford, UK,
United Kingdom
(Mellor) Sandwell & West Birmingham NHS Trust, Sandwell General Hospital,
West Bromwich, United Kingdom
(Brown) North Cumbria Integrated Care NHS Foundation Trust, Cumberland
Infirmary, Carlisle, UK, United Kingdom
(Harky) Department of Cardiothoracic Surgery, Liverpool Heart and Chest,
Liverpool, UK, United Kingdom
(Harky) Department of Cardiac Surgery, Alder Hey Children Hospital,
Liverpool, UK, United Kingdom
Publisher
Elsevier Ltd
Abstract
Blood disorders that can contribute to abnormal bleeding can have a
detrimental effect during cardiac surgery. Patients who are known to have
such pathologies should be investigated thoroughly and cautious measures
would need to be taken when cardiac surgery is needed in this cohort. The
majority of current literature for cardiac surgery in patients with von
Willebrand Disease and haemophilia are case reports. Nevertheless,
evidence shows that optimising factor levels pre, intra and
postoperatively offers outcomes similar to that of patients without these
disorders. Preoperative screening followed by appropriate iron therapy
reduces mortality for patients with anaemia. In this group, haemoglobin
levels can be improved postoperatively through iron supplementation. The
management strategy of cardiac surgery for people with blood disorders
requires a multidisciplinary approach that is highly individualised for
each patient. It is essential to adequately adjust preoperative,
perioperative and postoperative care to the patient's blood disorder in
order to achieve outcomes similar to that of patients without blood
disorders. Copyright © 2021 Australian and New Zealand Society of
Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of
Australia and New Zealand (CSANZ)

<62>
Accession Number
2020812331
Title
Perioperative Management of Antiplatelet Therapy: A Systematic Review and
Meta-analysis.
Source
Mayo Clinic Proceedings: Innovations, Quality and Outcomes. 6(6) (pp
564-573), 2022. Date of Publication: December 2022.
Author
Shah S.; Urtecho M.; Firwana M.; Nayfeh T.; Hasan B.; Nanaa A.; Saadi S.;
Flynn D.N.; Abd-Rabu R.; Seisa M.O.; Rajjoub N.S.; Hassett L.C.;
Spyropoulos A.C.; Douketis J.D.; Murad M.H.
Institution
(Shah, Urtecho, Firwana, Nayfeh, Hasan, Nanaa, Saadi, Abd-Rabu, Seisa,
Rajjoub, Murad) Evidence-Based Practice Research Program, Mayo Clinic,
Rochester, MN, United States
(Shah, Urtecho, Firwana, Nayfeh, Hasan, Nanaa, Saadi, Abd-Rabu, Seisa,
Rajjoub, Murad) Robert D. and Patricia E. Kern Center for the Science of
Health Care Delivery, Mayo Clinic, Rochester, MN, United States
(Hassett) Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, United States
(Flynn) University of North Carolina at Chapel Hill School of Medicine,
Chapel Hill, NC, United States
(Spyropoulos) Institute of Health Systems Science - Feinstein Institutes
for Medical Research and The Donald and Barbara Zucker School of Medicine
at Hofstra/Northwell, Department of Medicine, Anticoagulation and Clinical
Thrombosis Services, Northwell Health at Lenox Hill Hospital, NY, NY,
Belgium
(Douketis) Department of Medicine, McMaster University, Hamilton, Canada
Publisher
Elsevier B.V.
Abstract
Objective: To summarize the available evidence about the perioperative
management of patients who are receiving long-term antiplatelet therapy
and require elective surgery/procedures. Method(s): This systematic
review supports the development of the American College of Chest
Physicians guideline on the perioperative management of antiplatelet
therapy. A literature search of MEDLINE, EMBASE, Scopus and Cochrane
databases was conducted from each database's inception to July 16, 2020.
Meta-analyses were conducted when possible. Result(s): In patients
receiving long-term antiplatelet therapy and undergoing elective
noncardiac surgery, the available evidence did not show a significant
difference in major bleeding between a shorter vs longer antiplatelet
interruption, with low certainty of evidence (COE). Compared with patients
who received placebo perioperatively, aspirin continuation was associated
with increased risk of major bleeding (relative risk [RR], 1.31; 95% CI,
1.15-1.50; high COE) and lower risk of major thromboembolism (RR, 0.74;
95% CI, 0.58-0.94; moderate COE). During antiplatelet interruption,
bridging with low-molecular-weight heparin was associated with increased
risk of major bleeding compared with no bridging (RR, 1.86; 95% CI,
1.24-2.79; very low COE). Continuation of antiplatelets during minor
dental and ophthalmologic procedures was not associated with a
statistically significant difference in the risk of major bleeding (very
low COE). Conclusion(s): This systematic review summarizes the
current evidence about the perioperative management of antiplatelet
therapy and highlights the urgent need for further research, particularly
with the increasing prevalence of patients taking 1 or more antiplatelet
agents. Copyright © 2022 The Authors

<63>
Accession Number
2016697681
Title
Topical Vancomycin and Risk of Sternal Wound Infections: A Double-Blind
Randomized Controlled Trial.
Source
Annals of Thoracic Surgery. 114(5) (pp 1555-1561), 2022. Date of
Publication: November 2022.
Author
Servito M.; Khani-Hanjani A.; Smith K.-M.; Tsuyuki R.T.; Mullen J.C.
Institution
(Servito) School of Medicine, Faculty of Health Sciences, Queen's
University, Kingston, ON, Canada
(Khani-Hanjani) Division of Cardiac Surgery, Royal University Hospital,
University of Saskatchewan, Saskatoon, SK, Canada
(Smith, Mullen) Division of Cardiac Surgery, Faculty of Medicine and
Dentistry, University of Alberta, Edmonton, AB, Canada
(Tsuyuki) Department of Pharmacology, Faculty of Medicine and Dentistry,
University of Alberta, Edmonton, AB, Canada
(Tsuyuki) Division of Cardiology, Department of Medicine, Faculty of
Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
Publisher
Elsevier Inc.
Abstract
Background: The use of topical vancomycin in the reduction of sternal
wound infection (SWI) risk has become a point of contention. The earlier
literature consists of observational studies and 1 unblinded trial. Hence,
the objective of this study was to assess whether vancomycin reduces the
incidence of SWI in a double-blind randomized controlled trial.
 Method(s): Patients were randomized 1:1 to either vancomycin-soaked
(vancomycin) or saline-soaked (control) sponges. The sponges were applied
once the sternum was opened and were removed just before sternal closure.
Patients were followed up at 3 months and at 1 year postoperatively to
determine the incidence of SWI in each group. Results were analyzed
according to the modified intention-to-treat principle. Result(s):
This study assessed 1038 patients for eligibility and enrolled 1037
patients. There were 517 patients randomized to the vancomycin group and
520 patients randomized to the control group. Analysis was performed on
1021 patients. At 3 months postoperatively, there was no significant
difference in the incidence of SWI between the vancomycin and control
groups (2.7% vs 4.1%; P = .23). There was also no significant difference
between the vancomycin and control groups in the risk of superficial,
deep, and organ-space infections. Similar findings were observed 1 year
postoperatively. The most common organism isolated was coagulase-negative
Staphylococcus. Conclusion(s): The use of vancomycin applied to the
sternum during cardiac surgery does not reduce the incidence of
SWI. Copyright © 2022 The Society of Thoracic Surgeons

<64>
[Use Link to view the full text]
Accession Number
2020368931
Title
Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and
Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in
Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI
63B.
Source
Circulation. 146(12) (pp 907-916), 2022. Date of Publication: 20 Sep 2022.
Author
Bonaca M.P.; Morrow D.A.; Bergmark B.A.; Berg D.D.; Lima J.A.C.; Hoffmann
U.; Kato Y.; Lu M.T.; Kuder J.; Murphy S.A.; Spinar J.; Ophuis T.O.; Kiss
R.G.; Lopez-Sendon J.; Averkov O.; Wheatcroft S.B.; Kubica J.; Nicolau
J.C.; Furtado R.H.M.; Abuhatzira L.; Hirshberg B.; Omar S.A.; Vavere A.L.;
Chang Y.-T.; George R.T.; Sabatine M.S.
Institution
(Bonaca) CPC Clinical Research, Department of Medicine, University of
Colorado, Anschutz School of Medicine, Aurora, United States
(Morrow, Bergmark, Berg, Kuder, Murphy, Sabatine) TIMI Study Group,
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United
States
(Lima, Kato) Division of Cardiology, Johns Hopkins University, Baltimore,
MD, United States
(Hoffmann, Lu) Cardiovascular Imaging Research Center, Massachusetts
General Hospital, Harvard Medical School, Boston, United States
(Spinar) Internal Cardioangiology Department, St. Ann University Hospital,
Masaryk University, Brno, Czechia
(Ophuis) Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands
(Kiss) Department of Cardiology, Military Hospital, Budapest, Hungary
(Lopez-Sendon) IdiPaz Research Institute, Hospital Universitario La Paz,
UAM, Madrid, Spain
(Averkov) Pirogov Russian National Research Medical University, Moscow,
Russian Federation
(Wheatcroft) Leeds Institute of Cardiovascular and Metabolic Medicine,
University of Leeds, United Kingdom
(Kubica) Department of Cardiology and Internal Medicine, Collegium
Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
(Nicolau, Furtado) Instituto do Coracao, Hospital das Clinicas, Faculdade
de Medicina, Universidade de Sao Paulo, Brazil
(Furtado) Academic Research Organization, Hospital Israelita Albert
Einstein, Sao Paulo, Brazil
(Abuhatzira) Horizon Therapeutics, Gaithersburg, MD, United States
(Hirshberg) Regio Biosciences, Rockville, MD, United States
(Omar, Vavere, Chang, George) Early Clinical Development, Research and
Early Development, Cardiovascular, Renal and Metabolism,
BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: High-density lipoprotein plays a key role in reverse
cholesterol transport. In addition, high-density lipoprotein particles may
be cardioprotective and reduce infarct size in the setting of myocardial
injury. Lecithin-cholesterol acyltransferase is a rate-limiting enzyme in
reverse cholesterol transport. MEDI6012 is a recombinant human
lecithin-cholesterol acyltransferase that increases high-density
lipoprotein cholesterol. Administration of lecithin-cholesterol
acyltransferase has the potential to reduce infarct size and regress
coronary plaque in acute ST-segment-elevation myocardial infarction.
 METHOD(S): REAL-TIMI 63B (A Randomized, Placebo-controlled Phase 2b
Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST
Elevation Myocardial Infarction) was a phase 2B multinational,
placebo-controlled, randomized trial. Patients with ST-segment-elevation
myocardial infarction within 6 hours of symptom onset and planned for
percutaneous intervention were randomly assigned 2:1 to MEDI6012 (2- or
6-dose regimen) or placebo and followed for 12 weeks. The primary outcome
was infarct size as a percentage of left ventricular mass by cardiac MRI
at 10 to 12 weeks, with the primary analysis in patients with TIMI Flow
Grade 0 to 1 before percutaneous intervention who received at least 2
doses of MEDI6012. The secondary outcome was change in noncalcified plaque
volume on coronary computed tomographic angiography from baseline to 10 to
12 weeks with the primary analysis in patients who received all 6 doses of
MEDI6012. RESULT(S): A total of 593 patients were randomly assigned.
Patients were a median of 62 years old, 77.9% male, and 95.8% statin
naive. Median time from symptom onset to randomization was 146
(interquartile range [IQR], 103-221) minutes and from hospitalization to
randomization was 12.7 (IQR, 6.6-24.0) minutes, and the first dose of drug
was administered a median of 8 (IQR, 3-13) minutes before percutaneous
intervention. The index myocardial infarction was anterior in 69.6% and
TIMI Flow Grade 0 to 1 in 65.1% of patients. At 12 weeks, infarct size did
not differ between treatment groups (MEDI6012: 9.71%, IQR 4.79-16.38;
placebo: 10.48%, [IQR, 4.92-16.61], 1-sided P=0.79. There was also no
difference in noncalcified plaque volume (geometric mean ratio, 0.96 [95%
CI, NA-1.10], 1-sided P=0.30). There was no significant difference in
treatment emergent serious adverse events. CONCLUSION(S):
Administration of MEDI6012 in patients with acute ST-segment-elevation
myocardial infarction did not result in a significant reduction in infarct
size or noncalcified plaque volume at 12 weeks. MEDI6012 was well
tolerated with no excess in overall serious adverse events. Copyright
© 2022 American Heart Association, Inc.

<65>
Accession Number
2019658396
Title
The value of urinary interleukin-18 in predicting acute kidney injury: a
systematic review and meta-analysis.
Source
Renal Failure. 44(1) (pp 1717-1731), 2022. Date of Publication: 2022.
Author
Qin Z.; Li H.; Jiao P.; Jiang L.; Geng J.; Yang Q.; Liao R.; Su B.
Institution
(Qin, Jiang, Geng, Yang, Liao, Su) Department of Nephrology, National
Clinical Research Center for Geriatrics, West China Hospital of Sichuan
University, Chengdu, China
(Qin, Jiang, Geng, Yang, Liao, Su) Med-X Center for Materials, Sichuan
University, Chengdu, China
(Qin, Jiang, Geng, Yang, Liao, Su) Med + Biomaterial Institute of West
China Hospital/West China School of Medicine of Sichuan University,
Chengdu, China
(Li, Jiao) West China School of Medicine, West China Hospital of Sichuan
University, Chengdu, China
Publisher
Taylor and Francis Ltd.
Abstract
Aims: The aim of this study was to systematically review relevant studies
to evaluate the value of urinary interleukin-18 (uIL-18) in predicting
acute kidney injury (AKI). Method(s): A comprehensive search of
PubMed, Medline, Embase, and Cochrane Library was conducted for literature
published up to 1 August 2022. Quality Assessment Tool for Diagnostic
Accuracy Studies-2 (QUADAS-2) was applied to assess the literature
quality. Then, relevant data were extracted from each eligible study and a
random-effects regression model was utilized to pool sensitivity,
specificity, and construct summary receiver operating characteristic
(SROC) and area under curve (AUC). Result(s): Twenty-six studies with
7183 patients were enrolled and relevant information was extracted. The
estimated sensitivity and specificity of uIL-18 in the diagnosis of AKI
were 0.64 (95% confidence interval (CI): 0.54-0.73) and 0.77 (95%CI:
0.71-0.83), respectively. The pooled diagnostic odds ratio (DOR) was 6.08
(95%CI: 3.63-10.18), and the AUC of uIL-18 in predicting AKI was 0.78
(95%CI: 0.74-0.81). Subgroup analysis showed that uIL-18 in pediatric
patients was more effective in predicting AKI than in adults (DOR: 7.33
versus 5.75; AUC: 0.81 versus 0.77). Conclusion(s): Urinary IL-18
could be a relatively good biomarker with moderate predictive value for
AKI, especially in pediatric patients. However, further research and
clinical settings are still needed to validate our findings. Copyright
© 2022 The Author(s). Published by Informa UK Limited, trading as
Taylor & Francis Group.

<66>
Accession Number
2019346185
Title
Machine learning in predicting cardiac surgery-associated acute kidney
injury: A systemic review and meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 951881. Date of Publication: 15 Sep 2022.
Author
Song Z.; Yang Z.; Hou M.; Shi X.
Institution
(Song, Yang, Hou) Qinghai University Medical School, Xining, China
(Hou, Shi) Qinghai University Affiliated Hospital Intensive Care Unit,
Xining, China
Publisher
Frontiers Media S.A.
Abstract
Background: Cardiac surgery-associated acute kidney injury (CSA-AKI) is a
common complication following cardiac surgery. Early prediction of CSA-AKI
is of great significance for improving patients' prognoses. The aim of
this study is to systematically evaluate the predictive performance of
machine learning models for CSA-AKI. Method(s): Cochrane Library,
PubMed, EMBASE, and Web of Science were searched from inception to 18
March 2022. Risk of bias assessment was performed using PROBAST. Rsoftware
(version 4.1.1) was used to calculate the accuracy and C-index of CSA-AKI
prediction. The importance of CSA-AKI prediction was defined according to
the frequency of related factors in the models. Result(s): There were
38 eligible studies included, with a total of 255,943 patients and 60
machine learning models. The models mainly included Logistic Regression (n
= 34), Neural Net (n = 6), Support Vector Machine (n = 4), Random Forest
(n = 6), Extreme Gradient Boosting (n = 3), Decision Tree (n = 3),
Gradient Boosted Machine (n = 1), COX regression (n = 1), kappaNeural Net
(n = 1), and Naive Bayes (n = 1), of which 51 models with intact recording
in the training set and 17 in the validating set. Variables with the
highest predicting frequency included Logistic Regression, Neural Net,
Support Vector Machine, and Random Forest. The C-index and accuracy wer
0.76 (0.740, 0.780) and 0.72 (0.70, 0.73), respectively, in the training
set, and 0.79 (0.75, 0.83) and 0.73 (0.71, 0.74), respectively, in the
test set. Conclusion(s): The machine learning-based model is
effective for the early prediction of CSA-AKI. More machine learning
methods based on noninvasive or minimally invasive predictive indicators
are needed to improve the predictive performance and make accurate
predictions of CSA-AKI. Logistic regression remains currently the most
commonly applied model in CSA-AKI prediction, although it is not the one
with the best performance. There are other models that would be more
effective, such as NNET and XGBoost. Systematic review registration:
https://www.crd.york.ac.uk/; review registration ID:
CRD42022345259. Copyright © 2022 Song, Yang, Hou and Shi.

<67>
Accession Number
2019205614
Title
Anticoagulation Management in High Bleeding-Risk ECMO in Adults.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 884063. Date of Publication: 06 Apr 2022.
Author
De Paulis S.; Cavaliere F.
Institution
(De Paulis, Cavaliere) Department of Cardiovascular Sciences, Fondazione
Policlinico Gemelli IRCCS, Rome, Italy
(Cavaliere) Universita Cattolica del Sacro Cuore, Rome, Italy
Publisher
Frontiers Media S.A.

<68>
Accession Number
2019205445
Title
Pooled-Analysis of Association of Sievers Bicuspid Aortic Valve Morphology
With New Permanent Pacemaker and Conduction Abnormalities After
Transcatheter Aortic Valve Replacement.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 884911. Date of Publication: 26 May 2022.
Author
Zhang J.; Li X.; Xu F.; Chen Y.; Li C.
Institution
(Zhang, Xu, Chen, Li) Department of Emergency Medicine and Chest Pain
Center, Cheeloo College of Medicine, Qilu Hospital of Shandong University,
Jinan, China
(Zhang, Xu, Chen, Li) Key Laboratory of Emergency and Critical Care
Medicine of Shandong Province, Qilu Hospital of Shandong University,
Jinan, China
(Zhang, Xu, Chen, Li) Key Laboratory of Cardiovascular Remodeling and
Function Research, Qilu Hospital of Shandong University, Jinan, China
(Li) Department of Geriatrics, Qilu Hospital of Shandong University,
Jinan, China
Publisher
Frontiers Media S.A.
Abstract
Background: Studies on the association of Sievers bicuspid aortic valve
(BAV) morphology with conduction disorders after transcatheter aortic
valve replacement (TAVR) have not reached consensus. Method(s): We
here performed a pooled-analysis to explore whether Sievers type 1 BAV
morphology increased the risk of post-TAVR conduction abnormalities and
permanent pacemaker implantation (PPI) compared to type 0. Systematic
literature searches through EMBASE, Medline, and Cochrane databases were
concluded on 1 December 2021. The primary endpoint was post-TAVR new PPI
and pooled as risk ratios (RRs) and 95% confidence intervals (CIs).
Conduction abnormalities as the secondary endpoint were the composites of
post-TAVR PPI and/or new-onset high-degree of atrial-ventricle node block
and left-bundle branch block. Studies that reported incidence of outcomes
of interest in both type 1 and type 0 BAV morphology who underwent TAVR
for aortic stenosis were included. Result(s): Finally, nine studies
were included. Baseline characteristics were generally comparable, but
type 1 population was older with a higher surgical risk score compared to
type 0 BAV morphology. In the pooled-analysis type 1 BAV had significantly
higher risk of post-TAVR new-onset conduction abnormalities (RR = 1.68,
95%CI 1.09-2.60, p = 0.0195) and new PPI (RR = 1.97, 95%CI 1.29-2.99, p =
0.0016) compared to type 0. Random-effects univariate meta-regression
indicated that no significant association between baseline characteristics
and PPI. Conclusion(s): Sievers type 1 BAV morphology was associated
with increased risk of post-TAVR PPI and conduction abnormalities compared
to type 0. Dedicated cohort is warranted to further validate our
hypothesis. Copyright © 2022 Zhang, Li, Xu, Chen and Li.

<69>
Accession Number
2019182049
Title
Assessment and Management of Older Patients With Transthyretin Amyloidosis
Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 863179. Date of Publication: 17 May 2022.
Author
Irabor B.; McMillan J.M.; Fine N.M.
Institution
(Irabor, McMillan, Fine) Cumming School of Medicine, University of
Calgary, Calgary, AB, Canada
(McMillan) Division of Geriatrics, Departments of Medicine and Community
Health Sciences, Calgary, AB, Canada
(Fine) Division of Cardiology, Departments of Cardiac Sciences, Medicine
and Community Health Sciences, Libin Cardiovascular Institute, Calgary,
AB, Canada
Publisher
Frontiers Media S.A.
Abstract
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is commonly diagnosed
in older adults, in particular the wild-type (ATTRwt), which is regarded
as an age-related disease. With an aging population and improved
diagnostic techniques, the prevalence and incidence of ATTR-CM will
continue to increase. With increased availability of mortality reducing
ATTR-CM therapies, patients are living longer. The predominant clinical
manifestation of ATTR-CM is heart failure, while other cardiovascular
manifestations include arrhythmia and aortic stenosis. Given their older
age at diagnosis, patients often present with multiple age-related
comorbidities, some of which can be exacerbated by ATTR, including
neurologic, musculoskeletal, and gastrointestinal problems. Considerations
related to older patient care, such as frailty, cognitive decline,
polypharmacy, falls/mobility, functional capacity, caregiver support,
living environment, quality of life and establishing goals of care are
particularly important for many patients with ATTR-CM. Furthermore, the
high cost ATTR treatments has increased interest in establishing improved
predictors of response to therapy, with assessment of frailty emerging as
a potentially important determinant. Multidisciplinary care inclusive of
collaboration with geriatric and elder care medicine specialists, and
others such as neurology, orthopedic surgery, electrophysiology and
transcatheter aortic valve replacement clinics, is now an important
component of ATTR-CM management. This review will examine current aspects
of the management of older ATTR-CM patients, including shared care with
multiple medical specialists, the emerging importance of frailty
assessment and other considerations for using ATTR
therapies. Copyright © 2022 Irabor, McMillan and Fine.

<70>
Accession Number
2018898070
Title
Colchicine and Quality of Life in Patients With Acute Coronary Syndromes:
Results From the COPS Randomized Trial.
Source
Cardiovascular Revascularization Medicine. 44 (pp 53-59), 2022. Date of
Publication: November 2022.
Author
Dawson L.P.; Quinn S.; Tong D.; Boyle A.; Hamilton-Craig C.; Adams H.;
Layland J.
Institution
(Dawson, Tong, Layland) Department of Cardiology, Peninsula Health,
Melbourne, VIC, Australia
(Dawson, Layland) Department of Medicine, Monash University, Melbourne,
VIC, Australia
(Dawson) Department of Cardiology, Royal Melbourne Hospital, Melbourne,
VIC, Australia
(Quinn) Swinburne University of Technology, Department of Health Science
and Biostatistics, Hawthorn, VIC, Australia
(Tong) St Vincent's Hospital, Melbourne, VIC, Australia
(Boyle) School of Medicine and Public Health, University of Newcastle,
NSW, Australia
(Hamilton-Craig) The Prince Charles Hospital, Brisbane, QLD, Australia
(Hamilton-Craig) School of Medicine, Griffith University, Australia
(Adams) Royal Hobart Hospital, Hobart, TAS, Australia
Publisher
Elsevier Inc.
Abstract
Background: Recent data suggest that colchicine may reduce cardiovascular
events among patients presenting with acute coronary syndromes. This
sub-study of the Australian COPS trial aimed to assess whether colchicine
affects health status outcomes. Method(s): Health status was assessed
at baseline and 12-months using the EuroQol-5 Dimension 5-level (EQ-5D-5L)
score and the full 19-question Seattle Angina Questionnaire (SAQ). Data
were available for 786 patients (388 randomized to colchicine, 398 to
placebo). Result(s): Baseline characteristics were well matched
between groups; mean age was 60.1 (SD 14.8) years, and 20 % were female.
Baseline health status scores were impaired, and most parameters
demonstrated significant improvement from baseline to 12-months (EQ-5D-5L
Visual Analogue Score [VAS] 69.3 to 77.7; SAQ angina frequency score 83.0
to 95.3, both p < 0.001). No significant differences in adjusted mean
score change among any of the EQ-5D-5L or SAQ dimensions were observed
between treatment groups in either intention-to-treat or per-protocol
analysis. There were borderline interactions in EQ-5D-5L scores for those
with previous MI vs not, and in SAQ scores for those with obesity vs not.
In categorical analysis using observed data, patients treated with
colchicine were more likely to have clinically significant improvement in
physical limitation score over the period (36 % improved vs. 28 %, p <
0.05). Baseline health status scores were not associated with the primary
endpoint at 12 months. Conclusion(s): Treatment with colchicine did
not appear to affect change in measures of health status following acute
coronary syndromes, but it did lead to a greater likelihood of improvement
in physical limitation scores. Trial registration: ACTRN,
ACTRN12615000861550. Registered 18/08/2015,
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368973.Copyright © 2022 Elsevier Inc.

<71>
Accession Number
2018886897
Title
Effectiveness of Acapella along with institutional based chest
physiotherapy techniques on pulmonary functions and airway clearance in
post-operative CABG patients.
Source
Hong Kong Physiotherapy Journal. 42(2) (pp 81-89), 2022. Date of
Publication: 01 Dec 2022.
Author
Jage B.; Thakur A.
Institution
(Jage, Thakur) School of Physiotherapy, D. Y. Patil University,
Maharashtra, Navi Mumbai, India
Publisher
World Scientific
Abstract
Background: Patients undergoing Coronary Artery Bypass Graft (CABG)
surgery often develop pulmonary complications in the early post-operative
period as result of decreased lung function and impaired cough.
Conventional physiotherapy in early post-operative period aims at
increasing lung volumes and airway clearance. Objective(s): This
study aimed to determine the effectiveness of the addition of Acapella to
conventional chest physiotherapy in improving lung volumes and secretion
clearance in early post-operative CABG patients. Method(s): Twenty
patients of both genders (40-70 years) who had undergone CABG and were in
Phase I of Cardiac Rehabilitation were involved in this pilot randomized
control trial (9 control, 11 experimental). Post-surgery intervention
commenced on post-operative day 2 (POD 2) and continued till POD 6.
Patients in the control group were given conventional physiotherapy that
included breathing exercises, incentive spirometry and manual techniques.
Patient in the experimental group used an Acapella device along with the
conventional intervention. Outcome measures considered were pulmonary
function parameters (FVC, FEV1 & PEFR) and amount of sputum expectorated.
 Result(s): A significant increase in lung volumes was observed in
both the groups on POD 6 as compared to POD 2 (both<0.01). However, the
increase was significantly greater on POD 6 in experimental group than the
control group [mean difference (95% CI) FVC: 0.44L (0.24-0.63), FEV1:
0.43L (0.19-0.66), PEFR: 0.86L/s (0.57-1.14)]. The amount of sputum
expectoration significantly greater in the experimental group as compared
to the control group [2.71mL (0.53-4.90)]. Conclusion(s): The
addition of Acapella enhanced the effect conventional physiotherapy in
improving lung volumes and airway clearance in the early post-operative
period for CABG patients. Copyright © 2022 Hong Kong
Physiotherapy Association.

<72>
Accession Number
2018476588
Title
Migration of covered stents in thoracic central vein obstruction
procedures in patients with hemodialysis: Case report and literature
review.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 954443. Date of Publication: 27 Jul 2022.
Author
Chen B.; Lai Q.; Fedally S.; Wan Z.
Institution
(Chen) Department of Ultrasonography, The First Affiliated Hospital of
Chongqing Medical University, Chongqing, China
(Lai, Wan) Department of Nephrology, The First Affiliated Hospital of
Chongqing Medical University, Chongqing, China
(Fedally) Department of Nephrology, SSRN Hospital, Mauritius, Mauritius
Publisher
Frontiers Media S.A.
Abstract
Objective: The objective of the study is to present a case of hemodialysis
in which the covered stent that had migrated into the right ventricle was
retrieved by exploratory thoracotomy, and to review the literature on the
diagnosis and treatment of stent migration in thoracic central vein
obstruction (TCVO) procedures for hemodialysis patients. Method(s): A
systematic search of the PubMed database was performed to identify
clinical presentations, imaging strategies, stent types, and treatment
modalities for stent migration in hemodialysis patients. Result(s): A
total of 14 case reports on stent migration in TCVO procedures for
hemodialysis patients were included and analyzed. Ten cases included
migration to the cardiac chambers and the remainder migration to the
pulmonary artery. The common symptoms of stent migration in TCVO
procedures are reported to be chest pain and dyspnea, while three of the
cases studied involved no symptoms. Echocardiography, chest X-ray, and
computed tomography are the commonly used methods for the diagnosis of
stent migration and identification of the precise positioning of the
stent. Stent migration to the right subclavian or innominate veins was the
most prevalent case (seven cases). All were bare stents. Seven cases
involved retrieval by interventional surgery, while four cases involved
retrieval by open heart surgery. However, there were three cases in which
the "wait-and-see" approach was adopted since the patients were
asymptomatic. Conclusion(s): Stent migration in TCVO procedures is a
rare but extremely serious complication. The causes are not fully
understood. The current treatment strategies include interventional
surgery, open heart surgery, and the "wait-and-see"
approach. Copyright © 2022 Chen, Lai, Fedally and Wan.

<73>
Accession Number
2018232908
Title
Comparative Study Between Early versus Late Intraperitoneal Administration
of Either Bupivacaine/ Tramadol or Bupivacaine/Dexmedetomidine for
Perioperative Analgesia in Abdominal Laparoscopic Cancer Surgeries: A
Prospective Randomized Study.
Source
Journal of Pain Research. 15 (pp 3233-3243), 2022. Date of Publication:
2022.
Author
Shaker E.H.; Soliman M.S.; Hanafy A.; Elsabeeny W.Y.
Institution
(Shaker, Elsabeeny) Department of Anesthesia, Intensive Care and Pain
Management, National Cancer Institute, Cairo University, Cairo, Egypt
(Soliman) Department of Anesthesia, Surgical ICU and Pain Management,
Faculty of Medicine, Cairo University, Cairo, Egypt
(Hanafy) Department of Surgical Oncology, National Cancer Institute, Cairo
University, Cairo, Egypt
Publisher
Dove Medical Press Ltd
Abstract
Objective: Several modalities for analgesia after laparoscopic procedures
have been used. This study aimed to investigate the efficacy of early
versus late bupivacaine/tramadol combination and
bupivacaine/dexmedetomidine combination in analgesia for laparoscopic
cancer surgeries. Method(s): A total of 100 patients of both genders
scheduled for elective laparoscopic cancer surgeries were included.
Patients were randomly assigned to one of four groups each comprises 25
patients. Group 1: early bupivacaine/tramadol, Group 2: late bupivacaine/
tramadol, Group 3: early bupivacaine/dexmedetomidine, and Group 4: late
bupivacaine/dexmedetomidine. Early groups received the intraperitoneal
instillation before start of surgery and late groups received the
instillation after completion of surgery. Perioperative heart rate (HR)
and mean arterial blood pressure (MAP) were recorded. The degree of
postoperative pain was measured at rest and with cough using Visual
analogue scale (VAS) score at 2, 4, 6, 12, 18 and 24 h after surgery. In
addition, the total intraoperative fentanyl and postoperative morphine
doses were calculated. Result(s): Both late bupivacaine/tramadol,
bupivacaine/dexmedetomidine groups had longer time to receive first
analgesic requirement (13.4+/-3.9, 11.3+/-3.9 h) respectively as compared
to early bupivacaine/tramadol, bupivacaine/dexmedetomidine groups (9.8+/-
3.6, 8.4+/- 2.8 h), respectively. Between each early and late group,
intraoperative fentanyl consumption was higher for the late groups (75+/-
22.8, 73+/- 21.55microg) versus (32.7+/- 10.9, 37.5+/- 13.3 microg),
respectively. As regards to rescue analgesic requirements, both early
bupivacaine/ tramadol and bupivacaine/dexmedetomidine groups consumed more
analgesics (5.2+/- 2.0 and 6.1+/- 1.8 mg) as compared to the late groups
(3.2+/- 0.8 and 4.3+/- 1.5 mg), respectively. The four groups were
comparable for their perioperative HR and MAP values. Conclusion(s):
Intraperitoneal instillation of bupivacaine/tramadol and
bupivacaine/dexmedetomidine could be considered an effective route for
analgesic administration during laparoscopic cancer surgeries. Early
instillation reduced the intraoperative opioid consumption and late
instillation resulted in reduced postoperative opioid
consumption. Copyright © The Authors.

<74>
[Use Link to view the full text]
Accession Number
2020805715
Title
Comparison of regional cerebral oxygen saturation during one-lung
ventilation under desflurane or propofol anesthesia: A randomized trial.
Source
Medicine (United States). 101(41) (pp E30030), 2022. Date of Publication:
14 Oct 2022.
Author
Hayashi K.; Yamada Y.; Ishihara T.; Tanabe K.; Iida H.
Institution
(Hayashi, Yamada, Tanabe, Iida) Department of Anesthesiology and Pain
Medicine, Gifu University Graduate School of Medicine, Gifu, Japan
(Ishihara) Innovative and Clinical Research Promotion Center, Gifu
University Hospital, Gifu, Japan
(Iida) Anesthesiology and Pain Relief Center, Central Japan Medical
Center, Minokamo, Japan
Publisher
Lippincott Williams and Wilkins
Abstract
Background: During one-lung ventilation (OLV), deterioration of pulmonary
oxygenation reduces arterial oxygen saturation and cerebral oxygen
saturation (rSO2). However, oxidative stress during OLV causes lung
injury, so the fraction of inspiratory oxygen (FiO2) should be kept as low
as possible. We investigated the changes in rSO2 under propofol or
desflurane anesthesia while percutaneous oxygen saturation (SpO2) was kept
as low as possible during OLV. Method(s): Thirty-six patients
scheduled for thoracic surgery under OLV in the lateral decubitus position
were randomly assigned to propofol (n = 19) or desflurane (n = 17)
anesthesia. FiO2 was set to 0.4 at the start of surgery under two-lung
ventilation (measurement point: T3) and then adjusted to maintain an SpO2
of 92% to 94% after the initiation of OLV. The primary outcome was the
difference in the absolute value of the decrease in rSO2 from T3 to 30
minutes after the initiation of OLV (T5), which was analyzed by an
analysis of covariance adjusted for the rSO2 value at T3. Result(s):
The mean rSO2 values were 61.5% +/- 5.1% at T3 and 57.1% +/- 5.3% at T5 in
the propofol group and 62.2% +/- 6.0% at T3 and 58.6% +/- 5.3% at T5 in
the desflurane group. The difference in the absolute value of decrease
between groups (propofol group - desflurane group) was 0.95 (95%
confidence interval, [-0.32, 2.2]; P =.152). Conclusion(s): Both
propofol and desflurane anesthesia maintain comparable cerebral
oxygenation and can be used safely, even when the SpO2 is kept as low as
possible during OLV. Copyright © 2022 the Author(s). Published by
Wolters Kluwer Health, Inc.

<75>
[Use Link to view the full text]
Accession Number
2020805678
Title
The effectiveness of massage interventions on procedural pain in neonates:
A systematic review and meta-analysis.
Source
Medicine (United States). 101(41) (pp E30939), 2022. Date of Publication:
14 Oct 2022.
Author
Liu J.; Fang S.; Wang Y.; Gao L.; Xin T.; Liu Y.
Institution
(Liu, Gao, Xin, Liu) School of Nursing, Weifang Medical University,
Weifang, China
(Fang) Weifang People's Hospital, Weifang Medical University, Weifang,
China
(Wang) Weifang Maternal and Child Health Hospital, Weifang, China
Publisher
Lippincott Williams and Wilkins
Abstract
Background: The painful procedures experienced by neonates during
hospitalization have short-term or long-term effects on neonates. While
the limitations of previous interventions make it imperative to explore
effective interventions that are readily available. This systematic review
and meta-analysis was conducted to evaluate the safety and effectiveness
of massage for pain management in neonates. Method(s): This
systematic review was registered in PROSPER. PubMed, Embase, Cochrane
Library, and the Clinical Trials Registry were searched to December 2021.
Two reviewers independently carried out study selection, data extraction,
bias risk assessment. Continuous data were analyzed by mean differences
(MD). Dichotomous data were reported using relative risk. If at least two
studies reported identical results by the same pain assessment tool, a
meta-analysis was conducted using random effect model and inverse
variance. Result(s): Total 11 included studies involving 755 neonates
investigated the effects of massage on neonatal pain response compared to
standard care. The meta-analysis showed that massage could effectively
improve pain response in neonates compared to standard care no matter
whether neonatal infant pain scale (NIPS) or premature infant pain profile
(PIPP) was used as an assessment tool. Besides, massage was also effective
for crying duration, blood oxygen saturation both during and after the
procedure, but non-effective for the variation of respiratory rate after
the procedure, and heart rate both during and after the procedure.
 Conclusion(s): Massage may have a positive effect on pain relief of
neonate, and rigorous trials are needed in the future to determine the
most effective massage method. Copyright © 2022 the Author(s).
Published by Wolters Kluwer Health, Inc.

<76>
Accession Number
2020737825
Title
Comparison between coil and hook-wire localization before video-assisted
thoracoscopic surgery for lung nodules: a systematic review and
meta-analysis.
Source
Wideochirurgia I Inne Techniki Maloinwazyjne. 17(3) (pp 441-449), 2022.
Date of Publication: 2022.
Author
Wang J.-L.; Xia F.-F.; Dong A.-H.; Lu Y.
Institution
(Wang) Department of Radiology, Beijing Huairou Hospital of Traditional
Chinese Medicine, Beijing, China
(Xia) Department of Interventional Vascular Surgery, Binzhou People's
Hospital, Binzhou, China
(Dong) Center of Health Management, Binzhou People's Hospital, Binzhou,
China
(Lu) Department of Radiology, Xuzhou Central Hospital, Xuzhou, China
Publisher
Termedia Publishing House Ltd.
Abstract
Introduction: Both coil and hook-wire localization techniques are commonly
employed prior to video-assisted thoracic surgery (VATS) resection in
patients with lung nodules (LNs), but the relative advantages of each
remain uncertain. Aim(s): This meta-analysis was performed to explore
the relative safety and efficacy of coil localization (CL) and hookwire
localization (HWL) for patients with LNs. Material(s) and Method(s):
The PubMed, Embase, Cochrane Library, Wanfang, and CINK databases were
searched to identify relevant studies published as of February 2022, after
which pooled analyses of study outcomes were conducted. Result(s): In
total, 8 studies met the inclusion criteria for the present meta-analysis.
Successful localization rates were higher for the CL group relative to the
HWL group (p = 0.0001). The CL group additionally exhibited significantly
lower pooled total complication, pneumothorax, and lung hemorrhage rates
relative to the HWL group (p = 0.01, p = 0.0001, p = 0.0009). Pooled
duration of localization, VATS procedure duration, and wedge resection
duration values were comparable in both groups (p = 0.69, p = 0.16, p =
0.76), as were chest pain scores (p = 0.06). When specifically analyzing
the subset of patients with ground-glass LNs, pooled pneumothorax rates
were significantly lower in the CL group relative to the HWL group (p =
0.03). Significant publication bias was detected with respect to rates of
lung hemorrhage (Egger test, p = 0.029), but was not evident for other
analyzed variables. Conclusion(s): These results suggest that the
coil-based localization of LNs before VATS resection is safer and more
effective than hook-wire localization. Copyright © 2022 Termedia
Publishing House Ltd.. All rights reserved.

<77>
Accession Number
2015473795
Title
Conversion of urine protein-creatinine ratio or urine dipstick protein to
urine albumin-creatinine ratio for use in chronic kidney disease screening
and prognosis: An individual participant-based meta-analysis.
Source
Annals of Internal Medicine. 173(6) (pp 426-435), 2020. Date of
Publication: 15 Sep 2020.
Author
Sumida K.; Nadkarni G.N.; Grams M.E.; Sang Y.; Ballew S.H.; Coresh J.;
Matsushita K.; Surapaneni A.; Brunskill N.; Chadban S.J.; Chang A.R.;
Cirillo M.; Daratha K.B.; Gansevoort R.T.; Garg A.X.; Iacoviello L.;
Kayama T.; Konta T.; Kovesdy C.P.; Lash J.; Lee B.J.; Major R.W.; Metzger
M.; Miura K.; Naimark D.M.J.; Nelson R.G.; Sawhney S.; Stempniewicz N.;
Tang M.; Townsend R.R.; Traynor J.P.; Valdivielso J.M.; Wetzels J.;
Polkinghorne K.R.; Heerspink H.J.L.
Institution
(Sumida) Division of Nephrology, Department of Medicine, University of
Tennessee Health Science Center, 956 Court Avenue, Suite A220, Memphis, TN
38163, United States
(Nadkarni) One Gustave L. Levy Place, Box 1243, New York, NY 10029, United
States
(Grams, Sang, Ballew, Coresh, Matsushita, Surapaneni) Chronic Kidney
Disease Prognosis Consortium, 2024 East Monument Street, Baltimore, MD
21287, United States
(Brunskill) Department of Nephrology, Leicester General Hospital,
Gwendolen Road, Leicester LE5 4PW, United Kingdom
(Chadban) Kidney Centre RPA, Level 2, Professor Marie Bashir Centre, Royal
Prince Alfred Hospital, Missendon Road, Camperdown, NSW 2050, Australia
(Chang) 100 North Academy Ave, Danville, PA 17822, United States
(Cirillo) Department of Public Health, Azienda Ospedaliera Universitaria
Federico II, via Sergio Pansini 5, Naples 80131, Italy
(Daratha) Providence Sacred Heart Medical Center, Gonzaga University,
School of Anesthesia, Providence Sacred Heart Doctor's Building, 105 West
8th Avenue, Suite 6050W, Spokane, WA 99204, United States
(Gansevoort) Department of Nephrology, University Medical Center
Groningen, P.O. Box 30.001, Groningen 9700 RB, Netherlands
(Garg) Department of Medicine, Epidemiology and Biostatistics, Western
University, 800 Commissioners Road E, ELL-101, Victoria Hospital, P.O. Box
5010, London, ON N6A 5W9, Canada
(Iacoviello) IRCCS Neuromed, Via dell'Elettronica, IS, Pozzilli 86077,
Italy
(Kayama) Global Center of Excellence Program Study Group, Yamagata
University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan
(Konta) Department of Public Health and Hygiene, Yamagata University
Graduate School of Medical Science, 2-2-2 Iida-Nishi, Yamagata 990-9585,
Japan
(Kovesdy) Division of Nephrology, University of Tennessee Health Science
Center, 956 Court Avenue, Room B222, Memphis, TN 38163, United States
(Lash) Division of Nephrology, Department of Medicine, University of
Illinois at Chicago, 840 South Wood Street (M/C 793), Chicago, IL 60612,
United States
(Lee) Moanalua Medical Center, 3288 Moanalua Road, Honolulu, HI 96819,
United States
(Major) Department of Health Sciences, George Davies Centre, University of
Leicester, 15 Lancaster Road, Leicester LE1 7HA, United Kingdom
(Metzger) CESP INSERM U1018, Hopital Paul Brousse, Bat 15/16, 16 avenue
Paul Vaillant Couturier, Villejuif 94807, France
(Miura) Department of Public Health, Shiga University of Medical Science,
Seta-Tsukinowa-cho, Otsu, Shiga 520-2192, Japan
(Naimark) Rm. 386, 1929 Bayview Ave., Toronto, ON M4G 3E8, Canada
(Nelson) National Institutes of Health, 1550 East Indian School Road,
Phoenix, AZ 85014, United States
(Sawhney) Aberdeen Centre for Health Data Science, University of Aberdeen,
Foresterhill Campus, Aberdeen AB25 2AN, United Kingdom
(Stempniewicz) One Prince Street, Alexandria, VA 22314, United States
(Tang) University of British Columbia, 4/F Howe Site, 1081 Burrard Street,
Vancouver, BC V6Z1Y6, Canada
(Townsend) University of Pennsylvania, Renal Division, 3400 Spruce Street,
122 Founders Building, Philadelphia, PA 19104, United States
(Traynor) Glasgow Renal and Transplant Unit, Renal 1st Floor, Zone 3 OZ
1-3, Office Block, Queen Elizabeth University Hospital, 1345 Govan Road,
Glasgow G51 4TF, United Kingdom
(Valdivielso) Vascular and Renal Translational Research Group, Biomedical
Research Institute of Lleida, Av. Alcalde Rovira Roure, 80, Lleida 25198,
Spain
(Wetzels) Department of Nephrology 464, Radboud University Medical Center,
P.O. Box 9101, Nijmegen 6500 HB, Netherlands
(Polkinghorne) Monash Medical Centre, 246 Clayton Road, Clayton,
Melbourne, VIC 3168, Australia
(Heerspink) Department of Clinical Pharmacy and Pharmacology, De Brug
50C-1-011, EB70, University Medical Center Groningen, P.O. Box 30001,
Groningen 9700 AD, Netherlands
Publisher
American College of Physicians
Abstract
Background: Although measuring albuminuria is the preferred method for
defining and staging chronic kidney disease (CKD), total urine protein or
dipstick protein is often measured instead. Objective(s): To develop
equations for converting urine protein-creatinine ratio (PCR) and dipstick
protein to urine albumin-creatinine ratio (ACR) and to test their
diagnostic accuracy in CKD screening and staging. Design(s):
Individual participant-based meta-analysis. Setting(s): 12 research
and 21 clinical cohorts. Participant(s): 919 383 adults with same-day
measures of ACR and PCR or dipstick protein. Measurements: Equations to
convert urine PCR and dipstick protein to ACR were developed and tested
for purposes of CKD screening (ACR >=30 mg/g) and staging (stage A2: ACR
of 30 to 299 mg/g; stage A3: ACR >=300 mg/g). Result(s): Median ACR
was 14 mg/g (25th to 75th percentile of cohorts, 5 to 25 mg/g). The
association between PCR and ACR was inconsistent for PCR values less than
50 mg/g. For higher PCR values, the PCR conversion equations demonstrated
moderate sensitivity (91%, 75%, and 87%) and specificity (87%, 89%, and
98%) for screening (ACR >30 mg/g) and classification into stages A2 and
A3, respectively. Urine dipstick categories of trace or greater, trace to
+, and ++ for screening for ACR values greater than 30 mg/g and
classification into stages A2 and A3, respectively, had moderate
sensitivity (62%, 36%, and 78%) and high specificity (88%, 88%, and 98%).
For individual risk prediction, the estimated 2-year 4-variable kidney
failure risk equation using predicted ACR from PCR had discrimination
similar to that of using observed ACR. Limitation(s): Diverse methods
of ACR and PCR quantification were used; measurements were not always
performed in the same urine sample. Conclusion(s): Urine ACR is the
preferred measure of albuminuria; however, if ACR is not available,
predicted ACR from PCR or urine dipstick protein may help in CKD
screening, staging, and prognosis. Primary Funding Source: National
Institute of Diabetes and Digestive and Kidney Diseases and National
Kidney Foundation. Copyright © 2020 American College of
Physicians. All rights reserved.

<78>
Accession Number
2015473740
Title
Invasive therapy improved angina health status in patients with high-risk
stable coronary disease and more frequent angina.
Source
Annals of Internal Medicine. 173(4) (pp JC15), 2020. Date of Publication:
18 Aug 2020.
Author
Bates E.R.
Institution
(Bates) University of Michigan, Ann Arbor, MI, United States
Publisher
American College of Physicians

<79>
Accession Number
2015591895
Title
A chromosome 4q25 variant is associated with atrial fibrillation
recurrence after catheter ablation: A systematic review and meta-analysis.
Source
Journal of Atrial Fibrillation. 10(6) (no pagination), 2018. Date of
Publication: 2018.
Author
Rattanawong P.; Chenbhanich J.; Vutthikraivit W.; Chongsathidkiet P.
Institution
(Rattanawong) University of Hawaii Internal Medicine Residency Program,
Honolulu, HI, United States
(Rattanawong) Faculty of Medicine, Ramathibodi Hospital, Mahidol
University, Bangkok, Thailand
(Chenbhanich) Department of Internal Medicine, Metrowest Medical Center,
Framingham, MA, United States
(Vutthikraivit) Department of Medicine, Texas Tech University Health
Sciences Center, TX, United States
(Chongsathidkiet) Department of Pathology, Duke University Medical Center,
Durham, NC, United States
Publisher
CardioFront LLC
Abstract
Background: Recent studies suggested that variants on chromosome loci
4q25, 1q21, and 16q22 were associated with atrial fibrillation recurrence
after catheter ablation. In this study, we performed a systematic review
and meta-analysis to explore the association between variants on
chromosome loci 4q25, 1q21, and 16q22 and atrial fibrillation recurrence
after catheter ablation. Method(s): We comprehensively searched the
databases of MEDLINE and EMBASE from inception to January 2017. Included
studies were published prospective or retrospective cohort and case
control studies that compared the risk of atrial fibrillation recurrence
after catheter ablation in AF patients with chromosome 4q25, 1q21, and
16q22 variants versus no variants. Single-nucleotide polymorphism
rs1906617, rs2106261, rs7193343, rs2200733, rs10033464, rs13376333, and
rs6843082 were included in this analysis. Data from each study were
combined using the random-effects, generic inverse variance method of
DerSimonian and Laird to calculate the risk ratios and 95% confidence
intervals. Result(s): Seven studies from January 2010 to June 2017
involving 3,322 atrial fibrillation patients were included in this
meta-analysis. According to the pooled analysis, there was a strong
independent association between chromosome 4q25 variant (rs2200733) and
the risk of atrial fibrillation recurrence after catheter ablation (risk
ratio 1.45 [95% confidence interval 1.15-1.83], P = 0.002). No association
was found in other variants. Conclusion(s): Our meta-analysis
demonstrates a statistically significant increased risk of atrial
fibrillation recurrence after catheter ablation in 4q25 variant (only in
rs2200733) but not in 1q21 or 16q22 variants. Copyright © 2018
CardioFront LLC. All rights reserved.

<80>
Accession Number
2019705327
Title
Clinical impact of cardiac magnetic resonance in patients with suspected
coronary artery disease associated with chronic kidney disease
(AQUAMARINE-CKD study): study protocol for a randomized controlled trial.
Source
Trials. 23(1) (no pagination), 2022. Article Number: 904. Date of
Publication: December 2022.
Author
Noguchi T.; Ota H.; Matsumoto N.; Morita Y.; Oshita A.; Kawasaki E.;
Kawasaki T.; Moriwaki K.; Kato S.; Fukui K.; Hoshi T.; Watabe H.; Kanaya
T.; Asaumi Y.; Kataoka Y.; Otsuka F.; Takagi K.; Yoneda S.; Sawada K.;
Iwai T.; Matama H.; Honda S.; Fujino M.; Miura H.; Nishimura K.; Takase K.
Institution
(Noguchi, Asaumi, Kataoka, Otsuka, Takagi, Yoneda, Sawada, Iwai, Matama,
Honda, Fujino, Miura) Department of Cardiovascular Medicine, National
Cerebral and Cardiovascular Center, 6-1 Kishibe-shimmachi, Suita 564-8565,
Japan
(Ota) Department of Diagnostic Radiology, Tohoku University Hospital, 1-1
Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
(Matsumoto) Division of Cardiology, Department of Medicine, Nihon
University School of Medicine, Nihon University Hospital, 1-6
Kanda-surugadai, Chiyoda-ku, Tokyo 101-8309, Japan
(Morita) Department of Radiology, National Cerebral and Cardiovascular
Center, 6-1 Kishibe-Shimmachi, Suita 564-8565, Japan
(Oshita) Department of Cardiology, Ehime Prefectural Imabari Hospital,
4-5-5 Ishiicho, Imabari 794-0006, Japan
(Kawasaki) Department of Diabetes and Endocrinology, Shin-Koga Hospital,
120 Tenjin-cho, Kurume 830-8577, Japan
(Kawasaki) Cardiovascular and Heart Rhythm Center, Shin-Koga Hospital, 120
Tenjin-cho, Kurume 830-8577, Japan
(Moriwaki) Comprehensive Unit for Health Economic Evidence Review and
Decision Support, Research Organization of Science and Technology,
Ritsumeikan University, Kyoto 604-8520, Japan
(Kato, Fukui) Department of Cardiovascular Medicine, Kanagawa
Cardiovascular and Respiratory Center, Yokohama 236-0051, Japan
(Hoshi, Watabe) Cardiovascular Division, Faculty of Medicine, University
of Tsukuba, Ibaraki 305-8576, Japan
(Kanaya) Department of Cardiovascular Medicine, Dokkyo Medical University
Hospital, 880 kitakobayashi, Mibu, Tochigi 321-0293, Japan
(Nishimura) Department of Preventive Medicine and Epidemiology, National
Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita 564-8565,
Japan
(Takase) Department of Diagnostic Radiology, Tohoku University Graduate
School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan
Publisher
BioMed Central Ltd
Abstract
Background: Although screening for coronary artery disease (CAD) using
computed tomography coronary angiography in patients with stable chest
pain has been reported to be beneficial, patients with chronic kidney
disease (CKD) might have limited benefit due to complications of contrast
agent nephropathy and decreased diagnostic accuracy as a result of
coronary artery calcifications. Cardiac magnetic resonance (CMR) has
emerged as a novel imaging modality for detecting coronary stenosis and
high-risk coronary plaques without contrast media that is not affected by
coronary artery calcification. However, the clinical use of this
technology has not been robustly evaluated. Method(s): AQUAMARINE-CKD
is an open parallel-group prospective multicenter randomized controlled
trial of 524 patients with CKD at high risk for CAD estimated based on
risk factor categories for a Japanese urban population (Suita score)
recruited from 6 institutions. Participants will be randomized 1:1 to
receive a CMR examination that includes non-contrast T1-weighted imaging
and coronary magnetic angiography (CMR group) or standard examinations
that include stress myocardial scintigraphy (control group). Randomization
will be conducted using a web-based system. The primary outcome is a
composite of cardiovascular events at 1 year after study examinations:
all-cause death, death from CAD, nonfatal myocardial infarction, nonfatal
ischemic stroke, and ischemia-driven unplanned coronary intervention
(percutaneous coronary intervention or coronary bypass surgery).
 Discussion(s): If the combination of T1-weighted imaging and coronary
magnetic angiography contributes to the risk assessment of CAD in patients
with CKD, this study will have major clinical implications for the
management of patients with CKD at high risk for CAD. Trial registration:
Japan Registry of Clinical Trials (jRCT) 1,052,210,075. Registered on
September 10, 2021. Copyright © 2022, The Author(s).

<81>
Accession Number
639344553
Title
SYSTEMATIC REVIEW OF STRENGTH OF EVIDENCE SUPPORTING THE APPROVAL AND
CLINICAL USE OF HIGH-RISK MEDICAL DEVICES IN CARDIOVASCULAR MEDICINE: AN
UPDATE FROM THE CORE-MD CONSORTIUM.
Source
Heart. Conference: Irish Cardiac Society Annual Scientific Meeting and
AGM. Cork Ireland. 108(Supplement 3) (pp A21), 2022. Date of Publication:
October 2022.
Author
McGovern L.; Siontis G.; Frenk A.; Melvin T.; McGauran G.; Geertsma R.;
Schnell-Inderst P.; Fraser A.G.; Windecker S.; Byrne R.
Institution
(McGovern, Byrne) Cardiovascular Research Institute (CVRI) Dublin, Mater
Private Network, RCSI, Dublin, Ireland
(Siontis, Frenk, Windecker) University Hospital (BUH), Bern, Switzerland
(Melvin, McGauran) Health Products Regulatory Authority (HPRA), Dublin,
Ireland
(Geertsma) RIVM: National Institute for Public Health and the Environment,
Utrecht, Netherlands
(Schnell-Inderst) UMIT TIROL, Austria
(Fraser) University Hospital of Wales, European Society of Cardiology
(ESC), Cardiff, United Kingdom
Publisher
BMJ Publishing Group
Abstract
Introduction Implementation of the new Medical Device Regulation (MDR)
2017/745 by the European Union (EU) challenges the medical community to
engage with regulators, notified bodies and industry to develop
transparent, rigorous and proportionate methods to evaluate the clinical
safety and efficacy of medical devices and monitor their performance.
Against this background, as part of the EU Horizon 2020 funded project -
CORE-MD - we performed a systematic review of clinical evidence available
for selected class III implantable devices used in cardiovascular
medicine. Methods A systematic literature review was conducted using Ovid,
MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials
(CENTRAL) of studies of prospective design evaluating pre specified
high-risk medical devices in the field of cardiovascular medicine between
January 2000 and August 2021. We included selected high- risk devices that
received CE Mark approval from the year 2000 onwards. The date of CE-Mark
approval was defined through press releases available online, information
provided by regulatory sources such as notified bodies, and personal
communications with the corresponding manufacturers. We focused on any
study of prospective design (non-randomised or randomised clinical trials
of any design) in humans. We excluded retrospective studies, case reports,
reviews, systematic reviews, meta-analyses, and expert opinion documents.
We performed title and abstract screening, full-text review, risk of bias
evaluation and data collection independently and in duplicate. Results The
following classes of high-risk medical devices in the cardiovascular field
were evaluated: left atrial appendage occlusion (LAAO), transcatheter
aortic valve implantation (TAVI); transcatheter mitral valve
repair/replacement (TMVR); leadless pacemakers; subcutaneous implantable
cardioverterdefibrillators (S-ICD), bioresorbable scaffolds for
percutaneous coronary intervention; and surgical heart valve replacement
for native aortic and mitral valve pathologies. For the latter group, a
total of 17 surgical aortic valves and 4 surgical mitral valves were
included. An interim report of the systematic review of the CORE-MD
consortium with a focus on surgical heart valve replacement will be
available for presentation at ICS 2022. To date, the literature search has
identified 3696 and 4901 potentially eligible papers in the surgical
mitral valves category and surgical aortic valves categories,
respectively. Conclusion The goal of the CORE-MD consortium is to develop
awareness of and expertise within the clinical community in Europe in
relation to the regulation of high-risk medical devices. Data from the
systematic review of high-risk cardiovascular devices will enable
comparison of strength of evidence within and across classes of devices in
cardiovascular medicine and facilitate comparison against high-risk
devices in other medical specialties including orthopaedics and diabetes.

<82>
Accession Number
639344273
Title
STENT SIZING USING OPTICAL COHERENCE TOMOGRAPHY IMAGING.
Source
Heart. Conference: Irish Cardiac Society Annual Scientific Meeting and
AGM. Cork Ireland. 108(Supplement 3) (pp A9-A10), 2022. Date of
Publication: October 2022.
Author
Rai H.; Raber L.; Leister D.M.; Nef H.; Alfonso F.; Byrne R.A.; Kastrati
A.; Joner M.
Institution
(Rai, Byrne) Cardiovascular Research Institute Dublin, Mater Private
Network Dublin, Ireland
(Rai, Byrne) School of Pharmacy and Biomolecular Sciences, RCSI University
of Medicine and Health Sciences, Dublin, Ireland
(Raber) Universitatsklinik fur Kardiologie, Inselspital Bern, Bern,
Switzerland
(Leister) Department - Universitatsmedizin Berlin, Berlin, Germany
(Nef) Universitatsklinikum Giesen und Marburg, Giessen, Germany
(Alfonso) Hospital Universitario de La Princesa and Universidad Autonoma
de Madrid, CIBERCV, Madrid, Spain
(Kastrati, Joner) Deutsches Herzzentrum Munchen, Technische Universitat
Munchen, Munich, Germany
Publisher
BMJ Publishing Group
Abstract
Introduction Optical coherence tomography (OCT) aided preprocedural
measurement of lumen and vessel dimensions has the potential to enhance
accurate stent sizing and improve clinical outcomes. We aimed to
investigate the impact of stent sizing as per the criteria used in the
ILUMIEN IV randomized trial in unselected patients undergoing coronary
stenting at high volume tertiary care centres. Our secondary objective was
to test if correct stent sizing also associates with lower incidence of
follow-up major adverse cardiovascular events (MACE) in unselected
real-world cohorts Methods All consecutive lesions (and cases) undergoing
pre- PCI OCT in native coronary arteries (with significant, denovo/
restenotic, obstructive lesions requiring stenting) and received
stent/stents between 2012 to 2018 at 5 high volume European centres were
retrospectively included. Sizing analysis was performed as per the
criteria used in the ILUMIEN IV randomized trial. Ideal stent size was
determined from the algorithm and compared with the stent size implanted.
MACE during follow-up was defined as a composite of all-cause death,
myocardial Infarction, target lesion revascularization and stent
thrombosis. Results A total of 178 patients were include with 193 treated
lesions. Mean age was 65.1+/-11.2 years, 82.6% were male. A total of 11.8%
of the included lesions were restenotic, 21.2% had a major bifurcation,
while 26.4% had moderate to severe calcification; 63.7% of treated lesions
were complex in nature (type B2/C). Mean number of stents/scaffolds
implanted per lesion was 1.16+/-0.43. A total of 86.0% of lesions were
stented with conventional drug eluting stents, 13.0% were stented with
bioresorbable vascular/resorbable magnesium scaffolds. Maximum
stent/scaffold diameter used was 3 (3.00, 3.50) mm while total stented
length was 15 (15, 24) mm. Stent overlap was observed in 18.1% of lesions
and 60.1% of lesions received post-dilation. 138 (71.5%) lesions also had
post-intervention OCT available for stent expansion index (SEI)
assessment. Amongst 193 lesions analysed for sizing: 78 (40.4%) lesions
were correctly sized for stents; 68 (35.2%) lesions were undersized; 47
(24.4%) lesions were oversized. SEI was marginally higher in
correctly/oversized lesions as compared to the undersized lesions
(0.78+/-0.13 vs. 0.77 +/-0.10, p= 0.69). At a median of 604 (234, 1,098)
days MACE incidence in correctly sized group was 7.7%, in undersized group
was 10.3% and in oversized group was 16.7%. Kaplan-Meier plots for
cumulative MACE free log survival in three sizing groups is displayed as
figure 1. Conclusions The present real-world data highlights the fact that
less than half of treated lesions are being correctly sized for stents
during PCIs. MACE-free survival during follow-up of correctly sized
lesions seem to be marginally better highlight the potential impact of OCT
based correct sizing during PCI. This warrants further investigations with
larger unselected cohorts in order to establish a definitive benefit in
terms of event reduction during post PCI follow-up.

<83>
Accession Number
2020813297
Title
VALVULAR SURGERY IS ASSOCIATED WITH AN INCREASED RISK OF POST-OPERATIVE
ATRIAL FIBRILLATION: SECONDARY ANALYSIS OF THE SEARCH-AF CARDIOLINK-1
RANDOMIZED TRIAL.
Source
Canadian Journal of Cardiology. Conference: Canadian Cardiovascular
Congress 2022. Ottawa Canada. 38(10 Supplement 2) (pp S216), 2022. Date of
Publication: October 2022.
Author
Hibino M.; Verma S.; Pandey A.; Quan A.; Puar P.; Verma R.; Bisleri G.;
Verma A.; Mazer C.; Ha A.
Institution
(Hibino, Verma, Pandey, Pandey, Quan, Puar, Verma, Bisleri, Verma, Mazer,
Ha) ClevelandOHUnited States
Publisher
Elsevier Inc.
Abstract
Background: Patients undergoing valve surgery have a higher risk of
developing post-operative atrial fibrillation (POAF) relative to those
undergoing isolated coronary artery bypass grafting (CABG). Whether this
risk extends beyond hospital discharge is unknown. Methods and
Results: We examined the association between surgery type (isolated CABG
vs. valve repair or replacement) on the incidence of POAF from a
sub-analysis of the Post-Surgical Enhanced Monitoring for Cardiac
Arrhythmias and Atrial Fibrillation (SEARCH-AF) CardioLink-1 randomized
trial. It randomized 336 patients with risk factors for stroke
(CHA2DS2-VASc score >=2) and no history of preoperative AF were randomized
to usual care or continuous cardiac rhythm monitoring for 30 days after
discharge from cardiac surgery with a wearable, patched-based device. The
primary outcome was occurrence of cumulative atrial fibrillation/flutter
(AF/AFL) lasting for >=6 minutes detected by continuous monitoring or
AF/AFL documented by a 12-lead electrocardiogram within 30 days of
randomization. The trial excluded patients who underwent mechanical valve
replacement or left atrial appendage ligation. We compared the risk of
POAF between patients who underwent CABG vs. valve repair or replacement.
Patients who experienced post-operative AF during hospitalization were
excluded from this analysis. The overall cohort consisted of 255, 39, and
42 patients who underwent isolated CABG, isolated valve
replacement/repair, and CABG + valve repair/replacement, respectively.
Baseline characteristics were similar among the groups except for younger
age (p=0.0014), higher prevalence of preoperative myocardial infarction
(p=0.002) and lower ejection fraction (p=0.025) in the isolated CABG
group. Eighteen patients experienced post-operative AF during
hospitalization. Among 3 surgery subgroups, patients who underwent CABG +
valve surgery or isolated valve surgery were more likely to experience
post-operative AF compared with those who underwent isolated CABG
(Log-Rank ptrend=0.0096). Among patients who were randomized to continuous
cardiac rhythm monitoring, the probability of post-operative AF among
patients who underwent isolated CABG, valve surgery, and CABG + valve
surgery was 15.8%, 29.4%, and 35.0%, respectively (Log-Rank ptrend=0.017).
After multivariable adjustment, the risk of developing post-operative AF
within 30 days after discharge remained higher among patients who
underwent valve surgery compared with those who underwent isolated CABG
(hazard ratio (HR) 2.22, 95% CI 1.01-4.87. Patients who underwent CABG +
repair/replacement had the highest risk of experiencing post-operative AF
relative to patients who underwent isolated CABG (HR 2.78, 95% CI
1.12-6.86). Conclusion(s): An aggressive cardiac rhythm monitoring
strategy for AF detection should be considered for patients who are
discharged after valvular surgery in light of their elevated stroke risk.
[Formula presented] Copyright © 2022

<84>
Accession Number
2020813251
Title
AMI-PONT PROSPECTIVE RANDOMIZED CLINICAL TRIAL FOR ANTEROLATERAL TERRITORY
CORONARY ARTERY BYPASS GRAFTING STRATEGIES.
Source
Canadian Journal of Cardiology. Conference: Canadian Cardiovascular
Congress 2022. Ottawa Canada. 38(10 Supplement 2) (pp S198-S199), 2022.
Date of Publication: October 2022.
Author
Stevens L.; Chartrand-Lefebvre C.; Mansour S.; Beland V.; Prieto I.;
Basile F.; Forcillo J.; Soulez G.; Noiseux N.
Institution
(Stevens, Chartrand-Lefebvre, Mansour, Beland, Prieto, Basile, Forcillo,
Soulez, Noiseux) MontrealQuebec
Publisher
Elsevier Inc.
Abstract
Background: The main objective of the AMI-PONT trial was to assess whether
a CABG strategy including a bridge to distribute the LIMA outflow provides
non-inferior patency rates compared to conventional CABG surgery with
separated LIMA graft to LAD and aorto-coronary SVG to other anterolateral
targets. The bridge grafting strategy uses a short SVG interposed between
the LAD and at least one other anterolateral target, with the LIMA grafted
on the hood of the bridge just above the LAD anastomosis (almost direct
LIMA-LAD connection). This technique is easy to implement and has several
potential advantages including distribution of LIMA flow to a greater
vascular bed, bridge convenience for angioplasty, easier anastomosis of
the smaller/fragile LIMA graft on the bridge compared to
diseased/intramyocardial LAD targets, and use of shorter SVG. Methods
and Results: The power analysis was based on a non-inferiority principle,
considering the potential advantages of the bridge technique (unilateral
5% alpha, power 80%). From July 2012 to April 2021, 208 patients were
randomized to a bridge (n=105) or conventional grafting strategy (n=103).
Patients characteristics were comparable with a mean age of 65+/-8 years,
93% male, 34% diabetics, 22% recent myocardial infarction and LVEF of
57+/-9%. Patients underwent isolated CABG with cardiopulmonary bypass and
received 4.2+/-0.9 grafts/patients including 2.2+/-0.4 grafts/patients on
the anterolateral territory. There were three patient crossovers; data was
assessed as intention-to-treat. The anterolateral graft patency index
(i.e., non-occluded) was assessed using multislice spiral computed
tomography at one year. The anterolateral graft patency index was no
different at one year (bridge: 91.8% [145/158] vs conventional: 93.6%
[160/171]) with a risk difference of 1.8% (90%CI -3.1% to 6.7%), which did
not cross the specified boundary of -5%, demonstrating non-inferiority.
The LIMA-to-LAD graft patency was no different (98.7% [74/75] vs 96.2%
[75/78]; p=0.620). Intraoperatively, the bridge group exhibited greater
Medistim doppler flow in the LIMA pedicle (75+/-48ml/min vs 56+/-33ml/min;
p=0.002) and required shorter SVG length for the anterolateral targets
(53+/-21mm vs 97+/-34mm; p<.001). The composite outcome of death,
myocardial infarction or need for coronary intervention at 30 days was no
different (2.9% [3/105] vs 6.8% [7/103]; p=0.212). Conclusion(s): The
AMI-PONT trial shows non-inferiority of a composite grafting strategy
compared to conventional CABG strategy for anterolateral graft patency at
one year. The LSVB grafting strategy presents several technical advantages
for cardiac surgeons faced with an aging patient population with diffusely
diseased target vessels, limited availability of suitable conduits and
diseased ascending aortas. Ten-year clinical follow-up is
planned. Copyright © 2022

<85>
Accession Number
2020813240
Title
PERCUTANEOUS CORONARY INTERVENTION VERSUS CORONARY ARTERY BYPASS GRAFTING
FOR PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION: A META-ANALYSIS
OF KAPLAN-MEIER DERIVED INDIVIDUAL PATIENT DATA.
Source
Canadian Journal of Cardiology. Conference: Canadian Cardiovascular
Congress 2022. Ottawa Canada. 38(10 Supplement 2) (pp S211), 2022. Date of
Publication: October 2022.
Author
Lee G.; Malik A.; Vervoort D.; Tam D.; Marquis-Gravel G.; Gaudino M.;
Fremes S.
Institution
(Lee, Malik, Vervoort, Tam, Marquis-Gravel, Gaudino, Fremes)
TorontoOntario
Publisher
Elsevier Inc.
Abstract
Background: Coronary artery disease is a common etiology of ischemic left
ventricular systolic dysfunction (LVSD), for which the optimal
revascularization strategy remains unclear. We aimed to determine whether
percutaneous coronary intervention (PCI) or coronary artery bypass
grafting (CABG) results in greater survival advantage in patients with
LVSD by performing a a) study-level and b) reconstructed individual
patient data meta-analysis of Kaplan-Meier (KM) survival curves.
 Methods and Results: A systematic search of MEDLINE, EMBASE, and
Cochrane was conducted for observational studies and randomized trials
comparing PCI to CABG in patients with ischemic cardiomyopathy and left
ventricular ejection fraction <=40%. The primary outcome of interest was
all-cause mortality at longest follow-up. The secondary outcomes were
myocardial infarction (MI), stroke, repeat revascularization,
cardiovascular mortality, and major adverse cardiovascular and
cerebrovascular events (MACCE). An initial study-level meta-analysis was
performed using reported hazard ratios (HR). KM curves were digitized to
reconstruct individual patient data. Flexible parametric models with
restricted cubic splines were constructed to obtain time-varying HRs due
to non-proportional hazards between PCI and CABG. Thirteen studies (10
observational, 3 RCTs) were included with a total of 12,756 patients
(PCI=6,229, CABG=6,527) followed for 4.55+/-1.05 years. Over the entire
follow-up, PCI was associated with a higher rate of all-cause mortality
(HR 1.35 [95% confidence interval: 1.13-1.62]), MI (HR 2.08 [1.53-2.82]),
repeat revascularization (HR 2.45 [1.23-4.64]) and MACCE (HR 1.50
[1.19-1.88]) but not stroke or cardiovascular mortality compared to CABG
(Table). Digitized curves from 6 observational studies (CABG=5,151,
PCI=4,493) over 5.24+/-1.73 years were used to reconstruct individual
patient data (Table). PCI resulted in an overall increased risk of
all-cause mortality (HR 1.56 [1.32-1.85]) and instantaneous HRs calculated
0.1 years apart were statistically significant for the first 6.7 years
(Figure). PCI was associated with a much higher rate of repeat
revascularization (HR 5.59 [4.38-7.14]), for which instantaneous HRs were
significant for 6.1 years. PCI was associated with an overall lower risk
of stroke (HR 0.62 [0.40-0.99]) due to fewer events within the first 7
months, after which instantaneous HRs became non-significant.
 Conclusion(s): In patients with LVSD, study-level data indicated PCI
was associated with a higher rate of all-cause mortality, MI, repeat
revascularization, and MACCE compared to CABG. An individual patient data
meta-analysis confirmed a larger effect size for mortality and repeat
revascularization. Clinically, PCI appears less beneficial than CABG in
the long-term but is associated with almost 40% reduction in stroke hazard
during the initial 7 months post-treatment. [Formula presented] [Formula
presented] Copyright © 2022

<86>
Accession Number
2020813237
Title
DIRECT ORAL ANTICOAGULATION VERSUS WARFARIN IN PATIENTS WITH ATRIAL
FIBRILLATION AND BIOPROSTHETIC HEART VALVES: A RETROSPECTIVE, REAL WORLD
COHORT STUDY.
Source
Canadian Journal of Cardiology. Conference: Canadian Cardiovascular
Congress 2022. Ottawa Canada. 38(10 Supplement 2) (pp S203-S204), 2022.
Date of Publication: October 2022.
Author
Eikelboom R.; Whitlock R.; Nguyen F.; Perez R.; Weitz J.; Belley-Cote E.
Institution
(Eikelboom, Whitlock, Nguyen, Perez, Weitz, Belley-Cote) Hamilton, Ontario
Publisher
Elsevier Inc.
Abstract
Background: Data are limited on the efficacy and safety of direct oral
anticoagulants (DOACs) compared to warfarin in atrial fibrillation (AF)
patients with bioprosthetic heart valves, particularly in the real world.
In this retrospective cohort study of consecutive patients with AF and
surgical or transcatheter implantation of a bioprosthetic valve, we
compared the efficacy and safety of DOACs and warfarin. The primary
efficacy outcome was the composite of death and thrombosis (stroke,
transient ischemic attack, systemic embolism, and myocardial infarction).
The principal safety outcome was the composite of death and bleeding
requiring hospitalization. Methods and Results: Using linked health
administrative databases housed at the Institute for Clinical Evaluative
Sciences, consecutive patients in Ontario (Canada), 65 years of age or
older with AF who underwent bioprosthetic valve replacement between April
1, 2012, and March 31, 2017, were identified. A time-varying Cox model was
used to examine the relationship between the type of anticoagulant and
time to thrombosis or bleeding events after adjustment for baseline
thrombosis and bleeding risks using the CHA2DS2-VASc and HASBLED scores,
respectively, with prespecified subgroup analyses according to whether
valve implantation was surgical or transcatheter. We identified 2245
eligible patients. Median age was 79 years, 41% were female, and 39% had
transcatheter aortic valve replacement. Median follow-up was 795 (IQR
470-1196) days. Most patients (83.1%) had preoperative AF, and 63% were
taking anticoagulation preoperatively. Mean CHA2DS2-VASc and HASBLED
scores were 4.0 (SD 1.3) and 2.5 (SD 0.9), respectively. There was no
difference in risk of death or thrombosis between direct oral
anticoagulants and warfarin after adjustment for CHA2DS2-VASc score
(hazard ratio [HR] 1.02, 95% confidence interval [CI], 0.83-1.25). There
was no difference in risk of death or bleeding between direct oral
anticoagulants and warfarin after adjustment for HAS-BLED score (HR 0.89,
95% CI 0.75-1.07). Subgroup analyses of surgical or transcatheter valves
were consistent with overall results. Conclusion(s): In a real-world
population of patients with AF and bioprosthetic valve replacement, DOACs
may be associated with an increased risk of thrombosis and bleeding after
adjustment for the baseline risk of thrombosis and bleeding. Comparison of
adjusted and unadjusted analyses suggests that baseline risk of bleeding
and thrombosis are key determinants of outcomes. These findings suggest
that patient selection is critical when choosing between an anticoagulant
in such patients, and highlight the need for a randomized trial to
determine whether DOACs are effective and safe for AF patients with
bioprosthetic valves. [Formula presented] Copyright © 2022

<87>
Accession Number
2020813158
Title
DIRECT ORAL ANTICOAGULANTS VERSUS VITAMIN K ANTAGONISTS IN THE FIRST 3
MONTHS AFTER BIOPROSTHETIC VALVE REPLACEMENT: A SYSTEMATIC REVIEW AND
META-ANALYSIS.
Source
Canadian Journal of Cardiology. Conference: Canadian Cardiovascular
Congress 2022. Ottawa Canada. 38(10 Supplement 2) (pp S203), 2022. Date of
Publication: October 2022.
Author
Eikelboom R.; Siegal D.; Schulman S.; Whitlock R.; Belley-Cote E.
Institution
(Eikelboom, Siegal, Schulman, Whitlock, Belley-Cote) Hamilton, Ontario
Publisher
Elsevier Inc.
Abstract
Background: Guidelines recommend vitamin K antagonists (VKAs) in patients
who require anticoagulation in the first three months after bioprosthetic
valve replacement. Limited observational data suggest no increase in
bleeding with use of DOACs early after surgery. The efficacy and safety of
DOACs compared with VKAs early after bioprosthetic valve replacement, when
thrombotic and bleeding risk are highest, are uncertain. Methods and
Results: We systematically searched EMBASE, MEDLINE and CENTRAL until
November 16, 2021 for randomized trials comparing DOACs to VKAs in the
first three months after bioprosthetic valve replacement. After duplicate
title, abstract and full text screening, data abstraction, and risk of
bias evaluation, we pooled data using the Mantel-Haenzel method and random
effects modelling. We assessed the certainty of evidence using Grading of
Recommendations, Assessments, Development and Evaluation (GRADE). We
examined thrombotic events (a composite of stroke, systemic embolism, and
valve thrombosis), major bleeding, death, and net clinical adverse events
(a composite of thrombotic events and major bleeding). We preplanned a
sensitivity analysis of studies that initiated treatment prior to hospital
discharge. We included 5 trials with 2311 patients and a median follow-up
of 12 months (range three to 18 months; Table 1). Two studies included
patients with transcatheter valve replacement and three included patients
with surgical bioprosthetic valve replacement. Three studies initiated
therapy prior to hospital discharge. Risk of bias was low or presented
some concerns in all studies. There were fewer thrombotic events and more
bleeding events with DOACs compared to VKAs but these results were not
statistically significant (Table 1). There was no difference in risk of
deaths between groups. Net adverse clinical events were similar between
groups. Sensitivity analyses were consistent with overall results; risk of
major bleeding was higher with DOACs than VKAs in patients who initiated
treatment prior to hospital discharge but the estimate is imprecise.
 Conclusion(s): Moderate certainty evidence suggests that use of DOACs
in the first 3 months after bioprosthetic valve replacement may be
associated with higher risk of bleeding when initiated prior to hospital
discharge. Assessment of net adverse clinical events reveals no
significant difference: decreased numbers of thrombotic events with DOACs
are counterbalanced by increased numbers of bleeding events. Future
studies should focus on bleeding associated with initiation of DOAC
therapy prior to hospital discharge. Conclusions about net adverse
clinical events may require consideration of additional patient-important
factors such as cost, ease of administration, and subclinical valve
thrombosis. [Formula presented] Copyright © 2022

<88>
Accession Number
2020813149
Title
HIGH-INTENSITY INTERVAL TRAINING FOR HEART FAILURE AND POST-HEART
TRANSPLANT: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Source
Canadian Journal of Cardiology. Conference: Canadian Cardiovascular
Congress 2022. Ottawa Canada. 38(10 Supplement 2) (pp S160-S161), 2022.
Date of Publication: October 2022.
Author
Dirk K.; Khoury M.; Hartling L.; Krysler A.; Foshaug R.
Institution
(Dirk, Khoury, Hartling, Krysler, Foshaug) EdmontonAlberta
Publisher
Elsevier Inc.
Abstract
Background: Heart failure (HF) continues to have a growing burden on
health care systems with profound effects on patients' health-related
quality-of-life (HRQoL), exercise capacity, hospitalizations, and
mortality. Heart transplant (HTx) is the gold standard treatment for
medically refractory end-stage HF. However, HTx recipients continue to
have reduced exercise capacity that in turn is linked with adverse
long-term outcomes. High-intensity interval training (HIIT) has
effectively improved fitness in numerous populations, including those with
cardiovascular disease. We thus sought to evaluate the safety and impact
of HIIT exercise interventions on exercise capacity, HRQoL, and vascular
stiffness and function in patients with HF and post-HTx. We hypothesized
that HIIT is a safe and effective strategy across the HF/HTx clinical
continuum. Methods and Results: Embase, CINAHL, Cochrane, and MEDLINE
databases were searched for randomized control trials using
'cardiovascular disease' and 'HIIT' search terms in May 2021 with an
updated search performed in April 2022. We identified 1812 studies, of
which 328 underwent full text review. Participants were HF patients or HTx
recipients participating in >=6-weeks of HIIT. Risk of bias was evaluated
with Cochrane Collaboration's Tool. Meta-analysis was done pooling
outcomes using mean differences (MD, 95% confidence interval), and grouped
by comparison group (HIIT vs. moderate-intensity continuous exercise
(MICE) or control groups). A total of 1144 participants (185 HTx and 959
HF, 70% male, average 59.17 years of age) across 26 RCT (22 HF and 4 HTx)
across 36 studies were included. HIIT improved exercise capacity (for peak
oxygen consumption [VO2peak]) mean difference (MD) 2.17 (95% CI,1.17 to
4.75) ml/kg/min for HF, and 2.46 (95% CI, 1.64 to 3.29) for HTx
participants), HRQoL (MD HF=0.53 [95%CI 0.09 to 0.97], MD HTx for
mental=3.13 [95% CI -1.91 to 11.46]), and endothelial function (for FMD,
MF HF=1.56 [95%CI, -1.69 to 4.81], MD HTx=3.40 [95% CI, 2.36 to 4.44]).
Interventions were equally safe between HIIT and other interventions
across HF and HTx groups with no differences (MD=0 across all) in adverse
events directly related HIIT interventions vs other interventions or
control arms. Conclusion(s): HIIT is a promising, safe, and
accessible tool with the potential to improve exercise capacity and
long-term outcomes in HF and HTx populations. Key populations remain
understudied, including women, children and adolescents, and those with
congenital heart disease, highlighting key knowledge gaps for this
potentially effective exercise strategy. [Formula presented] [Formula
presented] Copyright © 2022

<89>
Accession Number
2020813147
Title
THE IMPACT OF STATIN ON POST-OPERATIVE ATRIAL FIBRILLATION AFTER DISCHARGE
FROM CARDIAC SURGERY: SECONDARY ANALYSIS OF THE SEARCH-AF CARDIOLINK-1
RANDOMIZED TRIAL.
Source
Canadian Journal of Cardiology. Conference: Canadian Cardiovascular
Congress 2022. Ottawa Canada. 38(10 Supplement 2) (pp S124-S125), 2022.
Date of Publication: October 2022.
Author
Hibino M.; Verma S.; Quan A.; Puar P.; Verma R.; Pandey A.; Bisleri G.;
Verma A.; Ha A.; Mazer C.
Institution
(Hibino, Verma, Quan, Puar, Verma, Pandey, Bisleri, Verma, Ha, Mazer)
Cleveland, OH, United States
Publisher
Elsevier Inc.
Abstract
Background: There is conflicting evidence regarding the use of statins to
reduce the risk of post-operative atrial fibrillation (POAF) in patients
undergoing cardiac surgery. Methods and Results: We sought to
determine the effects of statin use on the incidence of post-discharge
POAF in the Post-Surgical Enhanced Monitoring for Cardiac Arrhythmias and
Atrial Fibrillation (SEARCH-AF) CardioLink-1 randomized controlled trial.
This trial randomized 336 patients with risk factors for stroke
(CHA2DS2-VASc score >=2) and no history of preoperative AF were randomized
to usual care or continuous cardiac rhythm monitoring for 30 days after
discharge from cardiac surgery with a wearable, patched-based device. The
primary endpoint was the occurrence of cumulative AF/AFL lasting for >=6
minutes detected by continuous monitoring or AF/AFL documented by a
12-lead electrocardiogram within 30 days of randomization. We evaluated
the association between the risk of post-operative AF in relation to
statin use and dosing intensity (low, moderate, high) at the time of
discharge. We excluded patients who experienced post-operative AF during
hospitalization in this analysis. In the overall cohort (n=336), 260
(77.4%) patients were treated with statins at the time of hospital
discharge. There were 18 (5.4%) patients who experienced post-operative AF
during hospitalization. Patients prescribed with statins were more likely
to be male (p=0.018), had lower CHA2DS2-VASc scores (p=0.011), and were
more likely to undergo isolated coronary artery bypass grafting (CABG)
(p=0.083). Patients treated with statins at discharge had a 2-fold lower
rate of POAF than those who were not treated with statins in the overall
cohort (17.6% vs. 8.2%, Log-Rank p=0.017) and in those randomized to
continuous cardiac rhythm monitoring (31.6% vs. 16.0%, Log-Rank p=0.027)
(Figure). After adjusting for surgery type (CABG vs. valve surgery) and
the CHA2DS2-VASc score, statin use at discharge was associated with a
lower risk of post-operative AF within 30 days after surgery (hazard ratio
0.48, 95% CI 0.24-0.97). Increased intensity of statin therapy was
associated with lower risk of POAF (P=0.0012 for trend). (Figure)
 Conclusion(s): High-intensity statin could reduce the risk of POAF
among cardiac surgical patients with risk factors for stroke. This merits
further study. [Formula presented] Copyright © 2022

<90>
Accession Number
2020813136
Title
STROKE RISK AND ORAL ANTICOAGULATION USE WITH EXTENDED CARDIAC MONITORING
FOR ATRIAL FIBRILLATION VERSUS USUAL CARE: A SYSTEMATIC REVIEW AND
META-ANALYSIS.
Source
Canadian Journal of Cardiology. Conference: Canadian Cardiovascular
Congress 2022. Ottawa Canada. 38(10 Supplement 2) (pp S148-S149), 2022.
Date of Publication: October 2022.
Author
Cheung C.; MacDonald B.; Turgeon R.; Field T.; Hill M.; Andrade J.
Institution
(Cheung, MacDonald, Turgeon, Field, Hill, Andrade) San FranciscoCAUnited
States
Publisher
Elsevier Inc.
Abstract
Background: Extended cardiac monitoring is used to detect atrial
fibrillation (AF) in high-risk populations, including those with a history
of cryptogenic stroke. Despite demonstrated effectiveness in AF detection,
randomized trials have not clearly demonstrated a reduction in stroke and
systemic embolism (SSE) or transient ischemic attack (TIA). We performed a
systematic review and meta-analysis of randomized trials evaluating
extended monitoring versus usual care on reduction of stroke/SSE and TIA
(PROSPERO #CRD42021277611). Methods and Results: Studies were
identified through CENTRAL, MEDLINE, and Embase searches using "atrial
fibrillation" and separate terms for all monitoring devices. We included
studies with >=100 participants and >=30 days follow-up. The primary
outcome was a composite of SSE/TIA (or most inclusive outcome reported),
with secondary outcomes including: AF incidence, oral anticoagulation
(OAC) initiation, major bleeding, and adverse events. Meta-analyses were
performed using R 'meta' package reporting risk ratios (RR) with 95%
confidence intervals (95% CI) using a random-effects model. Risk-of-bias
assessments were performed using the Cochrane Risk of Bias (RoB2) tool.
From 1411 records, we included 9 RCTs (n=10,205). Mean age of was 69.5
years, 40.4% were female, and mean CHADS2 score was 4.0. Four studies used
implantable cardiac monitors, 3 used external cardiac monitors, and 2 used
handheld ECG devices (Table 1). Study populations included post-stroke or
embolic stroke of undetermined significance (n=5), risk factors for AF or
stroke (n=2), and post-cardiac surgery (n=1). Mean follow-up was 15.7
months (range 3.0-64.5). All studies had a low risk of bias or some
concerns across most domains. Extended monitoring did not significantly
reduce the primary outcome (Figure 1, RR 0.87, 95% CI 0.72-1.04, I2=0%,
moderate certainty), or its individual components, versus usual care.
Extended monitoring increased AF detection (RR 4.56, 95% CI 3.01-6.92,
I2=65%, high certainty) and OAC use (RR 2.25, 95% CI 2.01-2.53, I2=0%,
high certainty), but not major bleeding (RR 1.23, 95% CI 0.84-1.82, I2=0%,
low certainty) or adverse events (RR 0.93, 95% CI 0.68-1.27, 1 trial, very
low certainty). Conclusion(s): In this meta-analysis of RCTs,
extended monitoring was associated with increased AF detection and OAC
use. However, it remains unclear whether extended monitoring is associated
with a reduced risk of thromboembolic events. [Formula presented] [Formula
presented] Copyright © 2022

<91>
Accession Number
2020930749
Title
Assessing the impact of publications: A bibliometric analysis of the
top-cited articles from The Journal of Thoracic and Cardiovascular
Surgery.
Source
Journal of Thoracic and Cardiovascular Surgery. (no pagination), 2022.
Date of Publication: 2022.
Author
Castro-Varela A.; Schaff H.V.
Institution
(Castro-Varela, Schaff) Department of Cardiovascular Surgery, Mayo Clinic,
Rochester, Minn
Publisher
Elsevier Inc.
Abstract
Objective: After 90 years, The Journal of Thoracic and Cardiovascular
Surgery (JTCVS) remains one of the most influential and widely read
journals in our specialty. This study analyzes the characteristics of its
top-cited articles over the past 6 decades. Method(s): Using
Elsevier's Scopus database, we identified all papers published in JTCVS
since 1959. After exclusion of expert consensus guidelines, articles were
grouped by decade and ranked by the total number of citations. We included
the field-weighted citation impact (FWCI) when available. We analyzed the
characteristics of the 10 most cited documents overall and per decade.
 Result(s): The Journal published a total of 32,335 papers, of which
14,052 were published between 2010 and 2021. The order of the top-cited
articles differs when ranked by citations versus FWCI. During the last 6
decades, the 10 most cited articles per decade have a mean number of 604
citations (range, 240-1670) and a mean FWCI of 13.1 (range, 4.3-24.7).
There is no overlap in positions when articles are ranked by citations
versus FWCI. The majority of the 60 top 10 cited articles over the past 6
decades were presented at a major meeting (n = 38, 63%), most commonly the
Annual Meeting of the American Association for Thoracic Surgery. Topics in
adult cardiac surgery and general thoracic surgery predominated among the
most-cited papers, which originated most often from the United States
followed by Japan, Canada, France, England, and Germany.
 Conclusion(s): JTCVS continues to provide a global platform to share
impactful knowledge related to surgery for thoracic diseases. The use of
citations to determine an article's impact has limitations and
nontraditional metrics may prove to be an excellent complementary tool for
more equitable evaluations. Copyright © 2022 The American
Association for Thoracic Surgery

<92>
Accession Number
2020898401
Title
Impella Versus Extracorporeal Membranous Oxygenation (ECMO) for
Cardiogenic Shock: A Systematic Review and Meta-analysis.
Source
Current Problems in Cardiology. 48(1) (no pagination), 2023. Article
Number: 101427. Date of Publication: January 2023.
Author
Ahmad S.; Ahsan M.J.; Ikram S.; Lateef N.; Khan B.A.; Tabassum S.; Naeem
A.; Qavi A.H.; Ardhanari S.; Goldsweig A.M.
Institution
(Ahmad) Department of Internal Medicine, East Carolina University,
Greenville, NC
(Ahsan) Division of Cardiovascular Medicine, Iowa Heart Center, Des
Moines, IA, United States
(Ikram) Department of Internal Medicine, SEGi University, MY, Petaling
Jaya, Malaysia
(Lateef, Goldsweig) Division of Cardiovascular Medicine, University of
Nebraska Medical Center, Omaha, NE, United States
(Khan) Department of Internal Medicine, The Jewish Hospital - Mercy
Health, Cincinnati, OH, United States
(Tabassum, Naeem) Department of Internal Medicine, King Edward Medical
University, Lahore, PK
(Qavi, Ardhanari) Division of Cardiovascular Medicine, East Carolina
University, Greenville, NC
Publisher
Elsevier Inc.
Abstract
The use of mechanical circulatory support (MCS) in cardiogenic shock (CS)
is increasing. We conducted a systematic review and meta-analysis to
compare the outcomes of Impella use with extracorporeal membranous
oxygenation (ECMO) support in patients with CS. We searched the Medline,
EMBASE, Cochrane, and Clinicaltrials.gov databases for observational
studies comparing Impella to ECMO in patients with CS. Risk ratios (RRs)
for categorical variables and standardized mean differences (SMDs) for
continuous variables were calculated with 95% confidence intervals (CIs)
using a random-effects model. Twelve retrospective studies and one
prospective study (Impella n=6652, ECMO n=1232) were identified. Impella
use was associated with lower incidence of in-hospital mortality (RR 0.88
[95% CI 0.80-0.94], P=0.0004), stroke (RR 0.30 [0.21-0.42], P<0.00001),
access-site bleeding (RR 0.50 [0.37-0.69], P<0.0001), major bleeding (RR
0.56 [0.39-0.80], P=0.002), and limb ischemia (RR 0.42 [0.27-0.65],
P=0.0001). Baseline lactate levels were significantly lower in the Impella
group (SMD -0.52 [-0.73- -0.31], P<0.00001). There was no significant
difference in mortality at 6-12 months, MCS duration, need for MCS
escalation, bridge-to-LVAD or heart transplant, and renal replacement
therapy use between Impella and ECMO groups. In patients with CS, Impella
device use was associated with lower in-hospital mortality, stroke, and
device-related complications than ECMO. However, patients in the ECMO
group had higher baseline lactate levels. Copyright © 2022
Elsevier Inc.

<93>
Accession Number
2018374468
Title
Efficacy of Primary Closure Technique in Treatment of Post-Sternotomy
Mediastinitis in Paediatric Group: A Randomized Controlled Trial.
Source
International Journal of General Medicine. 15 (pp 7929-7939), 2022. Date
of Publication: 2022.
Author
Fadaly A.S.; Abdellatif G.M.; Saeed S.E.; Brik A.; Elsharawy M.; Deebis
A.; Elfwakhry R.M.; Shemais D.S.
Institution
(Fadaly, Saeed, Brik, Elsharawy, Deebis, Shemais) Department of
Cardiothoracic Surgery, Faculty of Human Medicine, Zagazig University,
Zagazig, Egypt
(Abdellatif) Department of Pediatric medicine, Faculty of Human Medicine,
Zagazig University, Zagazig, Egypt
(Elfwakhry) Department of Radiodiagnosis, Faculty of Human Medicine,
Zagazig University, Zagazig, Egypt
Publisher
Dove Medical Press Ltd
Abstract
Purpose: To assess the efficacy of primary sternal closure technique
compared to vacuum-assisted closure technique in treatment of post-cardiac
surgery mediastinitis in paediatric age group. Additionally, assessed
postoperative need for IV drug use, hospital stay length, wound and
sternal healing and survival. Hypotheses: primary sternal closure is a
reliable technique for treatment of poststernotomy mediastinitis following
cardiac surgery in paediatric age group. Material(s) and Method(s): A
prospective randomized controlled trial included 217 pediatric patients
developed post-cardiac surgery mediastinitis from 2016 to 2022. They were
randomly divided into primary sternal closure group (A) and
vacuum-assisted closure group (B) and operated by two cardiothoracic
surgeons. Follow-up of the patients was done for 6-months duration
following treatment of mediastinitis to assess postoperative need for
hospitalization, IV drug use, wound complications, sternal stability and
survival. Result(s): The final analysis included 101 patients in each
group. The chance of survival over 6 months after surgery was more for
primary sternal closure group (175.2) days versus (157.6) days for the
vacuum-assisted closure group, with significant difference Log Rank test
p-value (0.005). Duration for IV antibiotics use in the primary closure
group was 8.55+/-3.57 and it was 32.61+/-8.39 showing high statistically
significant difference (p<0.001). Patients in the primary closure group
had earlier discharge from hospital 15.77+/-4.18 than vacuum assisted
group 42.61+/-8.39, with high statistically significant difference
(p<0.001). Primary closure group showed better sternal stability and
sternotomy wound healing on clinical follow-up. Conclusion(s):
Primary sternal closure technique is a favorable technique over
vacuum-assisted closure technique for treatment of paediatric
mediastinitis following cardiac surgery. The reinforced sternal closure
technique is a reliable technique with promising results regarding IV
drugs need, hospitalization duration, survival and sternotomy wound
healing. Copyright © 2022 Fadaly et al.

<94>
[Use Link to view the full text]
Accession Number
2020806036
Title
A 20-year experience in cardiac tumors: a single center surgical
experience and a review of literature.
Source
Journal of Cardiovascular Medicine. 23(11) (pp 722-727), 2022. Date of
Publication: 01 Nov 2022.
Author
Restivo L.; De Luca A.; Fabris E.; Pagura L.; Pierri A.; Korcova R.;
Franzese I.; Fiocco A.; Rauber E.; Mazzaro E.; Bussani R.; Belgrano M.;
Pappalardo A.; Sinagra G.
Institution
(Restivo, De Luca, Fabris, Pagura, Pierri, Korcova, Sinagra)
Cardiothoracovascular Department, Division of Cardiology, Azienda
Sanitaria Universitaria Giuliano Isontina, University of Trieste, Italy
(Franzese, Fiocco, Rauber, Mazzaro, Pappalardo) Cardiothoracovascular
Department, Division of Cardiac Surgery, Azienda Sanitaria Universitaria
Giuliano Isontina, Trieste, Italy
(Fiocco) Department of Surgical, Medical and Molecular Pathology and
Critical Care, Division of Cardiac Surgery, University of Pisa, Pisa,
Italy
(Bussani) Pathology Department, Azienda Sanitaria Universitaria Giuliano
Isontina, University of Trieste, Italy
(Belgrano) Department of Radiology, Azienda Sanitaria Universitaria
Integrata, University of Trieste, Trieste, Italy
Publisher
Lippincott Williams and Wilkins
Abstract
IntroductionCardiac tumors are rare and heterogeneous entities which still
remain a diagnostic and therapeutic challenge. The treatment for most
cardiac tumors is prompt surgical resection. We sought to provide an
overview of surgical results from a series of consecutive patients treated
at our tertiary care center during almost a 20-year experience.Methods and
ResultsIn this single center study, 55 consecutive patients with diagnosis
of cardiac tumor underwent surgical treatment from January 2002 to April
2021. Of these, 23 (42%) were male and the mean age was 62 +/- 12 years.
Fifteen (27%) patients were symptomatic at the time of the diagnosis,
mostly for dyspnea and palpitations. The most frequent benign cardiac
tumor was myxoma (32; 58%), occurring mainly in the left atrium (31; 97%).
Pleomorphic sarcoma was the most frequent primary malignant cardiac tumor
(4; 7%), mainly located in the ventricles (1; 25% in the left ventricle;
2; 50% in the right ventricle). In all cases of benign tumors surgery was
successful with no relapses. Two (50%) pleomorphic sarcomas showed
subsequent relapses. After a median follow-up of 44 months, 15 (27%)
patients died. Although malignant tumors presented a limited survival,
benign tumors showed a very good prognosis.ConclusionCardiac tumors
require a multidisciplinary approach to guarantee a prompt diagnosis and
appropriate treatment. In our surgical experience, outcome after surgery
of benign tumors was excellent, while malignant tumors had poor prognosis
despite radical surgery. Copyright © 2021 Wolters Kluwer Health,
Inc. All rights reserved.

<95>
Accession Number
2019764647
Title
Colchicine in Cardiac Surgery: The COCS Randomized Clinical Trial.
Source
Journal of Cardiovascular Development and Disease. 9(10) (no pagination),
2022. Article Number: 363. Date of Publication: October 2022.
Author
Shvartz V.; Le T.; Enginoev S.; Sokolskaya M.; Ispiryan A.; Shvartz E.;
Nudel D.; Araslanova N.; Petrosyan A.; Donakanyan S.; Chernov I.; Bockeria
L.; Golukhova E.
Institution
(Shvartz, Le, Sokolskaya, Ispiryan, Petrosyan, Donakanyan, Bockeria,
Golukhova) Bakulev Scientific Center for Cardiovascular Surgery, Moscow
121552, Russian Federation
(Enginoev, Nudel, Araslanova, Chernov) Federal Center for Cardiovascular
Surgery of the Russian Federation Ministry of Healthcare (Astrakhan),
Astrakhan 414011, Russian Federation
(Enginoev) Astrakhan State Medical University of the Russian Federation
Ministry of Healthcare, Astrakhan 414000, Russian Federation
(Shvartz) National Medical Research Center for Therapy and Preventive
Medicine, Moscow 101990, Russian Federation
Publisher
MDPI
Abstract
Background. In patients who underwent cardiac surgery, first-time
postoperative atrial fibrillation (POAF) is associated with increased
incidence of hospital-acquired complications and mortality. Systemic
inflammation is one of confirmed triggers of its development. The
anti-inflammatory properties of colchicine can be effective for the POAF
prevention. However, the results of several studies were questionable and
required further investigation. Hence, we aimed to evaluate the
effectiveness of low-dose short-term colchicine administration for POAF
prevention in patients after the open-heart surgery. This double-blind
randomized placebo-controlled trial included 267 patients, but 27 of them
dropped out in the course of the study. Study subjects received the test
drug on the day before the surgery and on postoperative days 2, 3, 4 and
5. The rhythm control was conducted immediately after the operation and
until the discharge from the hospital. The final analysis included 240
study subjects: 113 in the colchicine group and 127 in the placebo group.
POAF was observed in 21 (18.6%) patients of the colchicine group vs. 39
(30.7%) control patients (OR 0.515; 95% Cl 0.281-0.943; p = 0.029). We
observed no statistically significant differences between the patient
groups in the secondary endpoints of the study (hospital mortality,
respiratory failure, stroke, bleeding, etc.). For other parameters
characterizing the severity of inflammation (pericardial effusion, pleural
effusion, WBC count, neutrophil count), there were statistically
significant differences between the groups in the early postoperative
period (days 3 and 5). Also, statistically significant differences between
the groups in the frequency of adverse events were revealed: the incidence
of diarrhea in the colchicine group was 25.7% vs. 11.8% in the placebo
group (OR 2.578; 95% Cl 1.300-5.111; p = 0.005); for abdominal pain,
incidence values were 7% vs. 1.6%, correspondingly (OR 4.762; 95% Cl
1.010-22.91; p = 0.028). Thus, there were statistically significant
differences between groups in the primary endpoint, thereby confirming the
effectiveness of short-term colchicine use for the POAF prevention after
coronary artery bypass grafting and/or aortic valve replacement. Also, we
detected statistically significant differences between groups in the
frequency of side effects to colchicine: diarrhea and abdominal pain were
more common in the colchicine group. This clinical trial is registered
with ClinicalTrials database under a unique identifier:
NCT04224545. Copyright © 2022 by the authors.

<96>
Accession Number
2019701904
Title
Anatomical variation in the branching pattern of the aortic arch: a
literature review.
Source
Irish Journal of Medical Science. (no pagination), 2022. Date of
Publication: 2022.
Author
Murray A.; Meguid E.A.
Institution
(Murray) Queen's University Belfast, University Road, Belfast BT7 1NN,
United Kingdom
(Meguid) School of Medicine, Dentistry and Biomedical Sciences, Whitla
Medical Building, Queen's University Belfast, 1st Floor, 97 Lisburn Road,
Belfast BT9 7AE, United Kingdom
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Many anatomical variations of the branching pattern of the
aortic arch have been documented in the literature. These find their
origin in alterations to the embryological development of the arch and
have significant implications for surgical and radiological interventions.
 Method(s): Embase and Medline database searches were carried out in
June 2021 and identified 1197 articles, of which 24 were considered
eligible. Result(s): Twenty-eight variations were found. The
prevalence of the six main variations found is as follows: normal
configuration (61.2-92.59%); bovine arch type 1 (4.95-31.2%); bovine arch
type 2 (0.04-24%); origin of left vertebral artery (0.17-15.3%); aberrant
right subclavian artery (0.08-3.33%); thyroid ima artery (0.08-2%).
Concomitant variations present in conjunction with these variations are
also documented, as were other variations which could not be classified
into these six groups. Conclusion(s): Anatomical variations in the
branching pattern of the aortic arch are present in over one-third of
individuals in some populations. These are important pre- and
intra-operatively during thoracic, neck and thyroid surgery. A greater
effort should be employed to construct an official classification to
facilitate greater understanding among clinicians. Copyright ©
2022, The Author(s).

<97>
Accession Number
639360214
Title
Usefulness of Analgesia Nociception Index for guiding intraoperative
opioid administration: a systematic review and meta-analysis.
Source
Minerva anestesiologica. (no pagination), 2022. Date of Publication: 25
Oct 2022.
Author
Hung K.-C.; Chang P.-C.; Hsu C.-W.; Lan K.-M.; Liao S.-W.; Lin Y.-T.;
Huang P.-W.; Sun C.-K.
Institution
(Hung, Lan, Liao, Lin) Department of Anesthesiology, Chi Mei Medical
Center, Tainan, Taiwan (Republic of China)
(Chang) Division of Thoracic Surgery, Department of Surgery, Kaohsiung
Medical University Hospital/Kaohsiung Medical University, Kaohsiung,
Taiwan (Republic of China)
(Chang) Weight Management Center, Kaohsiung Medical University
Hospital/Kaohsiung Medical University, Kaohsiung, Taiwan (Republic of
China)
(Chang) Department of Sports Medicine, College of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan (Republic of China)
(Chang) Program in Biomedical Engineering, College of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan (Republic of China)
(Hsu) Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and
Chang Gung University College of Medicine, Kaohsiung, Taiwan (Republic of
China)
(Huang) Department of Emergency Medicine, Show Chwan Memorial Hospital,
Taiwan (Republic of China)
(Sun) Department of Emergency Medicine, E-Da Hospital, Kaohsiung, Taiwan
(Republic of China)
(Sun) College of Medicine, I-Shou University, Kaohsiung, Taiwan (Republic
of China)
Publisher
NLM (Medline)
Abstract
INTRODUCTION: This study primarily aimed at investigating the efficacy of
analgesia nociception index (ANI) for guiding intraoperative opioid
administration in patients receiving surgery under general anesthesia.
EVIDENCEACQUISITION: The Medline, Embase, Google scholar, and the Cochrane
Library databases were searched from inception to April 2022 for
randomized controlled trials. The primary outcome was intraoperative
opioid administration, while the secondary outcomes included postoperative
opioid consumption, pain score, emergency time, risk of nausea/vomiting
(PONV), and postanesthesia care unit (PACU) stay. EVIDENCE SYNTHESIS: Six
studies including 399 participants (published from 2015 to 2022) focused
on non-cardiac surgery, including spine surgery (two trials), breast
surgery (two trials), gynecologic surgery (one trial), and laparoscopic
cholecystectomy (one trial) were included. Meta-analysis revealed no
difference in intraoperative opioid administration with the use of
ANI-guided analgesia compared to the control group that used conventional
clinical measurements (e.g., heart rate) to guide opioid use [standardized
mean difference (SMD)=-0.17, 95% CI: -0.56 to 0.22, p=0.39, I2=72%, six
trials, 399 participants]. Gender-based subgroup analysis showed
effectiveness of ANI for reducing opioid administration in female patients
(SMD=-0.53, p=0.02). There were no differences in postoperative recovery
characteristics including pain score [Mean difference (MD): -0.03,
p=0.79], opioid consumption (SMD: -0.34, p=0.08), emergence time (MD=1.12,
p=0.47), length of stay in the PACU (MD: -0.56, p=0.83), and risk of PONV
[risk ratio(RR): 0.75, p=0.46] between the two groups. CONCLUSION(S):
Analgesia nociception index-guided analgesia was unable to reduce
intraoperative opioid administration compared to monitoring using
conventional clinical parameters. Further studies are required to support
our findings.

<98>
Accession Number
2015417478
Title
Suspicion, screening, and diagnosis of wild-type transthyretin amyloid
cardiomyopathy: a systematic literature review.
Source
ESC Heart Failure. 9(3) (pp 1524-1541), 2022. Date of Publication: June
2022.
Author
Bay K.; Gustafsson F.; Maiborg M.; Bagger-Bahnsen A.; Strand A.M.;
Pilgaard T.; Poulsen S.H.
Institution
(Bay) Bay Writing, Copenhagen, Denmark
(Bay, Bagger-Bahnsen, Strand, Pilgaard) Pfizer Denmark, Ballerup, Denmark
(Gustafsson) The Heart Center, Copenhagen University Hospital,
Rigshospitalet, Copenhagen, Denmark
(Maiborg) Odense Amyloidosis Center & Department of Cardiology, Odense
University Hospital, Odense, Denmark
(Poulsen) Department of Cardiology, Aarhus University Hospital, Aarhus,
Denmark
Publisher
John Wiley and Sons Inc
Abstract
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt CM) is a more
common disease than previously thought. Awareness of ATTRwt CM and its
diagnosis has been challenged by its unspecific and widely distributed
clinical manifestations and traditionally invasive diagnostic tools.
Recent advances in echocardiography and cardiac magnetic resonance (CMR),
non-invasive diagnosis by bone scintigraphy, and the development of
disease-modifying treatments have resulted in an increased interest,
reflected in multiple publications especially during the last decade. To
get an overview of the scientific knowledge and gaps related to patient
entry, suspicion, diagnosis, and systematic screening of ATTRwt CM, we
developed a framework to systematically map the available evidence of (i)
when to suspect ATTRwt CM in a patient, (ii) how to diagnose the disease,
and (iii) which at-risk populations to screen for ATTRwt CM. Articles
published between 2010 and August 2021 containing part of or a full
diagnostic pathway for ATTRwt CM were included. From these articles, data
for patient entry, suspicion, diagnosis, and screening were extracted, as
were key study design and results from the original studies referred to. A
total of 50 articles met the inclusion criteria. Of these, five were
position statements from academic societies, while one was a clinical
guideline. Three articles discussed the importance of primary care
providers in terms of patient entry, while the remaining articles had the
cardiovascular setting as point of departure. The most frequently
mentioned suspicion criteria were ventricular wall thickening (44/50),
carpal tunnel syndrome (42/50), and late gadolinium enhancement on CMR
(43/50). Diagnostic pathways varied slightly, but most included bone
scintigraphy, exclusion of light-chain amyloidosis, and the possibility of
doing a biopsy. Systematic screening was mentioned in 16 articles, 10 of
which suggested specific at-risk populations for screening. The European
Society of Cardiology recommends to screen patients with a wall thickness
>=12 mm and heart failure, aortic stenosis, or red flag symptoms,
especially if they are >65 years. The underlying evidence was generally
good for diagnosis, while significant gaps were identified for the
relevance and mutual ranking of the different suspicion criteria and for
systematic screening. Conclusively, patient entry was neglected in the
reviewed literature. While multiple red flags were described, high-quality
prospective studies designed to evaluate their suitability as suspicion
criteria were lacking. An upcoming task lies in defining and evaluating
at-risk populations for screening. All are steps needed to promote early
detection and diagnosis of ATTRwt CM, a prerequisite for timely
treatment. Copyright © 2022 The Authors. ESC Heart Failure
published by John Wiley & Sons Ltd on behalf of European Society of
Cardiology.

<99>
Accession Number
2020520604
Title
An intubation method for mono-pulmonary ventilation in patients with
difficult airway.
Source
European Review for Medical and Pharmacological Sciences. 26(18) (pp
6647-6657), 2022. Date of Publication: 2022.
Author
Yu Y.; Wang X.-L.; Wang Y.-F.; Zhou L.-J.; Yang Z.
Institution
(Yu, Wang, Wang, Zhou) Anesthesiology Department, First Hospital of
Qinhuangdao, Haigang District, Hebei, Qinhuangdao, China
(Yang) Kangtai Medical System (Qinhuangdao) Co.,LTD, R&D Center,
Economicand Technological Development Zone, Hebei Province, Qinhuangdao,
China
Publisher
Verduci Editore s.r.l
Abstract
OBJECTIVE: This study aimed to compare the clinical effect between thermal
softening PVC double-lumen tube (DLT) and single-lumen tube (SLT) guided
by laryngoscope and bronchoscopy in patients with difficult airways.
 PATIENTS AND METHODS: 72 patients with chest surgery in need of
mono-pulmonary ventilation, aged 20-70 years old, with ASA rating I-III
and Arne scoring >= 11, were enrolled. Patients were categorized randomly
into two groups with 36 patients in each: the D group (DLT was used) and
the S group (SLT was used). Bronchoscopy was used for guiding the
intubation and aligning in both groups. Laryngoscope would also be used
immediately after failure in two trials of intubation. Intubation
resistance, intubation success rate, laryngoscopy assist rate, time for
intubation, time for alignment, incidence of catheter dislocation, VAS
score for post-operative throat pain, and the damage extent of vocal cord
were recorded. RESULT(S): No significant differences were seen
between two the groups in terms of intubation resistance, intubation
success rate, laryngoscopy assist rate, time for intubation, VAS score for
post-operative throat pain, and the damage extent of vocal cord. However,
shorter time for alignment and lower incidence of catheter dislocation
were observed in the D group than in the S group (both p < 0.05).
 CONCLUSION(S): For intubation in patients with difficult airway, the
thermal softening DLT was as safe as the SLT, but simpler in alignment and
had a lower dislocation incidence. Meanwhile, video laryngoscope could
increase the success rate of intubation with either tube. Copyright
© 2022 Verduci Editore s.r.l. All rights reserved.

<100>
Accession Number
2020221049
Title
Use of Anticoagulation Therapy in Patients With Perioperative Atrial
Fibrillation After Cardiac Surgery: A Systematic Review and Meta-analysis.
Source
CJC Open. 4(10) (pp 840-847), 2022. Date of Publication: October 2022.
Author
Wang M.K.; Heo R.; Meyre P.; Park L.; Blum S.; McIntyre W.F.; Belley-Cote
E.; Birchenough L.; Vuong K.; Healey J.S.; Devereaux P.J.; Lamy A.; Conen
D.
Institution
(Wang, McIntyre, Belley-Cote, Healey, Devereaux, Conen) Department of
Medicine, McMaster University, Hamilton, ON, Canada
(Wang, Blum, McIntyre, Belley-Cote, Healey, Devereaux, Lamy, Conen)
Population Health Research Institute, McMaster University, Hamilton, ON,
Canada
(Wang, McIntyre, Belley-Cote, Healey, Devereaux, Lamy, Conen) Department
of Health Research Methods, Evidence & Impact, McMaster University,
Hamilton, ON, Canada
(Heo) Michael G. DeGroote School of Medicine, McMaster University,
Hamilton, ON, Canada
(Meyre, Blum) Division of Cardiology and Cardiovascular Research Institute
Basel, University Hospital Basel, Basel, Switzerland
(Park, Birchenough) Faculty of Health Sciences, McMaster University,
Hamilton, ON, Canada
(Vuong) Faculty of Sciences, Western University, London, ON, Canada
(Lamy) Department of Surgery, McMaster University, Hamilton, ON, Canada
Publisher
Elsevier Inc.
Abstract
Background: Perioperative atrial fibrillation (POAF) after cardiac surgery
is associated with an increased risk of stroke. However, the efficacy and
safety of using anticoagulation therapy in this population are unknown.
 Method(s): We performed a systematic review and meta-analysis of
studies comparing use of anticoagulation therapy vs no anticoagulation
therapy in patients with POAF after cardiac surgery. Outcomes included
arterial thromboembolism (ie, stroke +/- systemic embolism) and bleeding.
Data were pooled using fixed-effects models. We reported summary risk
ratios (RRs) for studies with multivariable adjustment and estimated
absolute risk differences with 95% confidence intervals (CIs).
 Result(s): Nine observational studies met eligibility criteria. No
randomized trials were identified. Of the 254,200 POAF patients included,
27.3% received anticoagulation. Six studies reported outcomes after
long-term follow-up (median 5.0 years; range 4.2-10.0). The risk of
arterial thromboembolism was lower in patients receiving anticoagulation
therapy (RR 0.83; 95% CI, 0.69-0.99; I2 = 57%; P = 0.04; 6
studies). The estimated short-term and long-term absolute risk reductions
in arterial thromboembolism with use of anticoagulation therapy were 0.8%
(95% CI, 0.4-1.4) and 2 events per 1000 person-years (95% CI, 0-4),
respectively. The risk of bleeding was higher in patients receiving
anticoagulation therapy (RR 3.22; 95% CI, 2.82-3.68; I2 = 98%;
P < 0.001; 2 studies). The estimated short-term and long-term absolute
risk increases in bleeding with use of anticoagulation therapy were 0.5%
(95% CI, 0.4-0.6) and 42 events per 1000 person-years (95% CI, 35-51),
respectively. Conclusion(s): Use of anticoagulation therapy is
associated with a small reduction in the risk of arterial thromboembolism,
but also an increased risk of bleeding. Randomized controlled trials are
needed to address this issue. Copyright © 2022 The Authors

<101>
Accession Number
2020045864
Title
An Overview of the Role of Radiotherapy in the Treatment of Small Cell
Lung Cancer - A Mainstay of Treatment or a Modality in Decline?.
Source
Clinical Oncology. 34(11) (pp 741-752), 2022. Date of Publication:
November 2022.
Author
Merie R.; Gee H.; Hau E.; Vinod S.
Institution
(Merie) Icon Cancer Centre, Concord Repatriation General Hospital,
Concord, NSW, Australia
(Merie, Vinod) South West Sydney Clinical Campuses, University of NSW,
Liverpool, NSW, Australia
(Gee, Hau) Sydney West Radiation Oncology Network (SWRON), Sydney, NSW,
Australia
(Gee, Hau) Sydney Medical School, Westmead Hospital, University of Sydney,
Sydney, NSW, Australia
(Gee) Children's Medical Research Institute (CMRI), University of Sydney,
Sydney, NSW, Australia
(Hau) The Westmead Institute for Medical Research (WIMR), Westmead, NSW,
Australia
(Vinod) Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW,
Australia
(Vinod) Ingham Institute for Applied Medical Research, Liverpool, NSW,
Australia
Publisher
Elsevier Ltd
Abstract
Aims: Small cell lung cancer (SCLC) accounts for about 15% of all lung
cancers. Chemotherapy, immunotherapy and radiotherapy all play important
roles in the management of SCLC. The aim of this study was to provide a
comprehensive overview of the role and evidence of radiotherapy in the
cure and palliation of SCLC. Material(s) and Method(s): The search
strategy included a search of the PubMed database, hand searches,
reference lists of relevant review articles and relevant published
abstracts. ClinicalTrials.gov was also queried for relevant trials.
 Result(s): Thoracic radiotherapy improves overall survival in limited
stage SCLC, but the timing and dose remain controversial. The role of
thoracic radiotherapy in extensive stage SCLC with immunotherapy is the
subject of several ongoing trials. Current evidence supports the use of
prophylactic cranial irradiation (PCI) for limited stage SCLC but the
evidence is equivocal in extensive stage SCLC. Whole brain radiotherapy is
well established for the treatment of brain metastases but evidence is
rapidly accumulating for the use of stereotactic radiosurgery. Further
studies will define the role of PCI, whole brain radiotherapy and
hippocampal avoidant PCI in the immunotherapy era. Conclusion(s):
Radiotherapy is an essential component in the multimodality management of
SCLC. Technological advances have allowed safer delivery of radiotherapy
with reduced toxicities. Discussion at multidisciplinary team meetings is
important to ensure radiotherapy is considered and offered in appropriate
patients. Copyright © 2022

<102>
Accession Number
2019845087
Title
Angiographic and clinical outcome of SARS-CoV-2 positive patients with
ST-segment elevation myocardial infarction undergoing primary angioplasty:
A collaborative, individual patient data meta-analysis of six
registry-based studies.
Source
European Journal of Internal Medicine. 105 (pp 69-76), 2022. Date of
Publication: November 2022.
Author
De Luca G.; Silverio A.; Verdoia M.; Siudak Z.; Tokarek T.; Kite T.A.;
Gershlick A.H.; Rodriguez-Leor O.; Cid-Alvarez B.; Jones D.A.; Rathod
K.S.; Montero-Cabezas J.M.; Jurado-Roman A.; Nardin M.; Galasso G.
Institution
(De Luca) Division of Clinical and Experimental Cardiology, Azienda
Ospedaliero-Universitaria Sassari, Viale S. Pietro, 43/B, Sassari, Italy
(De Luca) Division of Clinical and Interventional Cardiology, Istituto
Clinico Sant'Ambrogio, Milano, Italy
(Silverio, Galasso) Department of Medicine, Surgery and Dentistry,
University of Salerno, Salerno, Baronissi, Italy
(Verdoia) Division of Cardiology, Ospedale degli Infermi, ASL, Biella,
Italy
(Siudak) Jan Kochanowski University, Kielce, Poland
(Tokarek) Institute of Cardiology, Jagiellonian University Medical
College, Kopernika 17 Street, Krakow 31-501, Poland
(Tokarek) 2nd Department of Cardiology and Cardiovascular Interventions,
University Hospital, Krakow, Poland
(Kite, Gershlick) Department of Cardiovascular Sciences and the NIHR
Leicester Biomedical Research Centre, Glenfield Hospital, University of
Leicester and University Hospitals of Leicester NHS Trust, Leicester,
United Kingdom
(Rodriguez-Leor) Institut del Cor, Hospital Universitari Germans Trias i
Pujol, Badalona, Spain
(Rodriguez-Leor) CIBER de Enfermedades CardioVasculares (CIBERCV)
Instituto de Salud Carlos III, Madrid, Spain
(Rodriguez-Leor) Institut de Recerca en Ciencies de la Salut Germans Trias
i Pujol, Badalona, Spain
(Cid-Alvarez) Servicio de Cardiologia, Hospital Clinico de Santiago de
Compostela, A Coruna, Santiago de Compostela, Spain
(Jones, Rathod) Department of Cardiology, Barts Heart Centre, St.
Bartholomew's Hospital, London, United Kingdom
(Jones, Rathod) Centre for Cardiovascular Medicine and Devices, William
Harvey Research Institute, Queen Mary University of London, London, United
Kingdom
(Montero-Cabezas) Department of Cardiology, Leiden University Medical
Center, Leiden, Netherlands
(Jurado-Roman) Department of Cardiology, Hospital Universitario La Paz.,
Madrid, Spain
(Nardin) Department of Internal Medicine, Ospedale Riuniti, Brescia, Italy
Publisher
Elsevier B.V.
Abstract
Background: The characteristics and outcome of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)-positive patients with ST-Elevation
Myocardial Infarction (STEMI) undergoing primary percutaneous coronary
intervention (PPCI) are still poorly known. Method(s): The PANDEMIC
study was an investigator-initiated, collaborative, individual patient
data (IPD) meta-analysis of registry-based studies. MEDLINE,
ScienceDirect, Web of Sciences, and SCOPUS were searched to identify all
registry-based studies describing the characteristics and outcome of
SARS-CoV-2-positive STEMI patients undergoing PPCI. The control group
consisted of SARS-CoV-2-negative STEMI patients undergoing PPCI in the
same time period from the ISACS-STEMI COVID 19 registry. The primary
outcome was in-hospital mortality; the secondary outcome was
postprocedural reperfusion assessed by TIMI flow. Result(s): Of 8
registry-based studies identified, IPD were obtained from 6 studies
including 941 SARS-CoV-2-positive patients; the control group included
2005 SARS-CoV-2-negative patients. SARS-CoV-2-positive patients showed a
significantly higher in-hospital mortality (p < 0.001) and worse
postprocedural TIMI flow (<3, p < 0.001) compared with SARS-CoV-2-negative
subjects. The increased risk for SARS-CoV-2-positive patients was
significantly higher in males compared to females for both the primary
(p<inf>interaction</inf> = 0.001) and secondary outcome
(p<inf>interaction</inf> = 0.023). In SARS-CoV-2-positive patients, age >=
75 years (OR = 5.72; 95%CI: 1.77-18.5), impaired postprocedural TIMI flow
(OR = 11.72; 95%CI: 2.64-52.10), and cardiogenic shock at presentation (OR
= 11.02; 95%CI: 2.84-42.80) were independent predictors of mortality.
 Conclusion(s): In STEMI patients undergoing PPCI, SARS-CoV-2
positivity is independently associated with impaired reperfusion and with
a higher risk of in-hospital mortality, especially among male patients.
Age >= 75 years, cardiogenic shock, and impaired postprocedural TIMI flow
independently predict mortality in this high-risk
population. Copyright © 2022

<103>
Accession Number
2019681340
Title
Cardiac cephalalgia: a narrative review and ICHD-3 criteria evaluation.
Source
Journal of Headache and Pain. 23(1) (no pagination), 2022. Article Number:
136. Date of Publication: December 2022.
Author
Navarro-Perez M.P.; Bellosta-Diago E.; Olesen J.; Santos-Lasaosa S.
Institution
(Navarro-Perez, Bellosta-Diago, Santos-Lasaosa) Neurology Department,
Hospital Clinico Universitario Lozano Blesa, San Juan Bosco 15, Saragossa
50009, Spain
(Navarro-Perez, Bellosta-Diago, Santos-Lasaosa) Aragon Institute for
Health Research (IIS Aragon), Saragossa, Spain
(Olesen) Danish Headache Center, Department of Neurology,
Rigshospitalet-Glostrup, University of Copenhagen, Copenhagen, Denmark
Publisher
BioMed Central Ltd
Abstract
Background: Cardiac cephalalgia is an unusual condition that occurs during
an episode of myocardial ischemia. Information about cardiac cephalalgia
is scarce and its characteristics and physiopathology remain unclear. Our
aim is to provide a narrative review of clinical characteristics and
physiopathology of cardiac cephalalgia and to evaluate the current
diagnostic criteria. Method(s): A search through PubMed was
undertaken for studies on cardiac cephalalgia published until
20th September 2022. We summarized the literature and provide a
comprehensive review of the headache characteristics and possible
mechanisms. We also evaluated current International Classification of
Headache Disorders third edition diagnostic criteria based on prior
reported cases. Result(s): In total, 88 cases were found. Headache
characteristics were variable. Occipital location and throbbing pain were
the most frequently reported. Headache was accompanied in most cases by
cardiac symptoms. Criterion B was fulfilled by 98% of cases, criterion C1
by 72%, and criteria C2a and C2b by 37 and 93.2%, respectively. Regarding
headache features described in diagnostic criterion C3, 'moderate to
severe intensity', 'accompanied by nausea', 'not accompanied by
photophobia or phonophobia' and 'aggravated by exertion', were reported in
75, 31, 55 and 55% of cases, respectively. Conclusion(s): Cardiac
cephalalgia characteristics are variable and the headache features
described in the diagnostic criterion C3 might not be adequate. Given that
cardiac cephalalgia can be the manifestation of a life-threatening
condition it is important to increase the knowledge about this
entity. Copyright © 2022, The Author(s).

<104>
Accession Number
2019543689
Title
Evidence basis for using dexmedetomidine to enhance the quality of
paravertebral block: A systematic review and meta-analysis of randomized
controlled trials.
Source
Frontiers in Pharmacology. 13 (no pagination), 2022. Article Number:
952441. Date of Publication: 29 Sep 2022.
Author
Tang R.; Liu Y.-Q.; Zhong H.-L.; Wu F.; Gao S.-X.; Liu W.; Lu W.-S.; Wang
Y.-B.
Institution
(Tang, Liu, Zhong, Wu, Gao, Liu, Lu, Wang) Department of Anesthesiology,
Lanzhou University Second Hospital, Lanzhou, China
Publisher
Frontiers Media S.A.
Abstract
Background: Dexmedetomidine is considered an adjunct to local anaesthesia
(LA) to prolong peripheral nerve block time. However, the results from a
previous meta-analysis were not sufficient to support its use in
paravertebral block (PVB). Therefore, we performed an updated
meta-analysis to evaluate the efficacy of dexmedetomidine combined with LA
in PVB. Method(s): We performed an electronic database search from
the date of establishment to April 2022. Randomized controlled trials
(RCTs) investigating the combination of dexmedetomidine and LA compared
with LA alone for PVB in adult patients were included. Postoperative pain
scores, analgesic consumption, and adverse reactions were analyzed.
 Result(s): We identified 12 trials (701 patients) and found that the
application of dexmedetomidine as a PVB adjunct reduced the postoperative
pain severity of patients 12 and 24 h after surgery compared to a control
group. Expressed as mean difference (MD) (95% CI), the results were -1.03
(-1.18, -0.88) (p < 0.00001, I2 = 79%) for 12 h and -1.08
(-1.24, -0.92) (p < 0.00001, I2 = 72%) for 24 h.
Dexmedetomidine prolonged the duration of analgesia by at least 173.27 min
(115.61, 230.93) (p < 0.00001, I2 = 81%) and reduced
postoperative oral morphine consumption by 18.01 mg (-22.10, 13.92) (p <
0.00001, I2 = 19%). We also found no statistically significant
differences in hemodynamic complications between the two groups. According
to the GRADE system, we found that the level of evidence for postoperative
pain scores at 12 and 24 h was rated as moderate. Conclusion(s): Our
study shows that dexmedetomidine as an adjunct to LA improves the
postoperative pain severity of patients after surgery and prolongs the
duration of analgesia in PVB without increasing the incidence of adverse
effects. Copyright © 2022 Tang, Liu, Zhong, Wu, Gao, Liu, Lu and
Wang.

<105>
Accession Number
2019266437
Title
A Randomized Comparison of the Healing Response Between the Firehawk Stent
and the Xience Stent in Patients With ST-Segment Elevation Myocardial
Infarction at 6 Months of Follow-Up (TARGET STEMI OCT China Trial): An
Optical Coherence Tomography Study.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 895167. Date of Publication: 01 Jun 2022.
Author
He Y.; Wang R.; Liu J.; Li F.; Li J.; Li C.; Zhou J.; Zhao Z.; Yang W.;
Mou F.; Wang J.; Kan J.; Li X.; Li Y.; Zheng M.; Chen S.; Gao C.; Tao L.
Institution
(He, Wang, Liu, Li, Li, Li, Zhou, Zhao, Yang, Mou, Wang, Gao, Tao)
Department of Cardiology, Xijing Hospital, Air Force Medical University,
Xi'an, China
(Wang, Gao) Department of Cardiology, Radboud University, Nijmegen,
Netherlands
(Wang, Gao) Department of Cardiology, National University of Ireland,
Galway, Ireland
(Kan, Li, Chen) Department of Cardiology, Nanjing First Hospital, Nanjing
Medical University, Nanjing, China
(Li) Department of Cardiology, Tangdu Hospital, Air Force Medical
University, Xi'an, China
(Zheng) Shanghai MicroPort Medical (Group), Shanghai, China
Publisher
Frontiers Media S.A.
Abstract
Background: The healing response of the Firehawk stent in patients with
ST-segment elevation myocardial infarction (STEMI) remains unclear.
 Aim(s): We compared the vascular healing of a biodegradable polymer
sirolimus-eluting stent (Firehawk) vs. a durable polymer
everolimus-eluting stent (Xience) at 6 months after percutaneous coronary
intervention (PCI) in patients with STEMI. Method(s): In this
prospective, multicenter, randomized, non-inferiority study, patients
within 12 h of STEMI onset were randomized in a ratio of 1:1 to receive
Firehawk or Xience stents. Optical coherence tomography (OCT) follow-up
was performed 6 months after the index procedure and assessed frame by
frame. The primary endpoint was the neointimal thickness (NIT) at 6 months
evaluated by OCT. The safety endpoint was target lesion failure (TLF) at
12 months. Result(s): The Firehawk stent was non-inferior to the
Xience stent in terms of the neointimal thickness (73.03 +/- 33.30 mum vs.
78.96 +/- 33.29 mum; absolute difference: -5.94 [one-sided 95% lower
confidence bound: -23.09]; P<inf>non-inferiority</inf> < 0.001). No
significant difference was observed between the Firehawk and Xience groups
regarding the percentage of uncovered struts (0.55 [0.08, 1.32]% vs. 0.40
[0.21, 1.19]%, P = 0.804), the percentage of malapposed struts (0.17
[0.00, 1.52]% vs. 0.17 [0.00, 0.69]%, P = 0.662), and the healing score
(1.56 [0.23, 5.74] vs. 2.12 [0.91, 3.81], P = 0.647). At 12 months, one
patient in the Firehawk group experienced a clinically indicated target
lesion revascularization. No other TLF events occurred in both groups.
Independent risk factors of the NIT included body mass index,
hyperlipidemia, B2/C lesions, thrombus G3-G5, thrombus aspiration, and
postdilation pressure. Conclusion(s): In patients with STEMI,
Firehawk was non-inferior to Xience in vascular healing at 6 months. Both
stents exhibited nearly complete strut coverage, moderate neointimal
formation, and minimal strut malapposition. Clinical Trial Number:
NCT04150016. Copyright © 2022 He, Wang, Liu, Li, Li, Li, Zhou,
Zhao, Yang, Mou, Wang, Kan, Li, Li, Zheng, Chen, Gao and Tao.

<106>
Accession Number
2019205973
Title
Knowledge Mapping of the Links Between the Gut Microbiota and Heart
Failure: A Scientometric Investigation (2006-2021).
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 882660. Date of Publication: 28 Apr 2022.
Author
Mu F.; Tang M.; Guan Y.; Lin R.; Zhao M.; Zhao J.; Huang S.; Zhang H.;
Wang J.; Tang H.
Institution
(Mu, Tang, Guan, Lin, Zhao, Huang, Wang) Department of Pharmacy, Xijing
Hospital, The Fourth Military Medical University, Xi'an, China
(Mu, Tang) Department of Chinese Materia Medica and Natural Medicines,
School of Pharmacy, The Fourth Military Medical University, Xi'an, China
(Zhao) Department of Pharmacy, Shaanxi University of Chinese Medicine,
Xianyang, China
(Zhang) Department of Health Statistics, School of Preventive Medicine,
The Fourth Military Medical University, Xi'an, China
Publisher
Frontiers Media S.A.
Abstract
Background: There is considerable research value and extensive application
perspectives to explore the link between gut microbiota and heart failure.
The purpose of this study is to provide an overview of overall
characteristics, evolutionary pathways, frontier research hotspots, and
future trends in this field. Method(s): Research datasets were
acquired from the Web of Science Core Collection (WoSCC) between January
1, 2006 and December 31, 2021. Three different analysis tools including
one online platform, VOS viewer V1.6.17.0, and CiteSpace V5.8.R2 software
were used in order to conduct collaboration network analysis, co-cited
analysis, co-occurring analysis, and citation burst detection.
 Result(s): A total of 873 publications in the WoSCC database met the
requirement. The overall characteristics analysis showed that a steady
growth trend in the number of publications and citations, with the
predominant literature type being articles and the most frequent subject
category being cardiac cardiovascular systems. The United States was the
most prolific country and the center of national collaboration. Cleveland
Clinic and Nathalie M. Delzenne provided the leading influence with
publications, the cooperation between the institutes and authors were
relatively weak. Moreover, gut microbiota, heart failure, risk factor,
obesity, and inflammation were the keywords that appeared more frequently
in the clustering analysis of reference co-citation and keyword
co-occurrence. Burst detection analysis of top keywords showed that
trimethylamine N-oxide (TMAO), bile acid, blood pressure, hypertension,
and fermentation were the new research foci on the association between gut
microbiota and heart failure. Strategies to improve gut microbiota hold
promise as a new approach to treat heart failure. Conclusion(s): The
comprehensive bibliometric study indicates that the structured information
may be helpful in understanding research trends in the link between gut
microbiota and heart failure, and locating research hotspots and gaps in
this domain, especially further advances in this field will lead to
significant breakthroughs in the development of novel therapeutic tools
for metabolic modulation of heart failure. Copyright © 2022 Mu,
Tang, Guan, Lin, Zhao, Zhao, Huang, Zhang, Wang and Tang.

<107>
Accession Number
2019171036
Title
Patients With Bicuspid Aortic Stenosis Undergoing Transcatheter Aortic
Valve Replacement: A Systematic Review and Meta-Analysis.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 794850. Date of Publication: 16 Mar 2022.
Author
Zhang Y.; Xiong T.-Y.; Li Y.-M.; Yao Y.-J.; He J.-J.; Yang H.-R.; Zhu
Z.-K.; Chen F.; Ou Y.; Wang X.; Liu Q.; Li X.; Li Y.-J.; Liao Y.-B.; Huang
F.-Y.; Zhao Z.-G.; Li Q.; Wei X.; Peng Y.; He S.; Wei J.-F.; Zhou W.-X.;
Zheng M.-X.; Bao Y.; Zhou X.; Tang H.; Meng W.; Feng Y.; Chen M.
Institution
(Zhang, Xiong, Li, Yao, He, Yang, Zhu, Chen, Ou, Wang, Liu, Li, Li, Liao,
Huang, Zhao, Li, Wei, Peng, He, Wei, Zhou, Zheng, Bao, Tang, Feng, Chen)
Department of Cardiology, West China Hospital, Sichuan University,
Chengdu, China
(Zhou) Department of Radiology, West China Hospital, Sichuan University,
Chengdu, China
(Meng) Department of Cardiovascular Surgery, West China Hospital, Sichuan
University, Chengdu, China
Publisher
Frontiers Media S.A.
Abstract
Objective: We sought to conduct a systematic review and meta-analysis of
clinical adverse events in patients undergoing transcatheter aortic valve
replacement (TAVR) with bicuspid aortic valve (BAV) vs. tricuspid aortic
valve (TAV) anatomy and the efficacy of balloon-expandable (BE) vs.
self-expanding (SE) valves in the BAV population. Comparisons
aforementioned will be made stratified into early- and new-generation
devices. Differences of prosthetic geometry on CT between patients with
BAV and TAV were presented. In addition, BAV morphological presentations
in included studies were summarized. Method(s): Observational studies
and a randomized controlled trial of patients with BAV undergoing TAVR
were included according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guideline. Result(s): A total of
43 studies were included in the final analysis. In patients undergoing
TAVR, type 1 BAV was the most common phenotype and type 2 BAV accounted
for the least. Significant higher risks of conversion to surgical aortic
valve replacement (SAVR), the need of a second valve, a moderate or severe
paravalvular leakage (PVL), device failure, acute kidney injury (AKI), and
stroke were observed in patients with BAV than in patients with TAV during
hospitalization. BAV had a higher risk of new permanent pacemaker
implantation (PPI) both at hospitalization and a 30-day follow-up. Risk of
1-year mortality was significantly lower in patients with BAV than that
with TAV [odds ratio (OR) = 0.85, 95% CI 0.75-0.97, p = 0.01]. BE
transcatheter heart valves (THVs) had higher risks of annular rupture but
a lower risk of the need of a second valve and a new PPI than SE THVs.
Moreover, BE THV was less expanded and more elliptical in BAV than in TAV.
In general, the rates of clinical adverse events were lower in
new-generation THVs than in early-generation THVs in both BAV and TAV.
 Conclusion(s): Despite higher risks of conversion to SAVR, the need
of a second valve, moderate or severe PVL, device failure, AKI, stroke,
and new PPI, TAVR seems to be a viable option for selected patients with
severe bicuspid aortic stenosis (AS), which demonstrated a potential
benefit of 1-year survival, especially among lower surgical risk
population using new-generation devices. Larger randomized studies are
needed to guide patient selection and verified the durable performance of
THVs in the BAV population. Copyright © 2022 Zhang, Xiong, Li,
Yao, He, Yang, Zhu, Chen, Ou, Wang, Liu, Li, Li, Liao, Huang, Zhao, Li,
Wei, Peng, He, Wei, Zhou, Zheng, Bao, Zhou, Tang, Meng, Feng and Chen.

<108>
Accession Number
2019169545
Title
1-Year Outcomes of a Multicenter Randomized Controlled Trial of the Ankura
II Thoracic Endoprosthesis for the Endovascular Treatment of Stanford Type
B Aortic Dissections.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 805585. Date of Publication: 15 Mar 2022.
Author
Shu C.; He H.; Fu W.; Guo W.; Li M.; Xi E.; Guo S.; Chen X.; Xiao Z.; Yu
S.; Huang J.; Dai X.; Wang Z.; Li W.; Zheng Q.; Li Q.; Wang L.; Li X.;
Wang J.; Gu F.
Institution
(Shu, He, Li, Li, Wang, Li, Wang, Gu) Department of Vascular Surgery,
Second Xiangya Hospital, Central South University, Changsha, China
(Shu) Department of Vascular Surgery, Fuwai Hospital, Chinese Academy of
Medical Science & Peking Union Medical College, Beijing, China
(Fu) Department of Vascular Surgery, Institute of Vascular Surgery,
Zhongshan Hospital, Fudan University, Shanghai, China
(Guo) Department of Vascular and Endovascular Surgery, Chinese PLA General
Hospital, Beijing, China
(Li) Department of Vascular Surgery, The First Affiliated Hospital of
Medical School of Zhejiang University, Hangzhou, China
(Xi) Department of Vascular Surgery, Wuhan General Hospital of Guangzhou
Military Region, Wuhan, China
(Guo) Department of Vascular Surgery, Kunming General Hospital of Chengdu
Military Region, Kunming, China
(Chen) Department of Vascular Surgery, Beijing Friendship Hospital,
Capital Medical University, Beijing, China
(Xiao) Department of Vascular Surgery, Hainan Provincial People's
Hospital, Haikou, China
(Yu) Department of Vascular Surgery, The First Affiliated Hospital of the
Fourth Military Medical University, Xi'an, China
(Huang) Department of Vascular Surgery, Xiangya Hospital, Central South
University, Changsha, China
(Dai) Department of Vascular Surgery, General Hospital of Tianjin Medical
University, Tianjin, China
(Wang) Department of Vascular Surgery, General Hospital of Tianjin Medical
University, Tianjin, China
(Li) Medical Research and Statistics Center, Fuwai Hospital, Chinese
Academy of Medical Sciences, Beijing, China
(Zheng) Drug Clinical Research Center, Shanghai University of Traditional
Chinese Medicine, Shanghai, China
Publisher
Frontiers Media S.A.
Abstract
Background: The Ankura II Thoracic Stent Graft System (Lifetech, Shenzhen,
China) is an evolution of the Ankura stent graft. This study reports
one-year outcomes of the Ankura II Thoracic Stent Graft System for
endovascular treatment of Stanford type B aortic dissections.
 Method(s): The Ankura II Thoracic Aortic Endovascular Trial was a
randomized, single-blinded, clinical trial conducted at 12 Chinese
institutes. The enrolled patients diagnosed with Stanford type B aortic
dissections (TBADs) were randomly assigned to the Ankura group or Ankura
II group. Standard follow-up examinations were performed at 1, 6, and 12
months. Safety and efficacy data were analyzed. Result(s): 132
patients with TBADs were enrolled. The outcomes for the primary safety end
points revealed that the Ankura II stent graft was statistically
non-inferior compared to the Ankura stent graft. The 1-month
device-related major adverse events (1.6 vs. 0%; p = 0.48), 1-month
all-cause mortality (1.7 vs. 4.5%; p = 0.621), 12-month survival rate
(95.2 +/- 2.7% vs. 94.1 +/- 2.9%; p = 0.769), and major adverse event
(MAE) rate (5.1 vs. 4.7% at 1 month; p = 0.73 and 5.8 vs. 8.9% at 12
months; p = 0.718) of Ankura II group are all comparable to Ankura group.
The two groups showed similar primary effectiveness and true lumen
expansion effect, and false lumen remodeling was improved in Ankura II
group (-100.0 vs. -48.5%; p = 0.08). Conclusion(s): The one-year
outcomes from this prospective, randomized, multicenter study demonstrate
that Ankura II stent graft shows comparable results to Ankura for treating
TBADs, resulting in low mortality rates, MAEs and reintervention rates.
Clinical Trial Registration: ChiCTR-TRC-12002844. Copyright ©
2022 Shu, He, Fu, Guo, Li, Xi, Guo, Chen, Xiao, Yu, Huang, Dai, Wang, Li,
Zheng, Li, Wang, Li, Wang and Gu.

<109>
Accession Number
2018813828
Title
The effects of preoperative focused cardiac ultrasound in high-risk
patients: A randomised controlled trial (PREOPFOCUS).
Source
Acta Anaesthesiologica Scandinavica. 66(10) (pp 1174-1184), 2022. Date of
Publication: November 2022.
Author
Pallesen J.; Bhavsar R.; Fjolner J.; Bakke S.A.; Krog J.; Andersen M.A.S.;
Bondergaard M.H.; Jessing T.D.; Mortensen L.; Nielsen M.B.; Vang M.;
Malachauskiene L.; Juhl-Olsen P.
Institution
(Pallesen, Bondergaard, Jessing, Mortensen, Vang) Department of
Anaesthesiology, Randers Regional Hospital, Randers, Denmark
(Bhavsar, Bakke, Nielsen, Malachauskiene) Department of Anaesthesiology,
Hospital of Southern Jutland, Aabenraa, Denmark
(Fjolner) Department of Surgery & Intensive Care, Regional Hospital
Central Jutland, Viborg, Denmark
(Krog, Andersen) Department of Anaesthesiology, Aarhus University
Hospital, Aarhus, Denmark
(Krog, Juhl-Olsen) Department of Clinical Medicine, Aarhus University,
Aarhus, Denmark
(Juhl-Olsen) Department of Cardiothoracic and Vascular Surgery,
Anaesthesia Section, Aarhus University Hospital, Aarhus, Denmark
Publisher
John Wiley and Sons Inc
Abstract
Background: Surgery is the third most common cause of mortality worldwide.
Focused cardiac ultrasound (FOCUS) yields information on cardiac status
and discloses the presence of unknown pathology. Preoperative FOCUS
changes patient treatment, allowing for a patient-tailored anaesthesia. We
hypothesised that preoperative FOCUS would reduce the proportion of
patients who were either admitted to hospital for more than 10 days or who
were dead within 30 days after high-risk, non-cardiac surgery.
 Method(s): This was a randomised, controlled, multi-center study.
Patients >=65 years of age, admitted for urgent orthopaedic- or abdominal
surgery, scheduled for general- or neuraxial anaesthesia and with ASA 3/4
were eligible for inclusion. Patients were randomised in a 1:1 ratio to
preoperative FOCUS or no preoperative FOCUS performed in accordance with a
predefined protocol. Primary endpoint was the proportion of patients
admitted more than 10 days or who were dead within 30 days. Secondary
endpoints included major complications, days of admission and changes in
anaesthesia handling. Result(s): During the second COVID-19 wave the
study monitoring committee terminated the study prematurely. We included
338 patients of which 327 were included in the final analysis. In the
FOCUS group, 41/163 (25%) patients met the criteria for the primary
endpoint versus 35/164 (21%) for the control group, adjusted odds ratio
1.37 (95% CI 0.86-2.30), p =.36. The proportions of patients who developed
major complications did not differ significantly between groups. Length of
hospital stay was 4 (3-8) days in the FOCUS group and 4 (3-7) days on the
control group (adjusted p =.24). Conclusion(s): The routine
availability of preoperative FOCUS assessment in this cohort does not
appear to reduce the risk for hospitalisation exceeding 10 days or 30-day
mortality, although study enrolment was prematurely
terminated. Copyright © 2022 The Authors. Acta Anaesthesiologica
Scandinavica published by John Wiley & Sons Ltd on behalf of Acta
Anaesthesiologica Scandinavica Foundation.

<110>
Accession Number
2017960755
Title
Meta-Analysis of Catheter Ablation Outcomes in Patients With Cardiac
Sarcoidosis Refractory Ventricular Tachycardia.
Source
American Journal of Cardiology. 174 (pp 136-142), 2022. Date of
Publication: 01 Jul 2022.
Author
Adhaduk M.; Paudel B.; Liu K.; Ashwath M.; Giudici M.
Institution
(Adhaduk, Paudel) Division of General Internal Medicine
(Liu, Ashwath, Giudici) Division of Cardiovascular Medicine, Department of
Internal Medicine, University of Iowa, Iowa City, IA, United States
Publisher
Elsevier Inc.
Abstract
Cardiac sarcoidosis (CS) frequently leads to ventricular tachycardia (VT),
which is often refractory to antiarrhythmic and/or immunosuppressive
medications and requires catheter ablation. We conducted a systematic
review and meta-analysis to evaluate the role of catheter ablation in
patients with refractory VT undergoing catheter ablation. We searched
PubMed, Embase, and Scopus databases from their inception to December 31,
2021 with search terms "cardiac sarcoidosis" AND "electrophysiological
studies OR ablation." Fifteen studies were ultimately included for
evaluation. Patient demographics, VT mapping, and acute and long-term
procedural outcomes were extracted. A total of 15 studies were included in
our meta-analysis, with a total of 401 patients, of whom 66% were male,
with ages ranging from 39 to 64 years. A total of 95% of patients were on
antiarrhythmics and 79% of patients were on immunosuppressants. Left
ventricular ejection fraction ranged from 35% to 49% and procedure
duration ranged from 269 to 462 minutes. Ablation was reported using both
irrigated and nonirrigated catheter tips. A total of 25% of patients
(84/339) underwent repeat ablation. Acute procedural success was achieved
in 57% (161/285). Procedure complications occurred in 5.7% (17/297)
procedures. VT recurrence after first ablation was 55% (confidence
interval 48% to 63%, 213/401); VT recurrence after multiple ablations was
37% (81/220). The composite end point of death, heart transplant, and left
ventricular assist device implantation was 21% (confidence interval 14% to
30%, 55/297). In conclusion, catheter ablation is a useful modality in
patients with CS with refractory VT. However, patients with CS presenting
with refractory VT after undergoing VT ablation carry a poor
prognosis. Copyright © 2022 Elsevier Inc.

<111>
Accession Number
2016884138
Title
Meta-Analysis Investigating the Efficacy and Safety of the MANTA Versus
ProGlide Vascular Closure Devices After Transcatheter Aortic Valve
Implantation.
Source
American Journal of Cardiology. 169 (pp 151-154), 2022. Date of
Publication: 15 Apr 2022.
Author
Al-Abcha A.; Saleh Y.; Halboni A.; Wang E.; Salam M.F.; Abela G.
Institution
(Al-Abcha, Wang, Salam) Department of Internal Medicine, Michigan State
University, East Lansing, MI, United States
(Saleh) Department of Cardiology, Houston Methodist DeBakey Heart &
Vascular Center, Houston, Texas, United States
(Saleh) Department of Cardiology, Alexandria University, Alexandria, Egypt
(Halboni) Department of Internal Medicine, Wayne State University/Detroit
Medical Center, Detroit, MI, United States
(Abela) Department of Cardiology, Michigan State University, East Lansing,
MI, United States
Publisher
Elsevier Inc.

<112>
Accession Number
2012114963
Title
External stenting and disease progression in saphenous vein grafts two
years after coronary artery bypass grafting: A multicenter randomized
trial.
Source
Journal of Thoracic and Cardiovascular Surgery. 164(5) (pp 1532-1541.e2),
2022. Date of Publication: November 2022.
Author
Taggart D.P.; Gavrilov Y.; Krasopoulos G.; Rajakaruna C.; Zacharias J.; De
Silva R.; Channon K.M.; Gehrig T.; Donovan T.J.; Friedrich I.; Benedetto
U.; Vohra H.; Bittar M.N.; Bose A.; Berman M.; Kharbanda R.; Paraforos A.;
Ladyshenskij L.; Bonaros N.; Schachner T.; Sandner S.; Angleitner P.;
Bolotin G.; Jacobs S.; Thielmann M.; Wendt D.; Choi Y.-H.; Liakopoulos O.;
Ohri S.; Lipey A.
Institution
(Taggart) Nuffield Department of Surgical Sciences, University of Oxford,
John Radcliffe Hospital, Oxford, United Kingdom
(Gavrilov) TechnoSTAT Ltd, Raanana, Israel
(Krasopoulos) Oxford University Hospitals NHS Foundation Trust, Oxford,
United Kingdom
(Rajakaruna, Benedetto, Vohra) Department of Cardiothoracic Surgery,
University Hospitals Bristol, Bristol, United Kingdom
(Zacharias, Bittar, Bose) Department of Cardiothoracic Surgery, Blackpool
Victoria Hospital, Blackpool, United Kingdom
(De Silva, Berman) Department of Cardiothoracic Surgery, Papworth
Hospital, Cambridge, United Kingdom
(Channon, Kharbanda) Department of Cardiovascular Medicine, University of
Oxford, John Radcliffe Hospital, Oxford, United Kingdom
(Gehrig, Donovan, Friedrich, Paraforos) Herzzentrum Trier, Krankenhaus der
Barmherzigen Bruder, Trier, Germany
(Ladyshenskij) Department of Cardiothoracic Surgery, Immanuel Klinikum
Bernau Herzzentrum Brandenburg, Brandenburg, Bernau bei Berlin, Germany
(Bonaros, Schachner) Department of Cardiothoracic Surgery, Medical
University of Innsbruck, Innsbruck, Austria
(Sandner, Angleitner) Department of Cardiothoracic Surgery, Medizinische
Universitat Wien, Vienna, Wien, Austria
(Bolotin) Department of Cardiothoracic Surgery, Rambam Medical Center,
Haifa, Israel
(Jacobs) Department of Cardiothoracic Surgery, German Heart Centre Berlin,
Berlin, Germany
(Thielmann, Wendt) Department of Cardiothoracic Surgery, West-German Heart
and Vascular Center Essen, University Hospital Essen, Essen, Germany
(Choi, Liakopoulos) Department of Cardiac Surgery, Kerckhoff Heart Center,
Bad Nauheim, Germany
(Choi, Liakopoulos) Justus-Liebig-University Giesen, Campus Kerckhoff, Bad
Nauheim, Germany
(Choi, Liakopoulos) German Center for Cardiovascular Research (DZHK),
Partner Site Rhine Main, Frankfurt/Main, Germany
(Choi, Liakopoulos) Department of Cardiothoracic Surgery, Uniklinik Koln,
Koln, Germany
(Ohri) Department of Cardiothoracic Surgery, University Hospital
Southampton, Southampton, United Kingdom
(Lipey) Department of Cardiothoracic Surgery, Sheba Medical Center, Ramat
Gan, Israel
Publisher
Elsevier Inc.
Abstract
Objectives: Little data exist regarding the potential of external stents
to mitigate long-term disease progression in saphenous vein grafts. We
investigated the effect of external stents on the progression of saphenous
vein graft disease. Method(s): A total of 184 patients undergoing
isolated coronary artery bypass grafting, using an internal thoracic
artery graft and at least 2 additional saphenous vein grafts, were
enrolled in 14 European centers. One saphenous vein graft was randomized
to an external stent, and 1 nonstented saphenous vein graft served as the
control. The primary end point was the saphenous vein graft Fitzgibbon
patency scale assessed by angiography, and the secondary end point was
saphenous vein graft intimal hyperplasia assessed by intravascular
ultrasound in a prespecified subgroup at 2 years. Result(s):
Angiography was completed in 128 patients and intravascular ultrasound in
the entire prespecified cohort (n = 51) at 2 years. Overall patency rates
were similar between stented and nonstented saphenous vein grafts (78.3%
vs 82.2%, P =.43). However, the Fitzgibbon patency scale was significantly
improved in stented versus nonstented saphenous vein grafts, with
Fitzgibbon patency scale I, II, and III rates of 66.7% versus 54.9%, 27.8%
versus 34.3%, and 5.5% versus 10.8%, respectively (odds ratio, 2.02; P
=.03). Fitzgibbon patency scale was inversely related to saphenous vein
graft minimal lumen diameter, with Fitzgibbon patency scale I, II, and III
saphenous vein grafts having an average minimal lumen diameter of 2.62 mm,
1.98 mm, and 1.32 mm, respectively (P <.05). Externally stented saphenous
vein grafts also showed significant reductions in mean intimal hyperplasia
area (22.5%; P <.001) and thickness (23.5%; P <.001). Conclusion(s):
Two years after coronary artery bypass grafting, external stenting
improves Fitzgibbon patency scales of saphenous vein grafts and
significantly reduces intimal hyperplasia area and thickness. Whether this
will eventually lead to improved long-term patency is still
unknown. Copyright © 2021 The Authors

<113>
Accession Number
633132939
Title
Mid-Term Outcomes after Transapical and Transfemoral Transcatheter Aortic
Valve Implantation for Aortic Stenosis and Porcelain Aorta with a
Systematic Review of Transfemoral versus Transapical Approach.
Source
Thoracic and Cardiovascular Surgeon. 68(7) (pp 623-632), 2020. Date of
Publication: 01 Oct 2020.
Author
Useini D.; Haldenwang P.; Schlomicher M.; Christ H.; Naraghi H.;
Moustafine V.; Strauch J.
Institution
(Useini, Haldenwang, Schlomicher, Naraghi, Moustafine, Strauch) Department
of Cardiothoracic Surgery, Ruhr-University Hospital Bergmannsheil,
Buerkle-de-la-Camp-Platz-1, Bochum 44789, Germany
(Christ) Institute of Medical Statistics, Informatics and Epidemiology,
University of Cologne, Cologne, Germany
Publisher
Georg Thieme Verlag
Abstract
Background aWe have aimed to analyze early and mid-term outcomes of
patients undergoing transapical/transfemoral transcatheter aortic valve
implantation (TA-/TF-TAVI) for aortic stenosis and porcelain aorta (PAo)
in our institution. Additionally, we postulated that the TA approach may
be associated with a more favorable neurological outcome than the TF
approach; hence, a systematic literature review was conducted. Methods
aBetween 2011 and 2017, 15 patients with PAo underwent TA-TAVI and 4
patients with PAo TF-TAVI at our institution. The assessment of PAo was
done either intraoperatively after aborted sternotomy or via computed
tomography for elective TAVI. We conducted mid-term follow-up.
Furthermore, a systematic review was performed to compare the mortality
and neurological outcomes of TF and TA-TAVI approaches. Results
aTA/TF-TAVIs were performed with 100% device success, without paravalvular
leakage >= 2 and without procedural death. The 30-day mortality/stroke
rates were 6.6%/0% in TA-TAVI and 0%/25% in TF-TAVI, respectively. The
6-month, 1-year, and 2-year survival rates were in TA/TF-TAVI 93%/75%,
82%/66.6%, and 50%/0%, respectively. The pooled results derived from the
literature review were as follows: The prevalence of PAo in the TAVI
population is 9.74%; the mean logistic EuroSCORE is 41.9% in TA-TAVI
versus 16.2% in TF-TAVI; the mean 30-day mortality is 5.9% in TA-TAVI
versus 6.3% in TF-TAVI, and the mean stroke is 0.8% in TA-TAVI versus 9%
in TF-TAVI. Conclusion aTA-TAVI shows promising early and mid-term
outcomes in patients with PAo. TF-TAVI performed in patients with PAo is
likely to be associated with higher rates of stroke than
TA-TAVI. Copyright © 2020 Georg Thieme Verlag. All rights
reserved.

<114>
Accession Number
2015473741
Title
In patients with coronary disease and CKD, adding an invasive strategy to
MT did not improve outcomes.
Source
Annals of Internal Medicine. 173(4) (pp JC16-JC17), 2020. Date of
Publication: 18 Aug 2020.
Author
Herrington W.G.; Staplin N.
Institution
(Herrington, Staplin) MRC Population Health Research Unit, University of
Oxford, Oxford, United Kingdom
Publisher
American College of Physicians

<115>
Accession Number
2020808315
Title
Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology,
Pathophysiology, and Management.
Source
Clinical Therapeutics. (no pagination), 2022. Date of Publication: 2022.
Author
Williams S.; Raheim S.A.; Khan M.I.; Rubab U.; Kanagala P.; Zhao S.S.;
Marshall A.; Brown E.; Alam U.
Institution
(Williams, Raheim, Khan, Rubab, Kanagala, Brown, Alam) Department of
Medicine, Aintree University Hospital, Liverpool University Hospitals NHS
Foundation Trust, Liverpool, United Kingdom
(Kanagala, Zhao, Marshall, Brown, Alam) Department of Eye & Vision
Sciences, Institute of Life Course and Medical Sciences, University of
Liverpool, Liverpool, United Kingdom
(Zhao) Centre for Epidemiology Versus Arthritis, Division of
Musculoskeletal and Dermatological Sciences, School of Biological
Sciences, Faculty of Biology Medicine and Health, Manchester Academic
Health Science Centre, University of Manchester, Manchester, United
Kingdom
Publisher
Elsevier Inc.
Abstract
Purpose: Cardiac autonomic neuropathy (CAN) is a serious complication of
type 1 and type 2 diabetes and is independently associated with major
cardiovascular events, morbidity, and mortality. This narrative review
examines the epidemiology, pathophysiology, and management and identifies
areas of future research to address the challenge posed by CAN.
 Method(s): We conducted a comprehensive literature search using a
range of sources, including the electronic databases PubMed Central,
Google Scholar, OVID, and Open Athens, to search for studies on CAN,
diabetes mellitus, lifestyle intervention, and cardiovascular risk. We set
inclusion criteria to consider review articles or original research
published in peer-reviewed journals that examined CAN in diabetes.
 Finding(s): Epidemiologic data indicate a varied prevalence of CAN in
type 1 and 2 diabetes, with prevalences of 17% to 73%) depending on
clinical and demographic factors. Indeed, duration of diabetes and
hyperglycemia are the strongest risk factors for CAN development in type 1
diabetes. However, in type 2 diabetes, multifactorial risk factors,
including obesity, hypertension, and hyperlipidemia, are associated with
the development of CAN. Insulin resistance, which underpins type 2
diabetes and metabolic syndrome, has a direct role in the pathogenesis of
CAN. Lifestyle interventions, including dietary measures and tailored
exercise programs, have been beneficial in improving cardiac autonomic
function primarily measured through heart rate variability. In addition,
weight loss through bariatric surgery also improves heart rate variability
and may prevent or reduce CAN progression in people living with obesity
and concomitant type 2 diabetes. For optimization in type 2 diabetes, both
lifestyle and targeted pharmacologic interventions are required to achieve
glycemic/metabolic targets, and weight loss is required to prevent or
reverse early CAN or prevent the progression to definite and severe CAN.
Implications: The focused use of diagnostic testing for CAN, including
cardiac autonomic reflex testing in those at high risk of CAN, will enable
earlier diagnosis. This testing will allow timely interventions at a
reversible stage. Future research should examine targeted early diagnostic
testing with subsequent intervention with a combination of lifestyle
measures and newer pharmacotherapeutics (eg, sodium-glucose cotransporter
2 inhibitors and glucagon-like peptide 1 receptor agonists), which have
produced significant cardiovascular benefit in diabetes. (Clin Ther.
2022;XX:XXX-XXX) © 2022 Elsevier HS Journals, Inc.

<116>
Accession Number
2020808126
Title
Novel hardening bone putty enhances sternal closure and accelerates
postoperative recovery.
Source
Journal of Thoracic and Cardiovascular Surgery. (no pagination), 2022.
Date of Publication: 2022.
Author
Vasanthan V.; Hassanabad A.F.; Kang S.; Dundas J.; Ramadan D.; Holloway
D.; Adams C.; Ahsan M.; Fedak P.W.M.
Institution
(Vasanthan, Hassanabad, Kang, Dundas, Ramadan, Holloway, Adams, Ahsan,
Fedak) Section of Cardiac Surgery, Department of Cardiac Sciences, Libin
Cardiovascular Institute, Cumming School of Medicine, University of
Calgary, Calgary, AB, Canada
Publisher
Elsevier Inc.
Abstract
Objectives: Regaining and maintaining sternal stability are key to
recovery after cardiac surgery and resuming baseline quality of life.
Montage (ABYRX) is a moldable, calcium phosphate-based putty that adheres
to bleeding bone, hardens after application, and is resorbed and replaced
with bone during the remodeling process. We evaluate the feasibility,
safety, and efficacy of enhanced sternal closure with this novel putty to
accelerate recovery in patients after sternotomy. Method(s): A
single-center, single-blinded, randomized controlled trial was performed
(NCT03365843). Patients undergoing elective cardiac surgery via sternotomy
received sternal closure with either Montage bone putty and wire cerclage
(enhanced sternal closure; n = 33) or wire cerclage alone (control; n =
27). Standardized patient-reported outcomes assessed health-related
quality of life (EQ-5D Index) and physical disability (Health Assessment
Questionnaire). A Likert-type 11-point scale quantified pain. Spirometry
assessed respiratory function. Patients reached 6-week follow-up, with
1-year follow-up for safety end points. Result(s): There were no
device-related adverse events. Enhanced sternal closure improved physical
functional recovery (reduced Healthcare Index and Quality) and quality of
life (increased EQ-5D Index) at day 5/discharge, week 2, and week 4.
Enhanced sternal closure reduced incisional pain while resting, breathing,
sleeping, and walking at day 5/discharge. Enhanced sternal closure reduced
chest wall and back pain at day 3 and day 5 discharge. A higher proportion
of patients with enhanced sternal closure recovered to 60% of their
baseline forced vital capacity by day 5/discharge. Enhanced sternal
closure shortened hospital stay. Conclusion(s): Enhanced sternal
closure improves and accelerates postoperative recovery compared with
conventional wire closure. Earlier discharge may provide substantial cost
benefits for the healthcare system. Copyright © 2022 The American
Association for Thoracic Surgery

<117>
Accession Number
2019702256
Title
Acute iatrogenic complications after mitral valve repair.
Source
Journal of Cardiac Surgery. (no pagination), 2022. Date of Publication:
2022.
Author
Paparella D.; Squiccimarro E.; Di Mauro M.; Katsavrias K.; Calafiore A.M.
Institution
(Paparella, Squiccimarro) Department of Medical and Surgical Sciences,
Division of Cardiac Surgery, University of Foggia, Foggia, Italy
(Paparella) Division of Cardiac Surgery, Santa Maria Hospital, GVM Care &
Research, Bari, Italy
(Squiccimarro, Di Mauro) Cardio-Thoracic Surgery Department, Heart &
Vascular Centre, Maastricht University Medical Centre, Maastricht,
Netherlands
(Katsavrias) Division of Cardiac Surgery A, Henry Dunant Hospital, Athens,
Greece
(Calafiore) Department of Cardiovascular Diseases, Gemelli Molise,
Campobasso, Italy
Publisher
John Wiley and Sons Inc
Abstract
Background and Aim of the Study: Mitral valve repair is the procedure of
choice to correct mitral regurgitation. However, some dangerous iatrogenic
complications can occur at the end of the procedure. Therefore, we sought
to review the most frequent and clinically relevant acute iatrogenic
complication following mitral valve repair. Method(s): A thorough
review of the literature has been performed. Criteria for considering
studies for this non-systematic review were as follows: observational and
interventional studies investigating the acute iatrogenic complications
following mitral valve repair, and essential review studies pertinent to
the topic. Result(s): The most frequent is the systolic anterior
motion. Due to a systolic dislocation of the anterior leaflet toward the
outflow tract, it causes both obstruction of the outflow tract and mitral
regurgitation. Often it is due to excess of catecholamines or to reduced
filling of the left ventricle but sometimes needs further surgical
maneuvers, focused on moving posteriorly the coaptation line. It can be
obtained by shortening the posterior leaflet or increasing the size of the
ring or applying an Alfieri stitch to limit the movements of the anterior
leaflet. Another complication, often underdiagnosed and potentially
lethal, is the injury of the circumflex artery that happens at the level
of the anterolateral commissure or P1 zone. Two mechanisms are involved.
The first one is the direct injury of the artery by a stitch (roughly 25%
of the patients present a distance artery-annulus <3 mm. The second one is
the distortion of the artery, attracted toward the annulus by a misplaced
stitch. The attraction causes kinking with stenosis of different degrees
till functional occlusion. However, the artery has to be far from the
annulus and the atrial tissue has to be stiff and resistant, as after an
infective process, to move the circumflex artery toward the annulus
without tearing. Positioning the stitches very close to the mitral
leaflets in the dangerous area is the only prevention to the complication.
The treatment in the operating theater is partial or total
removal/reimplantation of the annular sutures or coronary artery bypass
grafting to the circumflex area. If the injury is demonstrated only after
coronary angiography, percutaneous revascularization can be attempted
before further surgical treatment. Conclusion(s): Acute iatrogenic
complication after mitral repair exists and may compromize patient
outcome. Raising awareness about these issues, the precautions to prevent
them, and the manners of resolution is therefore mandatory. Copyright
© 2022 Wiley Periodicals LLC.

<118>
Accession Number
639334111
Title
Effects of recombinant erythropoietin on hemoglobin levels and blood
transfusion needs in patients with preoperative anemia undergoing cardiac
surgery.
Source
Annals of Cardiac Anaesthesia. 25(4) (pp 466-471), 2022. Date of
Publication: October-December 2022.
Author
Totonchi Z.; Noohi F.; Futuhi F.; Azarfarin R.; Radbin P.
Institution
(Totonchi, Radbin) Department of Cardiac Anesthesia, Rajaie Cardiovascular
Medical and Research Center, Iran University of Medical Sciences, Tehran,
Iran, Islamic Republic of
(Noohi) Department of Cardiology, Cardiovascular Intervention Research
Center, Rajaie Cardiovascular Medical and Research Center, Iran University
of Medical Sciences, Tehran, Iran, Islamic Republic of
(Futuhi) Department of Nephrology, Loghman Hakim Hospital, Shahid Beheshti
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Azarfarin) Department of Cardiology, Cardio-Oncology Research Center,
Rajaie Cardiovascular Medical and Research Center, Iran University of
Medical Sciences, Tehran, Iran, Islamic Republic of
Publisher
Wolters Kluwer Medknow Publications
Abstract
Introduction: Preoperative anemia is an important and relatively common
problem in patients undergoing cardiac surgery, and its treatment is
crucial in improving postoperative outcomes. The use of recombinant
erythropoietin is one of the suggested methods in this field. Therefore,
in the present study, we sought to evaluate the effects of recombinant
erythropoietin on hemoglobin (Hb) levels and blood transfusion needs in
cardiac surgery in patients with preoperative anemia. Method(s): This
randomized nonblind clinical trial was performed on patients with
mild-To-moderate anemia (Hb <12 g/dL in men and Hb <11 g/dL in women)
undergoing cardiac surgery at a referral heart hospital (Tehran, Iran).
The patients were randomly divided into two groups of 33 patients. In the
intervention group, recombinant erythropoietin was administered at a dose
of 500 IU/kg one to three days before surgery. Intra-and postoperative Hb
levels and the need for blood transfusion were recorded during surgery and
for 3 days afterward. Result(s): The use of packed red blood cells in
the operating room was similar in the intervention and control groups (P =
0.156), but it was significantly lower in the intensive care unit in the
intervention group (P = 0.030). The mean Hb, which was initially identical
in the two groups (P > 0.05), showed a significantly lower decrease in the
intervention group (P = 0.001). No significant differences were observed
concerning other variables. Conclusion(s): The use of recombinant
erythropoietin (500 IU/kg/day) one to three days before cardiac surgery in
our anemic patients blunted a reduction in Hb levels and decreased blood
transfusion needs. Copyright © 2022 Wolters Kluwer Medknow
Publications. All rights reserved.

<119>
Accession Number
639334104
Title
A comparison of the success rate of radial artery cannulation between the
ultrasound-guided and conventional palpation techniques in elderly
patients undergoing cardiothoracic surgery.
Source
Annals of Cardiac Anaesthesia. 25(4) (pp 447-452), 2022. Date of
Publication: October-December 2022.
Author
Chanthawong S.; Tribuddharat S.; Sathitkarnmanee T.; Suwongkrua T.;
Silarat S.; Plengpanich P.
Institution
(Chanthawong, Tribuddharat, Sathitkarnmanee, Suwongkrua, Silarat,
Plengpanich) Department of Anesthesiology, Faculty of Medicine, Khon Kaen
University, Khon Kaen, Thailand
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: Ultrasound-guided (USG) radial artery cannulation against the
standard palpation technique increases the first attempt rate in both
pediatric and adult patients. The objective of this study was to evaluate
the benefits of USG versus the palpation technique in improving the first
attempt rate in elderly patients. Method(s): The patients over 65
years of age were randomized to the USG or Palpation group. The radial
artery identification in the USG group was performed with the aid of the
Sonimage HS 1. In the Palpation group, the radial artery was identified by
manual palpation. The operators were cardiothoracic anesthesiologists.
Overall success was defined as cannulation completed within 10 min.
 Result(s): Eighty patients (40 in each group) were recruited. The
respective first attempt and overall success rate for the USG group were
similar to the Palpation group (P > 0.999 and P = 0.732). The time to the
first attempt and overall success were also similar (P = 0.075 and P =
0.636). The number of attempts, number of catheters used, and failure
rates were similar between the groups (P = 0.935, P = 0.938, and P =
0.723). The number of successful cannulations within 10 min was similar
for both the groups as categorized by the radial artery diameter (P =
0.169). Conclusion(s): The USG did not increase the first attempt or
overall success rate of radial artery cannulation in the elderly patients
undergoing cardiothoracic surgery. The time to first attempt and overall
success were similar between both the groups. The number of attempts and
number of catheters used were similar between both groups. Copyright
© 2022 Wolters Kluwer Medknow Publications. All rights reserved.

<120>
Accession Number
639334101
Title
Randomized control study of nebulized colistin as an adjunctive therapy in
ventilator-Associated pneumonia in pediatric postoperative cardiac
surgical population.
Source
Annals of Cardiac Anaesthesia. 25(4) (pp 435-440), 2022. Date of
Publication: October-December 2022.
Author
Bharathi K.; Bhat A.; Pruthi G.; Simha P.
Institution
(Bharathi) Department of Cardiac Anaesthesiology, Sri Jayadeva Institute
of Cardiovascular Sciences and Research, Mysore, Karnataka, India
(Bhat, Pruthi, Simha) Department of Cardiac Anaesthesiology, Sri Jayadeva
Institute of Cardiovascular Sciences and Research, Karnataka, Bangalore,
India
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: Ventilator-Associated pneumonia (VAP) with multidrug-resistant
(MDR) gram negative organisms is a common problem in intensive care unit
(ICU). Aerosolized antibiotics enhance the efficacy of systemic
antibiotics when added as adjuvants. Aim(s): The primary objective of
the study was to compare the clinical and bacteriological outcome of
patients with VAP who were administered intravenous (IV) antibiotics alone
with those patients who were treated with adjunctive nebulized colistin
(NC) along with IV antibiotics. The secondary objective was to study the
occurrence of any adverse events during colistin nebulization. Settings
and Design: The study was a prospective, randomized, double-blinded
controlled study conducted at a tertiary-care teaching institution.
 Material(s) and Method(s): Ninety-eight children from surgical ICU
aged less than 12 years who were diagnosed with VAP due to gram negative
bacteria following cardiac surgery were chosen and divided randomly into
two groups. The experimental group (NC group) was treated with systemic
antibiotics along with NC, whereas the control group (NS group) was
administered systemic antibiotics with nebulized normal saline (NS).
Clinical and bacteriological outcomes were noted. Statistical analysis was
done using SPSS Version 20.0 software. The patient characteristics were
compared using independent Student's t test and Chi-square test.
 Result(s): There was a statistically significant reduction in the
duration of mechanical ventilation, postoperative ICU and hospital stay (P
< 0.05) in the NC group compared with the NS group. Conclusion(s):
Aerosolized colistin may be considered as an adjunct to systemic IV
antibiotics in pediatric patients with VAP due to gram negative bacteria
susceptible to colistin. Copyright © 2022 Wolters Kluwer Medknow
Publications. All rights reserved.

<121>
Accession Number
639334082
Title
The use of cerebral oximetry in cardiac surgery: A systematic review and
meta-Analysis of randomized controlled trials.
Source
Annals of Cardiac Anaesthesia. 25(4) (pp 384-398), 2022. Date of
Publication: October-December 2022.
Author
Chiong X.; Wong Z.; Lim S.; Ng T.; Ng K.
Institution
(Chiong) School of Medicine, University of Aberdeen, Netherlands
(Wong) School of Medicine, International Medical University, Kuala Lumpur,
Malaysia
(Lim, Ng, Ng) Department of Anesthesiology, Faculty of Medicine,
University of Malaya, Kuala Lumpur, Malaysia
Publisher
Wolters Kluwer Medknow Publications
Abstract
High prevalence of cerebral desaturation is associated with postoperative
neurological complications in cardiac surgery. However, the evidence use
of cerebral oximetry by correcting cerebral desaturation in the reduction
of postoperative complications remains uncertain in the literature. This
systematic review and meta-Analysis aimed to examine the effect of
cerebral oximetry on the incidence of postoperative cognitive dysfunction
in cardiac surgery. Databases of MEDLINE, EMBASE, and CENTRAL were
searched from their inception until April 2021. All randomized controlled
trials comparing cerebral oximetry and blinded/no cerebral oximetry in
adult patients undergoing cardiac surgery were included. Observational
studies, case series, and case reports were excluded. A total of 14 trials
(n = 2,033) were included in this review. Our pooled data demonstrated
that patients with cerebral oximetry were associated with a lower
incidence of postoperative cognitive dysfunction than the control group
(studies = 4, n = 609, odds ratio [OR]: 0.15, 95% confidence interval
[CI]: 0.04 to 0.54, P = 0.003, I 2 = 88%; certainty of evidence = very
low). In terms of postoperative delirium (OR: 0.75, 95%CI: 0.50-1.14, P =
0.18, I 2 = 0%; certainty of evidence = low) and postoperative stroke (OR:
0.81 95%CI: 0.37-1.80, P = 0.61, I 2 = 0%; certainty of evidence = high),
no significant differences (P > 0.05) were reported between the cerebral
oximetry and control groups. In this meta-Analysis, the use of cerebral
oximetry monitoring in cardiac surgery demonstrated a lower incidence of
postoperative cognitive dysfunction. However, this finding must be
interpreted with caution due to the low level of evidence, high degree of
heterogeneity, lack of standardized cognitive assessments, and cerebral
desaturation interventions. Copyright © 2022 Wolters Kluwer
Medknow Publications. All rights reserved.

<122>
Accession Number
2020693684
Title
Concomitant tricuspid annuloplasty in patients with mild to moderate
tricuspid valve regurgitation undergoing mitral valve surgery:
meta-analysis.
Source
Journal of Cardiovascular Surgery. 63(5) (pp 624-631), 2022. Date of
Publication: October 2022.
Author
Yokoyama Y.; Tsukagoshi J.; Takagi H.; Takayama H.; Kuno T.
Institution
(Yokoyama) Department of Surgery, St. Luke's University Health Network,
Bethlehem, PA, United States
(Tsukagoshi) Department of Surgery, University of Texas Medical Branch,
Galveston, TX, United States
(Takagi) Department of Cardiovascular Surgery, Shizuoka Medical Center,
Shizuoka, Japan
(Takayama) Department of Surgery, Columbia University Medical Center, New
york, Ny, United States
(Kuno) Department of Cardiology, Montefiore Medical Center, Albert
Einstein College of Medicine, New york, Ny, United States
Publisher
Edizioni Minerva Medica
Abstract
INTRODUCTION: Clinical effects of concomitant tricuspid annuloplasty (TA)
in patients with mild to moderate tricuspid regurgitation at the time of
mitral valve surgery (MVS) remains indefinite. We aimed to perform a
meta-analysis to determine the long-term clinical and echocardiographic
effects of concomitant TA in patients undergoing MVS. EVIDENCE
ACQUISITION: MEDLINE and EMBASE were searched through January 2022 to
identify randomized controlled trials (RCT) and observational studies with
adjusted outcomes that investigated outcomes of concomitant TA versus
conservative management for mild to moderate tricuspid regurgitation in
patients undergoing MVS. EVIDENCE SYNTHESIS: Two RCT and 11 observational
studies included in the meta-analysis with a total of 3,953 patients
underwent MVS with (N.=1837) or without (N.=2166) concomitant TA. Mean
follow-up period ranged from 24 to 115.5 months. MVS with concomitant TA
was associated with all-cause mortality (hazard ratio [HR] 1.15; 95%
confidence interval [CI]: 0.81-1.55; P=0.34, I2=0%) compared
with MVS alone. Similarly, heart failure events (HR 0.74; 95% CI:
0.46-1.20; P=0.22, I2=0%) as well as rates of tricuspid
reoperation (HR 0.55; 95% CI: 0.27-1.10; P=0.09, I2=1%) were
comparable between the groups. However, MVS with concomitant TA was
associated with a significant reduction in TR progression (HR 0.30; 95%
CI: 0.17-0.53; P<0.00001, I2=11%). CONCLUSION(S):
Concomitant TA for patients undergoing MVS was associated with similar
long-term clinical outcomes compared to MVS alone. However, concomitant TA
was associated with a significant reduction in TR progression. Longer
follow-up is necessary to assess the effect on further clinical
outcomes. Copyright © 2022 Edizioni Minerva Medica. All rights
reserved.

<123>
Accession Number
639333413
Title
Cardiovascular Outcomes of Older versus Newer Generation Transcatheter
Aortic Valve Replacement Recipients: A Systematic Review & Meta-Analysis.
Source
Current problems in cardiology. (pp 101467), 2022. Date of Publication:
19 Oct 2022.
Author
Sattar Y.; Prakash P.; Almas T.; Mir T.; Titus A.; Ahmad S.; Khan M.S.;
Aggarwal A.; Ullah W.; Alhharbi A.; Kakouros N.; Alraies M.C.; Qureshi
W.T.
Institution
(Sattar, Alhharbi) Department of Cardiology, West Virginia University,
Morgantown, WV, United States
(Prakash, Mir) Department of Internal Medicine, Detroit Medical center,
Wayne State University
(Almas) Royal College of Surgeons in Ireland, Dublin, Ireland
(Titus) Department of Internal Medicine, Saint Vincent Hospital,
Worcester, MA, United States
(Ahmad) Department of Internal Medicine, Icahn School of Medicine at Mount
Sinai - Elmhurst Hospital, Queens, NY, United States
(Khan) Department of Internal Medicine, Mercy St Vincent Medical Centre,
United States
(Aggarwal) Department of Internal Medicine, United States
(Ullah) Department of Internal Medicine, Abington Jefferson Health,
Abington, PA, United States
(Kakouros, Qureshi) Division of Cardiology, University of Massachusetts
School of Medicine, Worcester, MA, United States
(Alraies) Department of Interventional Cardiology, Detroit Medical Center,
DMC Heart Hospital, Detroit, MI, United States
Publisher
NLM (Medline)
Abstract
Newer generation transcatheter heart valves (THV) are presumed to yield
better clinical efficacy and post-procedural complication profile as
compared to transcatheter aortic valve replacement (TAVR) using older
generation THVs. The real impact of newer generation valves on TAVR
outcomes is not well known. Studies comparing older and newer generation
THVs were identified from online databases including PubMed, EMBASE,
Cochrane, and ClinicalTrials.gov from inception until August 2020. The
primary outcome of the study was to compare mortality. Secondary outcomes
included cerebrovascular events, myocardial infarction, major vascular
complications, major bleeding, acute kidney injury, paravalvular leak, and
post-procedural pacemaker implantation. Statistical analysis was performed
using the Mantel-Haenszel random effect model with an odds ratio (OR), 95%
confidence interval (CI), and p-value significance <=0.05. A total of 14
studies were included with a combined patient population of 5697 patients
(older generation n=1996; newer generation n=3701). Newer generation
valves showed statistically significant results favoring lower major
vascular complications (OR=2.05; 95% CI, 1.33-3.18; p=0.00), major
bleeding (OR=1.99; 95% CI, 1.35-2.93; p=0.00), acute kidney injury
(OR=1.71; 95% CI, 1.13-2.59; p=0.01), paravalvular leak (OR=2.41; 95% CI,
1.11-5.28; p=0.03) and mortality (OR=1.50; 95% CI, 1.10-2.06; p=0.01) as
compared to older generation valves. Cerebrovascular events, myocardial
infarction, and pacemaker placement rates were found to be similar between
older and newer generation valves. TAVR outcomes using newer generation
valves are superior to those of older generation valves in terms of major
vascular complications, acute kidney injury, paravalvular leak, and
mortality. Copyright © 2022. Published by Elsevier Inc.

<124>
Accession Number
639330866
Title
External applicability of the Effect of ticagrelor on Health Outcomes in
diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis
of patients with diabetes and coronary artery disease in the REduction of
Atherothrombosis for Continued Health (REACH) registry.
Source
International journal of cardiology. (no pagination), 2022. Date of
Publication: 18 Oct 2022.
Author
Abtan J.; Bhatt D.L.; Elbez Y.; Ducrocq G.; Goto S.; Smith S.C.; Ohman
E.M.; Eagle K.A.; Fox K.; Harrington R.A.; Leiter L.A.; Mehta S.R.; Simon
T.; Petrov I.; Sinnaeve P.R.; Pais P.; Lev E.; Bueno H.; Wilson P.; Steg
P.G.
Institution
(Abtan) FACT (French Alliance for Cardiovascular clinical Trials),
Universite de Paris, Hopital Bichat (Assistance Publique - Hopitaux de
Paris) and INSERM U-1148, all in Paris, France; Brigham and Women's
Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA
(Bhatt) Brigham and Women's Hospital Heart & Vascular Center, Harvard
Medical School, Boston, MA, United States
(Elbez, Ducrocq) FACT (French Alliance for Cardiovascular clinical
Trials), Universite de Paris, Hopital Bichat (Assistance Publique -
Hopitaux de Paris) and INSERM U-1148, all in Paris, France
(Goto) Department of Medicine (Cardiology), Tokai University School of
Medicine, Isehara, Kanagawa, Japan
(Smith) Division of Cardiology, Department of Medicine, University of
North Carolina, Chapel Hill, United States
(Ohman) Division of Cardiology, Department of Medicine, Duke University
School of Medicine, Durham, North Carolina; Duke Clinical Research
Institute, Durham, NC, USA
(Eagle) University of Michigan Cardiovascular Center, Ann Arbor, United
States
(Fox) National Heart and Lung Institute, Imperial College, London, United
Kingdom; Institute of Cardiovascular Medicine and Science, Royal Brompton
Hospital, London, United Kingdom
(Harrington) Stanford Center for Clinical Research, Department of
Medicine, Stanford University, CA, United States
(Leiter) Division of Endocrinology and Metabolism, Li Ka Shing Knowledge
Institute, St Michael's Hospital, University ot Toronto, ON, Canada
(Mehta) Population Health Research Institute and Department of Medicine,
McMaster University and Hamilton Health Sciences, Hamilton, Ontario,
Canada
(Simon) Plateforme de Recherche Clinique de l'Est Parisien
(URCEST-CRCEST-CRB), Saint-Antoine Hospital, AP-HP, Paris, France
(Petrov) University Hospital Acibadem City Clinic Sofia, Sofia University
St. Kliment Ohridski, Bulgaria
(Sinnaeve) Department of Cardiovascular Medicine, University Hospitals
Leuven, Belgium
(Pais) Division of Clinical Research and Training, St. John's Research
Institute, Bangalore, India
(Lev) Petach Tikva, Department of Cardiology, Assuta Ashdod University
Hospital, Faculty of Medicine, Ben Gurion University, Be'er Sheva, all in,
Rabin Medical Center, Ashdod, Israel
(Bueno) Cardiology Department, Centro Nacional de Investigaciones
Cardiovasculares, CIBER de enfermedades CardioVasculares (CIBERCV),
Hospital Universitario 12 de Octubre, Madrid, Spain
(Wilson) Mayo Clinic, Rochester, MN, United States
(Steg) FACT (French Alliance for Cardiovascular clinical Trials),
Universite de Paris, Hopital Bichat (Assistance Publique - Hopitaux de
Paris) and INSERM U-1148, all in Paris, France; National Heart and Lung
Institute, Imperial College, London, United Kingdom
Publisher
NLM (Medline)
Abstract
AIMS: THEMIS is a double-blind, randomized trial of 19,220 patients with
diabetes mellitus and stable coronary artery disease (CAD) comparing
ticagrelor to placebo, in addition to aspirin. The present study aimed to
describe the proportion of patients eligible and reasons for ineligibility
for THEMIS within a population of patients with diabetes and CAD included
in the Reduction of Atherothrombosis for Continued Health (REACH)
registry. METHODS AND RESULTS: The THEMIS eligibility criteria were
applied to REACH patients. THEMIS included patients >=50years with type 2
diabetes and stable CAD as determined by either a history of previous
percutaneous coronary intervention, coronary artery bypass grafting, or
documentation of angiographic stenosis of >=50% of at least one coronary
artery. Patients with prior myocardial infarction or stroke were excluded.
In REACH, 10,156 patients had stable CAD and diabetes. Of these, 6515
(64.1%) patients had at least one exclusion criteria. From the remaining
population, 784 patients did not meet inclusion criteria (7.7%) mainly due
to absence of aspirin treatment (7.2%), yielding a 'THEMIS-eligible
population' of 2857 patients (28.1% of patients with diabetes and stable
CAD). The main reasons for exclusion were a history of myocardial
infarction (53.1%), use of oral anticoagulation (14.5%), or history of
stroke (12.9%). Among the 4208 patients with diabetes and a previous PCI,
1196 patients (28.4%) were eligible for inclusion in the THEMIS-PCI
substudy. CONCLUSION(S): In a population of patients with diabetes
and stable coronary artery disease, a sizeable proportion appear to be
'THEMIS eligible.' CLINICAL TRIAL REGISTRATION: http://www.
CLINICALTRIALS: gov identifier: NCT01991795. Copyright © 2022.
Published by Elsevier B.V.

<125>
Accession Number
639330807
Title
Authorship Trends and Disparities in Cardiothoracic Surgery.
Source
The Annals of thoracic surgery. (no pagination), 2022. Date of
Publication: 18 Oct 2022.
Author
Papageorge M.V.; Luc J.G.Y.; Olive J.K.; Antonoff M.B.
Institution
(Papageorge) Department of Surgery, Yale University School of Medicine,
New Haven, CT, United States
(Luc) Division of Cardiovascular Surgery, University of British Columbia,
Vancouver, BC, Canada
(Olive) Division of Cardiothoracic Surgery, Department of Surgery, Duke
University School of Medicine, Durham, NC, United States
(Antonoff) Department of Thoracic and Cardiovascular Surgery, Division of
Surgery, University of Texas MD Anderson Cancer Center, Houston, TX,
United States
Publisher
NLM (Medline)
Abstract
BACKGROUND: Previous investigations have revealed significant gender
disparities in the academic arenas of cardiothoracic surgery. However, the
status of gender representation in cardiothoracic publications has not
been well described. This study aimed to evaluate authorship trends by
gender in two high-impact cardiothoracic surgical journals.
 METHOD(S): In this bibliometric analysis, PubMed was searched for
articles published in the Annals of Thoracic Surgery and The Journal of
Thoracic and Cardiovascular Surgery from 2010-2021. The web-based
application Genderize.io was used to classify names of first and last
authors as men versus women. The Cochran-Armitage trend test and
multivariable logistic regression were used to evaluate authorship per
year and the association of first and last author gender, respectively.
 RESULT(S): Among 14,443 articles, 16.7% had women first authors and
8.1% had women last authors. The proportion of articles written by women
authors increased, rising from 12.6% to 21.1% (p<0.0001) for first and
5.4% to 11.5% (p<0.0001) for last authors. Papers written with women as
first author were associated with 2.0 higher odds of having a woman as
last author (95% CI 1.7-2.3, p<0.0001). The mean number of last author
publications was higher for men than for women (2.4 versus 1.7, p<0.0001).
 CONCLUSION(S): Over the past decade, despite a welcomed increase in
women authorship in high-impact journals in cardiothoracic surgery, women
represent a small proportion of published authors. Women first authors are
more likely to publish with women last authors, demonstrating the impact
of same-gender collaborations while emphasizing a need for cross-gender
mentorship. Copyright © 2022 The Society of Thoracic Surgeons.
Published by Elsevier Inc. All rights reserved.

EPICORE Embase Updates

Sunday, November 6, 2022

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

No comments:

Post a Comment

Followers

Blog Archive

About Me